


"Express Mail" mailing number: EM143183493US  
Date of Deposit: January 28, 2008  
I hereby certify that this paper and all papers and fees referred to herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents, P. O. Box 1450, Alexandria, VA 22313-1450.



Belinda Perkins  
Belinda Perkins

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Nichols *et al.*

Group Art Unit: 1647

Serial No.: 10/726,216

Examiner: Allen, Marianne P.

Filed: December 2, 2003

Docket No.: 421/29/2/2

Confirmation No.: 4262

For: PURIFIED AND ISOLATED PLATELET CALCIUM CHANNEL NUCLEIC ACIDS  
AND POLYPEPTIDES AND THERAPEUTIC AND SCREENING METHODS  
USING SAME

\*\*\*\*\*

DECLARATION OF TIMOTHY C. NICHOLS, M.D.  
PURSUANT TO 37 C.F.R. §1.132

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

1. My name is Timothy C. Nichols, M.D., and I am Professor of Medicine and Pathology and the Director of the Francis Owen Blood Research Laboratory at the University of North Carolina at Chapel Hill, upon information and belief the assignee for the subject U.S. Patent Application Serial No. 10/726,216. I am also a co-inventor of the subject U.S. Patent Application Serial No. 10/726,216.

2. A true and accurate copy of my *curriculum vitae*, which evidences my expertise and credentials, is attached herewith and labeled **Exhibit A**.

3. I have had an opportunity to review the subject U.S. Patent Application Serial No. 10/726,216, including particularly claims 1-12 and 45-54 as currently pending.

4. I have also reviewed the following documents: the Final Official Action dated September 26, 2007 (hereinafter "the Final Official Action") on the subject U.S. Patent Application Serial No. 10/726,216 by the U.S. Patent and Trademark Office (hereinafter "the Patent Office"); the Non-Final Official Action dated January 24, 2007 (hereinafter "the Non-Final Official Action") on the subject U.S. Patent Application Serial No. 10/726,216 by the Patent Office; Kunzelmann-Marche *et al.* (2001) 276 J Biol Chem 5134-5139 (hereinafter "Kunzelmann-Marche *et al.*"); and U.S. Patent Application Publication No. 2002/0165353 of Malouf *et al.* (hereinafter "Malouf"), of which I am also a co-inventor.

5. Kunzelmann-Marche *et al.* employ a malignant cell line (human erythroleukemia (HEL) cells) in an effort to document that chemicals that block store-operated  $\text{Ca}^{2+}$  entry (SOCE) reduce phosphatidylserine (PS) exposure on those cells. See the Abstract, lines 10-13.

6. Kunzelmann-Marche *et al.* thus does not study platelets, particularly voltage-dependent calcium channels (VDCCs) that are present on platelets.

7. Kunzelmann-Marche *et al.* states that "little is known about the intracellular signals governing SOCE or the  $\text{Ca}^{2+}$  channels mediating this particular form of  $\text{Ca}^{2+}$  entry". See page 5134, right column, first full paragraph. Kunzelmann-Marche *et al.* uses agonists and antagonists of SOCE and draws conclusions about calcium signaling in HEL cells.

8. Kunzelmann-Marche *et al.* does not discuss the possibility of a VDCC participating in calcium entry into platelets, and thus there is no disclosure in

Kunzelmann-Marche et al. that would support linking a VDCC to PS exposure on HEL cells, much less on platelets.

9. As a consequence, it is believed that Kunzelmann-Marche et al. would not lead one working in this field to draw the conclusion that if SOCE exists physiologically in HEL cells, then VDCC must also exist as a protein structure, and that VDCC, even if it were present, must also participate in PS exposure on platelets.

10. Furthermore, when a manuscript discussing the subject matter of the present U.S. patent application was originally submitted for publication to the journal Blood, one of the primary concerns of the reviewers was that a malignant cell line (a cell line of megakaryocytic origin called MEG-01) was first employed for some of the studies.


11. This concern was based at least in part on the fact that malignant and/or transformed cell lines are known to express proteins or phenotypes that are not characteristic of a corresponding non-malignant (*i.e.*, normal, native, or wild type) or non transformed cell of the same cell or tissue type. This was deemed especially important for one reviewer, who cited two papers (copies of which are being submitted herewith as **Exhibits B** and **C**) that showed expression of VDCC in malignant or transformed cells but not in the wild type cell of the same origin. Thus, particularly with respect to the transport of  $\text{Ca}^{2+}$  by VDCCs, it was believed by the reviewer that malignant cells were not predictive of non-transformed cells.

12. All of the data in the subject U.S. Patent Application Serial No. 10/726,216 were generated with native platelets and native megakaryocytes, including the investigations into PS exposure associated with VDCC $\alpha$ 1 activity.

13. Kunzelmann-Marche et al. only discloses the use of a malignant cell and not native platelets, and further does not provide any evidence or suggestion that SOCE in malignant cells is mediated by and/or associated with a VDCC biological activity.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,

A handwritten signature in black ink that reads "Timothy C. Nichols, M.D." The signature is written in a cursive style with a large, stylized 'T' and 'N'.

---

Timothy C. Nichols, M.D.

---

January 26, 2008  
Date

Attachments: **Exhibits A-C**

**CURRICULUM VITAE****PERSONAL INFORMATION**

Name: Timothy C. Nichols

Social Security No. 226-62-9972

Home Address: 103 Wild Turkey Trail, Chapel Hill, NC, 27516

Phone: (919) 967-2495

Date and  
Place of Birth: July 9, 1952, Leesburg, Virginia

Marital Status: Married, Evelyn Byrd Quinlivan, M.D.

Children: Elizabeth Byrd Quinlivan Nichols, Aug 20, 1990  
Brooks Jervy Quinlivan Nichols, May 27, 1992

**EDUCATION**

Brown University, 1970-1972  
B.S. (Biology), Stanford University, 1972-1974  
M.D., Medical College of Virginia, 1974-1978

**PROFESSIONAL EXPERIENCE / EMPLOYMENT HISTORY**

Professor of Medicine, North Carolina Memorial Hospital, January 2000-present  
Professor of Pathology and Laboratory Medicine, North Carolina Memorial Hospital, January 2000-present  
Associate Professor of Medicine, North Carolina Memorial Hospital, July, 1992-1999  
Associate Professor of Pathology and Laboratory Medicine, North Carolina Memorial Hospital, July, 1992-1999  
Assistant Professor of Medicine, North Carolina Memorial Hospital, 1986-1992  
Assistant Professor of Pathology, North Carolina Memorial Hospital, 1991-1992  
Instructor in Medicine, Department of Internal Medicine, North Carolina Memorial Hospital, 1985-1986  
Clinical Instructor, Department of Internal Medicine, North Carolina Memorial Hospital, 1981-1985  
Cardiology Fellowship, North Carolina Memorial Hospital, Department of Internal Medicine, 1982-1985.  
This fellowship included 1 year (July 1, 1983, to June 30, 1984) of research in the laboratory of Thomas R. Griggs, M.D., supported by National Research Service Award Training Grant Number 5 T32 HL07470-04  
Chief Resident, Department of Internal Medicine, North Carolina Memorial Hospital, 1981-1982  
Resident, Department of Internal Medicine, North Carolina Memorial Hospital, 1979-1981  
Intern, Department of Internal Medicine, North Carolina Memorial Hospital, 1978-1979

**CERTIFICATION / LICENSURE**

American Board of Cardiology – Interventional Cardiology, November 7, 2001, #82464  
American Board of Cardiology, November 20, 1985, #82464  
American Board of Internal Medicine, September 16, 1982, #82464  
North Carolina Medical License, 1981, #25383  
National Boards, July 2, 1979, #195715

**PROFESSIONAL SOCIETIES**

Member, American College of Physicians  
Member, American College of Cardiology  
Member, American Heart Association, Thrombosis and Atherosclerosis Councils  
Member, International Society of Thrombosis  
Member, American Association of Pathologists

Member, American Society of Hematology

## HONORS AND AWARDS

1. Recipient of Young Investigator Award, International Society for Thrombosis and Hemostasis, XIth Congress, Brussels, July 1987.
2. James W. Woods Faculty Award, June, 1988.
3. Kenan Fellowship, 1992-1993

## BIBLIOGRAPHY

### PUBLISHED ARTICLES IN REFEREED JOURNALS

1. Nichols TC, Bellinger DA, Johnson TA, Lamb MA, Griggs TR. von Willebrand's disease prevents occlusive thrombosis in stenosed and injured porcine coronary arteries. *Circ Res*. 1986;59:15-26.
2. Bellinger DA, Nichols TC, Read MS, Reddick RL, Lamb MA, Brinkhous KM, Evatt BL, Griggs TR. Prevention of occlusive coronary artery thrombosis by a murine monoclonal antibody to porcine von Willebrand factor. *Proc Natl Acad Sci USA*. 1987;84:8100-8104.
3. Rowe WW, Simpson RJ Jr., Willis PW IV, Noneman JW, Nichols TC, Tate DA, Gettes LS, and The University of North Carolina Cardiology Consortium. Nonemergent cardiac catheterization and risk-stratified revascularization after early thrombolytic therapy for acute myocardial infarction: A critical analysis of therapy in the community setting. *Archives of Internal Medicine*. 1989;149:1611-1617.
4. Lange RA, Dehmer GJ, Wells PJ, Tate DA, Jain A, Flores ED, Nichols TC, Hillis LD. Limitations of the metabolic flow meter for measuring oxygen consumption and cardiac output. *American Journal of Cardiology*. 1989;64:783-786.
5. Reddick RL, Read MS, Brinkhous KM, Bellinger DA, Nichols TC, Griggs TR. Coronary atherosclerosis in the pig: Induced-plaque injury and platelet response. *Arteriosclerosis*. 1990;10:541-550.
6. Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. *American Journal of Cardiology*. 1990;66:1412-1417.
7. Sapin P, Franz E, Jain A, Nichols TC, Dehmer GJ. Coronary artery fistula: An abnormality effecting all age groups. *Medicine*. 1990;69:101-113.
8. Nichols TC, Bellinger DA, Tate DA, Reddick RL, Read MS, Koch GG, Brinkhous KM, Griggs TR. von Willebrand factor and occlusive arterial thrombosis: A study in normal and von Willebrand's disease pigs with diet-induced hypercholesterolemia and atherosclerosis. *Arteriosclerosis*. 1990;10:449-461.
9. Nichols TC, Bellinger DA, Davis KE, Koch GG, Reddick RL, Read MS, Rapacz J, Hasler-Rapacz J, Brinkhous KM, Griggs TR. Porcine von Willebrand disease and atherosclerosis: Influence of polymorphism in apolipoprotein B100 genotype. *Am J Pathol*. 1992;140:403-415.
10. Williams JK, Bellinger DA, Nichols TC, Griggs TR, Bumol TF, Fouts RL, Clarkson TB. Occlusive arterial thrombosis in cynomolgus monkeys with varying plasma concentrations of Lp(a). *Arteriosclerosis and Thrombosis*. 1993;13:548-554.
11. Nichols TC, Bellinger DA, Reddick RL, Smith SV, Koch GG, Davis K, Sigman J, Brinkhous KM, Griggs TR, Read MS. The roles of von Willebrand factor and factor VIII in arterial thrombosis: Studies in canine von Willebrand disease and hemophilia A. *Blood*. 1993;81:2644-2651.
12. Hasler-Rapacz JO, Nichols TC, Griggs TR, Bellinger DA, Rapacz J. Familial and diet-induced hypercholesterolemia in swine. Lipid, ApoB, and ApoA-I concentrations and distributions in plasma and lipoprotein subfractions. *Arterioscler Thromb*. 1994;14:923-930.
13. Read MS, Reddick RL, Bode AP, Bellinger DA, Nichols TC, Taylor KK, Smith SV, McMahon DK, Griggs TR, Brinkhous KM. Preservation of hemostatic and structural properties of rehydrated lyophilized platelets: Potential for long-term storage of dried platelets for transfusion. *Proc Natl Acad Sci USA*. 1995;92:397-401.
14. Nichols TC, Samama CM, Bellinger DA, Roussi J, Reddick RL, Bonneau M, Read MS, Bailliant O, Koch GG, Vaiman M, Sigman JL, Pignaud GA, Brinkhous KM, Griggs TR, Drouet L. Function of von Willebrand

factor after crossed bone marrow transplantation between normal and von Willebrand disease pigs: Effect on arterial thrombosis in chimeras. *Proc Natl Acad Sci USA*. 1995;92:2455-2459.

15. Sanders WE, Jr., Reddick RL, Nichols TC, Brinkhous KM, Read MS. Thrombotic thrombocytopenia induced in dogs and pigs. The role of plasma and platelet vWF in animal models of thrombotic thrombocytopenic purpura. *Arterioscler Thromb Vasc Biol*. 1995;15:793-800.

16. Sjöberg A, Seaman WT, Griggs TR, Nichols TC, Chowdhary BP. FISH mapping of the porcine vWF gene to chromosome 5q21 extends syntenic homology with human chromosome 12. *Hereditas*. 1996;199:202.

17. Ye D, Nichols TC, Dehmer GJ, Tate DA, Wehbie RS, Quinlivan EB. Absence of human herpesvirus 8 genomes in coronary atherosclerosis in immunocompetent patients. *Am J Card*. 1997;79:1245-1247.

18. Dehmer GJ, Nichols TC, Bode AP, Liles D, Sigman J, Koch G, Tate DA, Griggs TR. Assessment of platelet activation by coronary sinus blood sampling during balloon angioplasty and directional coronary atherectomy. *Am J Card*. 1997;80:871-877.

19. Nichols TC, Bellinger DA, Reddick RL, Koch GG, Sigman JL, Erickson G, du Laney T, Johnson T, Read MS, Griggs TR. von Willebrand factor does not influence atherogenesis in arteries subjected to altered shear stress. *Arterioscler Thromb Vasc Biol*. 1998;18:323-330.

20. Zhang Z, Eriksson M, Falk G, Graff C, Presnell SC, Read MS, Nichols TC, Blomback M, Anvret M. Failure to achieve gene conversion with chimeric circular oligonucleotides: potentially misleading PCR artifacts observed. *Antisense Nucleic Acid Drug Dev*. 1998;8:531-536.

21. Monahan PE, Samulski RJ, Tazelaar J, Xiao X, Nichols TC, Bellinger DA, Read MS, Walsh CE. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. *Gene Ther*. 1998;5:40-49.

22. Herzog RW, Yang EY, Couto LB, Hagstrom JN, Elwell D, Fields PA, Burton M, Bellinger DA, Read MS, Brinkhous KM, Podsakoff GM, Nichols TC, Kurtzman GJ, High KA. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. *Nature Medicine*. 1999;5:56-63.

23. Snyder RO, Miao C, Meuse L, Donahue BA, Lin H-F, Stafford DW, Patel S, Thompson A, Nichols T, Bellinger D, Read M, Brinkhous KM, Kay MA. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. *Nature Medicine*. 1999;5:64-70.

24. Nichols TC, du Laney T, Zheng B, Bellinger DA, Nickols GA, Engleman W, Clemmons DR. Reduction in atherosclerotic lesion size in pigs by alphaVbeta3 inhibitors is associated with inhibition of insulin-like growth factor-I-mediated signaling. *Circ Res*. 1999;85:1040-1045.

25. Dehmer GJ, Nichols TC, Li S, Koch GG, Tate DA, Griggs TA. Effects of ionic and nonionic contrast agent on von Willebrand factor assessed during coronary angiography. *Am J Card*. 1999;84:223-225.

26. Clemmons DR, Horvitz G, Engleman W, Nichols T, Moralez A, Nickols GA. Synthetic alphaVbeta3 antagonists inhibit insulin-like growth factor-1-stimulated smooth muscle cell migration and replication. *Endocrinology*. 1999;140:4616-4621.

27. Guzzo J, Nichols TC. Possible anaphylactic reaction to abciximab. *Catheter Cardiovasc Interv*. 1999;48:71-73.

28. Chao H, Samulski R, Bellinger D, Monahan P, Nichols T, Walsh C. Persistent expression of canine factor IX in hemophilia B canines. *Gene Ther*. 1999;6:1695-1704.

29. Wang L, Nichols TC, Read MS, Bellinger DA, Verma IM. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. *Molecular Therapy*. 2000;1:154-158.

30. Faile BA, Guzzo J, Tate DA, Nichols TC, Smith SC, Dehmer GJ a. Effect of sex, hemodynamics, body size and other clinical variables on the corrected Thrombolysis In Myocardial Infarction frame count used as an assessment of coronary blood flow. *Am Heart J*. 2000;140:308-314.

31. Herzog R, Arruda VR, Fischer TH, Read MS, Nichols TC, High KA. Absence of circulating factor IX antigen in hemophilia B dogs of the UNC-Chapel Hill Colony. *Thromb Haemost*. 2000;84:352-354.

32. Fischer T, Merricks E, Russell K, Raymer R, White G, Bode A, Nichols T, Read M. Intracellular Signalling in Rehydrated, Lyophilized Platelets. *Brit J Haem*. 2000;111:167-175.

33. Russell K.E., M.S. R, Bellinger D.A., Leitermann K., Rup B.J., McCarthy K.P., Keith J.C., Schaub R.G., Khor S.P., Nichols T.C. Intratracheal administration of recombinant human factor IX (BeneFix™) achieves therapeutic levels in hemophilia B dogs. *Thromb Haemost*. 2001;85:445-449.

34. Nichols TC, Fischer TH, Deliaris EN, Baldwin AS Jr. Role of NF-kB in Inflammation, Periodontitis, and Atherogenesis. *Annals of Periodontology*. 2001;6:20-29.

35. Arruda VR, Fields PA, Milner R, Wainwright L, De Miguel P, Donovan PJ, Herzog RW, Nichols TC, Biegel JA, Razavi M, Dake M, Huff D, Flake AW, Couto L, Kay M, High KA. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vectors in males. *Molecular Therapy*. 2001;4:586-592.
36. Fischer TH, Merricks E, Bellinger DA, Hayes PM, Smith RS, Raymer RA, Read MS, Nichols TC, Bode AP. Splenic clearance mechanisms of rehydrated, lyophilized platelets. *Art Cells, Blood Subs and Immob Biotech*. 2001;29:439-451.
37. Mount JD, Herzog RW, Tillson DM, Goodman SA, Robinson N, McClelland ML, Bellinger D, Nichols TC, Arruda VR, Lothrop CD, Jr., High KA. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. *Blood*. 2002;99:2670-2676.
38. Herzog RW, Fields PA, Arruda VR, Brewbaker J, Armstrong E, McClintock D, Bellinger DA, Couto LB, Nichols TC, High KA. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy for canine hemophilia B. *Human Gene Therapy*. 2002;13:1281-1291.
39. Fischer TH, Merricks EP, Bode AP, Bellinger DA, Russell K, Reddick R, Sanders WE, Nichols TC, Read MS. Thrombus formation with rehydrated, lyophilized platelets. *Hematology*. 2002;7:359-369.
40. McCarthy K, Stewart P, Sigman J, Read M, Keith JC, Brinkhous KM, Nichols TC, Schaub RG. Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys. *Thromb Haemost*. 2002;87:824-830.
41. Lozier JN, Dutra A, Pak E, Zhou N, Zheng Z, Nichols TC, Bellinger DA, Read M, Morgan RA. The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion. *Proc Natl Acad Sci*. 2002;99:12991-12996.
42. Brinkhous K, Sandberg H, Widlund L, Read M, Nichols T, Sigman J, Oswaldsson U, Schaub RG, Mikaelsson M. Preclinical pharmacology of albumin-free B-domain deleted recombinant factor VIII. *Semin Thromb Hemost*. 2002;28:269-272.
43. Pye J, Ardeshirpour F, McCain A, Bellinger DD, Merricks E, Adams J, Elliott PJ, Pien C, Fischer TH, Baldwin AS, Nichols TC. Proteasome Inhibition Ablates Activation of NF- $\kappa$ B Induced During Myocardial Reperfusion and Reduces Reperfusion Injury. *Am J Physiol Heart Circ Physiol*. 2003;284:H919-H926.
44. Xu L, Gao C, Sands MS, Cai SR, Nichols TC, Bellinger DA, Raymer RA, McCorquodale S, Ponder KP. Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B. *Blood*. 2003;101:3924-3932.
45. Olsen EHN, McCain AS, Merricks EP, Fischer TH, Dillon IM, Raymer RA, Bellinger DA, Fahs SA, Montgomery RR, Keith JC Jr, Schaub RG, Nichols TC. Comparative response of plasma VWF in dogs to up-regulation of VWF mRNA by interleukin-11 versus Weibel-Palade body release by desmopressin (DDAVP). *Blood*. 2003;102:436-441.
46. Fischer TH, Britain J, Trabalzinin L, Banes AJ, Smith CJ, White GC, Nichols TC. The ras binding domain of ral GDS-like protein-2 as a ras inhibitor in smooth muscle cells. *Biochem Biophys Res Commun*. 2003;305:934-940.
47. Rathore V, Stapleton MA, Hillery CA, Montgomery RR, Nichols TC, Merricks EP, Newman DK, Newman PJ. PECAM-1 negatively regulates GPIb/VI/IX signaling in murine platelets. *Blood*. 2003;102:3658-3664.
48. Baer JT, duLaney TV, Wyrick PB, McCain AD, Fischer TA, Merricks EP, Baldwin AS, Nichols TC. NF- $\kappa$ B Activation in Endothelium by Chlamydia pneumoniae without Active Infection. *J Infect Dis*. 2003;203:1094-1097.
49. Ehrhardt A, Xu H, Dillow AM, Bellinger DA, Nichols TC, Kay MA. A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia. *Blood*. 2003;102:2403-2411.
50. Lau CL, Cantu E, 3rd, Gonzalez-Stawinski GV, Holzknecht ZE, Nichols TC, Posther KE, Rayborn CA, Platt JL, Parker W, Davis RD. The role of antibodies and von Willebrand factor in discordant pulmonary xenotransplantation. *Am J Transplant*. 2003;3:1065-1075.
51. Russell KE, Olsen EHN, Raymer RA, Merricks EP, Bellinger DA, Read MS, Rup BJ, Keith JC Jr, McCarthy KP, Schaub RG, Nichols TC. Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune tolerant hemophilia B dogs. *Blood*. 2003;102:4393-4398.
52. Arruda VR, Schuettrumpf J, Herzog RW, Nichols TC, Robinson N, Lotfi Y, Mingozzi F, Xiao W, Couto LB, High KA. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia



B models by adeno-associated viral vector serotype 1. *Blood*. 2004;103:85-92.

53. Harding TC, Koprivnikar KE, Tu GH, Zayek N, Lew S, Subramanian A, Sivakumaran A, Frey D, Ho K, VanRoey MJ, Nichols TC, Bellinger DA, Yendluri S, Waugh J, McArthur J, Veres G, Donahue BA. Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B. *Gene Ther*. 2004;11:204-213.

54. Fischer TH, Robbins ME, Bode AP, Nichols TC, Bellinger DE, Schoenfisch MH. Evidence that rehydrated, lyophilized red blood cells are sufficiently deformable for normal microcirculation transit. *Microsc Res Tech*. 2004;65:62-71.

55. Schwaitzberg SD, Chan MW, Cole DJ, Read M, Nichols T, Bellinger D, Connolly RJ. Comparison of poly-N-acetyl glucosamine with commercially available topical hemostats for achieving hemostasis in coagulopathic models of splenic hemorrhage. *J Trauma*. 2004;57:S29-32.

56. Haberichter SL, Merricks EP, Fahs SA, Christopherson PA, Nichols TC, Montgomery RR. Re-establishment of VWF-dependent Weibel-Palade bodies in VWD endothelial cells. *Blood*. 2005;105:145-152.

57. Wang L, Calcedo R, Nichols TC, Bellinger DA, Dillow A, Verma IM, Wilson JM. Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. *Blood*. 2005;105:3079-3086.

58. Arruda VR SH, Nichols TC, Haskins ME, Nicholson M, Herzog RW, Couto LB, High KA. Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. *Blood*. 2005;105:3458-3464.

59. Xu L, Nichols TC, Sarkar R, McCorquodale S, Bellinger DA, Ponder KP. Absence of a DDAVP Response after Therapeutic Expression of Factor VIII in Hemophilia A Dogs with Liver-directed Neonatal Gene Therapy. *Proc Natl Acad Sci U S A*. 2005;102:6080-6085.

60. Brunetti-Pierri N, Nichols TC, McCorquodale S, Merricks E, Palmer DJ, Beaudet AL, Ng P. Sustained Phenotypic Correction of Canine Hemophilia B Following Systemic Administration of Helper Dependent Adenoviral Vector. *Human Gene Therapy*. 2005;16:811-820.

61. Brodala N, Merricks EP, Bellinger DA, Damrongsri D, Offenbacher S, Beck J, Madianos P, Sotres D, Chang YL, Koch G, Nichols TC. *Porphyromonas gingivalis* bacteremia induces coronary and aortic atherosclerosis in normocholesterolemic and hypercholesterolemic pigs. *Arterioscler Thromb Vasc Biol*. 2005;25:1456-1451.

62. Sarkar R, Mucci M, Addya S, Tetreault R, Bellinger DA, Nichols TC, Kazazian HH. Long-Term Efficacy of Adeno-associated Virus Serotypes 8 and 9 in Hemophilia A Dogs and Mice. *Hum Gene Ther*. 2006;17:427-439.

63. McCormack WM, Jr., Seiler MP, Bertin TK, Ubhayakar K, Palmer DJ, Ng P, Nichols TC, Lee B. Helper-dependent adenoviral gene therapy mediates long-term correction of the clotting defect in the canine hemophilia A model. *J Thromb Haemost*. 2006;4:1218-1225.

64. Dumont D, Behler RH, Nichols TC, Merricks EP, Gallippi CM. ARFI imaging for noninvasive material characterization of atherosclerosis. *Ultrasound Med Biol*. 2006;32:1703-1711.

65. Bellinger DA, Merricks EP, Nichols TC. Swine models of type 2 diabetes mellitus: Insulin resistance, glucose tolerance, and cardiovascular complications. *ILAR Journal*. 2006;47:243-258

66. Xu L, Mei M, Haskins ME, Nichols TC, O'Donnell P, Cullen K, Dillow A, Bellinger D, Ponder KP. Immune response after neonatal transfer of a human factor IX-expressing retroviral vector in dogs, cats, and mice. *Thromb Res*. 2007;120:269-280.

67. Nichols TC, Busby WH Jr, Merricks E, Sipos J, Rowland M, Sitko K, Clemmons DR: Protease Resistant IGFBP-4 Inhibits IGF-I Actions and Lesion Development in Porcine Model of Atherosclerosis, *Endocrinology*. 148:5002-5010, 2007

#### PUBLISHED ARTICLES IN REFEREED JOURNALS SELECTED FOR EDITORIAL REVIEW

1. Editorial for publication number 13: Aster RH. Freeze-dried blood cells: Therapeutic advance or laboratory curiosity? *Proc Natl Acad Sci USA* 92:2419-2420, 1995

2. Editorial for publication number 14: Mannucci PM. Platelet von Willebrand factor in inherited and acquired bleeding disorders. *Proc Natl Acad Sci USA* 92:2428-2432, 1995

3. Editorial for publication numbers 21 and 22: Linden RM, Woo SLC. AAVant-garde gene therapy.

Nature Medicine 5:21-22, 1999

4. Editorial for publication number 37 (Blood Plenary Paper): Katherine Ponder. Gene therapy for hemophilia B in dogs: finally prevention of bleeding, but concerns about inhibitors remain. Blood 99: 2635-2636, 2002

5. Editorial for publication number 45 (Blood Plenary Paper): Peter J. Lenting and Jan J. Sixma. DDAVP and interleukin-11: a boosting combination. Blood 102: 415-416, 2003

6. Editorial for publication number 63: Arruda VR. Toward gene therapy for hemophilia A with novel adenoviral vectors: successes and limitations in canine models. J Thromb Haemost. 2006;4:1215-1217

#### IN PRESS/ACCEPTED/SUBMITTED

1. Milbauer LC, Enenstein J, Roney M, Solovey A, Bodempudi V, Nichols TC, Hebbel RP. BOEC Migration and Trapping In Vivo: A Window into Gene Therapy. Revision submitted 2007.

2. Nichols TC, Busby WH Jr, Merricks E, Sipos J, Rowland M, Sitko K, Clemmons DR. Protease Resistant IGFBP-4 Inhibits IGF-I Actions and Neointimal Expansion in Porcine Model of Neointimal Hyperplasia. Submitted. 2007

#### NON-REFEREED JOURNALS

1. Griggs TR, Reddick RL, Lamb MA, Bellinger DA, Nichols TC, Read MS, Brinkhous KM: Studies of coronary thrombosis in swine with von Willebrand's disease. In: Swine in Biomedical Research, Vol. 3. Tumbleson, M.E., (ed.). Plenum Press, New York: 1543-1553, 1985.

2. Griggs TR., Reddick RL, Lamb MA, Bellinger DA, Nichols TC, Read MS, and Brinkhous KM: von Willebrand's disease in swine, a genetic model for the study of atherogenesis and thrombosis. In: Recent Advances in Arteriosclerosis Research, W.H. Hauss, R.W. Wissler, J. Grunwald, Eds., Westdeutscher Verlag, Germany, 1987, pp. 95-105.

3. Nichols TC, Bellinger DA, Reddick RL, Read MS, Brinkhous KM, Griggs TR: Role du facteur Willebrand dans la thrombose et l'atherosclerose: etudes chez le porc normal et atteint de la maladie de von Willebrand. Sang Thrombose Vaisseaux 1990;2:315-321

4. Nichols TC, Bellinger DA, Reddick RL, Read MS, Brinkhous KM, Griggs TR. von Willebrand Factor and Arterial Thrombosis: Studies in Normal and von Willebrand's Disease Pigs. Circulation 1991; 83 (suppl IV);IV-56 - IV-64.

5. Brinkhous KM, Reddick RL, Read MS, Nichols TC, Bellinger DA, Griggs TR. von Willebrand factor and animal models: Contributions to gene therapy, thrombotic thrombocytopenic purpura, and coronary artery thrombosis. Mayo Clinic Proc 1991; 66:733-742.

6. Van Cott KE, Monahan PE, Nichols TC, Velandier WH. Haemophilic factors produced by transgenic livestock: abundance that can enable alternative therapies worldwide. Haemophilia. 2004;10 Suppl 4:70-76

7. Paquette DW, Brodala N, Nichols T. Cardiovascular Disease, inflammation, and periodontal infection. Periodontology 2000. 2006;43: 1-14

#### BOOKS AND BOOK CHAPTERS

1. Nichols TC, Griggs TR. Pulmonary Hypertension and Thromboembolic Disease. In: Runge MS, Ohman EM, eds. Netter's Cardiology. Teterboro, New Jersey: Icon Learning Systems LLC; 2004:562-572

#### PUBLISHED ABSTRACTS

1. Nichols TC, Bellinger DA, Fleet WF, and Griggs TR: Von Willebrand's Disease Prevents Occlusive Thrombosis in Stenosed and Injured Porcine Coronary Arteries (Abstract supplement). Circulation 1984;70:II-361

2. Woelfel A, Starek, PJK, Foster JR, Noneman, JW, Nichols TC, Gettes LS. Induction of Ventricular Tachycardia in Patients with Left Ventricular Aneurysms and No History of Arrhythmia. Presented at the American College of Cardiology, March 8-12, 1987, New Orleans, Louisiana.

3. Nichols TC, Bellinger DA, Read MS, Reddick, Brinkhous KM, Lamb M, and Griggs TR. Prevention of

Occlusive Coronary Artery Thrombosis by a Monoclonal Antibody to Porcine Von Willebrand Factor. *Thrombosis and Haemostasis* 1987;58:9

4. Reddick RL, Bellinger DA, Nichols TC, Griggs TR, Read MS, and Brinkhous KM. Foam Cell Deposition in Aortic Valves of Swine Fed an Atherogenic Diet: A Possible Precursor Change Leading to Aortic Valve Disease. *FASEB J.* 1988;2:A1581

5. Bleich SD, Tate DA, Nichols TC, Schumacher RP, Cooke D, Steiner C, Brinkman D, Rolli-Mills JR. Effect of Heparin on bleeding complications, recurrent ischemia, and recurrent infarction following coronary thrombolysis with tissue plasminogen activator. *Thrombosis and Haemostasis* 1989;62:27

6. Nichols TC, Bellinger DA, Reddick RL, Tate DA, Read MS, Koch GG, Brinkhous KM, Griggs TR. Von Willebrand's Disease prevents coronary and carotid arterial thrombosis in pigs with diet-induced hypercholesterolemia and atherosclerosis. *Thrombosis and Haemostasis* 1989;62:26

7. Bleich SD, Nichols TC, Schumacher RP, Cooke D, Tate DA, Steiner C, Brinkman D. The role of heparin following coronary thrombolysis with tissue plasminogen activator (rt-PA). *Circulation* 1989;80:II-113

8. Tate DA, Nichols TC, Read MS, Davis CB, Sigman JL, Griggs TR. Von Willebrand factor following tissue plasminogen activator: increased antigen without increased in vitro functional activity. *Circulation* 1989;80:II-422

9. Bellinger DA, Nichols TC, Reddick RL, Read MS, Koch GG, Brinkhous KM, Griggs TR. Role of plasma and platelet von Willebrand factor in a porcine arterial thrombosis model. *Circulation* 1990;82:III-595

10. Nichols TC, Bellinger DA, Koch GG, Davis K, Reddick RL, Read MS, Rapacz J, Hasler-Rapacz J, Brinkhous KM, Griggs TR. Porcine von Willebrand Disease and Atherosclerosis: Influence of polymorphism in apolipoprotein B100 genotype in 35 male pigs. *Arteriosclerosis* 1990, 10(5):858a.

11. Nichols TC, Bellinger DA, Read MS, Reddick RL, Koch GG, Brinkhous KM, Griggs TR. von Willebrand factor, factor VIII, and arterial thrombosis: Studies in canine von Willebrand disease and hemophilia A. *Thrombosis and Haemostasis* 1991, 65 (6):855.

12. Griggs TR, Nichols TC, Bellinger DA, Davis KE, Koch GG, Reddick RL, Read MS, Rapacz J, Hasler-Rapacz J, Brinkhous KM. Porcine von Willebrand disease and atherosclerosis: Influence of polymorphism in apolipoprotein B100 genotype. Presented at the 9th International Atherosclerosis Meetings, Chicago, October 1991.

13. Bellinger DA, Nichols TC, Samama CM, Reddick RL, Bonneau M, Read MS, Bailliant O, Koch GG, Vaiman M, Brinkhous KM, Pignaud GA, Sigman JL, Griggs TR, Drouet L. Altered phenotypes of normal and von Willebrand disease pigs by bone marrow transplantation: Effects on thrombosis and hemostasis. *Blood* 1991;78 (No 10, Suppl 1) 179a

14. Tate DA, Bode AP, Nichols TC, Dehmer GJ. Platelet activation detected by platelet-derived microparticles in coronary sinus blood from patients with unstable coronary syndromes. *Circulation* 1992, 86 (Abstract from the 65th Scientific Sessions):I-802

15. Williams JK, Bellinger DA, Nichols TC, Griggs TR, Clarkson TB. Occlusive arterial thrombosis in monkeys with varying plasma concentrations of Lp(a). *Circulation* 1992, 86 (Abstract from the 65th Scientific Sessions):I-868

16. Tate DA, Bode AP, Liles D, Nichols TC, Hoffman M, Monroe D, Dehmer GJ. Platelet activation during coronary interventions detected by measurement of platelet derived microparticles and glycoprotein IIb/IIIa expression on platelets in coronary sinus blood. *JACC (Abstracts of the 42nd Annual Scientific Sessions)1993 (Suppl A):77a*

17. Read MS, Reddick RL, Nichols TC, Bellinger DA, Bode AP, Taylor KK, Brinkhous KM, Griggs TR. Transfused rehydrated platelets support hemostasis and thrombosis. *Blood* 1993, 82 (Suppl 10)159a

18. Read MS, Khandelwal G, Miller RS, Taylor KK, Bode AP, Nichols TC, Reddick RL, Griggs TR. Rehydrated lyophilized platelets: a proposed mechanism contributing to the hemostatic action. *Blood*, 86:907a, 1995.

19. Seaman WT, Sjoberg A, Read MS, Sigman J, Bellinger DA, Brinkhous KM, Griggs TR, Chowdhary BP, Nichols TC: Cloning of a 4.5 kb porcine von Willebrand Factor (vWF) cDNA: chromosomal localization of the porcine vWF gene to 5q21 reveals synteny with human chromosome 12. *Blood* 86:887a, 1995.

20. Seaman W, Griggs T, Nichols T; Sequence Comparison of Human and Porcine vWF cDNA. Presented at the ASBMP/ASIP/AAI Joint Meeting, New Orleans, June 1996

21. Khandelwal G, Sanders W Jr, Bode A, Nichols T, Erickson G, Read M: von Willebrand factor binding to rehydrated lyophilized platelet surface GPIb and inhibition by monoclonal antibody to GPIb. *FASEB J*

11:A312, 1997

22. Fischer TH, Brittain JE, Trabalzini L, Peterson SN, Nichols TC, White GC: The ras binding domain of ral GDS-like protein-2 inhibits the growth factor response of A10 rat aorta smooth muscle cells. *Thromb Haemost Abstract Suppl 742a*, 1997.

23. Greengard JS, Bodner M, McCormack J, Edwards WR, Sensintaffar JL, Sheridan PL, Phuong T, Mittelstaedt D, Brumm D, Nichols TC, Read MS, Brinkhous KM, Jolly DJ, Chang SMW. Systemic expression of human factor VIII from peripheral retroviral gene delivery in rabbits and dogs. *Blood 90*, 240a, 1997

24. Monahan PE, Tazelaar J, Xiao X, Nichols TC, Bellinger DA, Read MS, Samulski RJ, Walsh CE. Sustained expression of human factor IX in a hemophilic canine following direct intramuscular injection of an adeno-associated virus (AAV) vector. *Blood 90:240a*, 1997

25. Herzog R, Hagstrom J, Kung S, Yang E, Couto L, Kurtzman G, McQuiston S, Colosi P, Elwell D, Nichols T, Bellinger D, Read M, Brinkhous K, Tai S, High K. Absence of antibodies against factor IX following IM injection of an AAV vector encoding a species specific transgene. *Blood 90:240a*, 1997

26. Russell KE, Stewart DR, Elwell DR, Nichols TC, Bellinger DA, Brinkhous KM, Rup BJ, Keith JC, Leiterman K, McCarthy KP, Schaub RG, Read MS. Subcutaneous neonatal administration of recombinant factor IX (BeneFix™) induces immune tolerance in hemophilia B dogs. *Blood 90:599a*, 1997

27. Seaman WT, Nichols TC, Read MS. Rehydrated lyophilized platelets (RL-platelets) retain GPIb receptors capable of interacting with the A1 loop of von Willebrand factor. *Blood 90:72b*, 1997.

28. Herzog RW, Yang EY, Couto L, Hagstrom NJ, Elwell D, Tai SJ, Kung S, Yang E, Colosi P, Podsakoff GM, Read Ms, Bellinger DA, Brinkhous K, Nichols TC, Kurtzman GJ, High KA. AAV-mediated transfer in dogs with hemophilia B. *Am. Soc. Gene Therapy Abstracts 116a*, 1998.

29. Kren B, Bandyopadhyay P, Presnell S, Bellinger D, Nichols T, Steer C. Site-directed correction of the hemophilia B point mutation in genomic DNA of isolated dog hepatocytes by a chimeric RNA/DNA oligonucleotide. *Am. Soc. Gene Therapy Abstracts 181a*, 1998.

30. du Laney TV, Massaro EJ, Nichols TC. The effects of pluronic F-68 on calcium transients in porcine aortic endothelial cells in response to fluid shear stress. *Biomedical Engineering Society Annual Meeting*, October 1998.

31. du Laney TV, He Y, Nichols TC, Graves LM. Shear-stress induced CADTK activation in vascular smooth muscle cells. Presented at the 71st Scientific Sessions of the American Heart Association.

32. Herzog, R.W., Hagstrom, J.N., Yang, E.Y., Elwell, D., Fields, P.A., Burton, M., Bellinger, D.A., Read, M.S., Brinkhous, K.M., Podsakoff, G.M., Nichols, T.C., Couto, L.B., High, K.A. Long-term phenotypic correction of hemophilia B in a large animal model by AAV-mediated gene transfer. *Blood 92(10, suppl 1): 53a*, 1998.

33. Russell, K.E., Nichols, T.C., Elwell, D.R., Bellinger, D.A., Raymer, R.A., McElveen, P.R., Rup, B.J., Keith, J.C., Leitermann, K., McCarthy, K.P., Schaub, R.G., Read, M.S. Intratracheal administration of recombinant human factor IX (BeneFix™) achieves therapeutic levels. *Blood 92(10, suppl 1): 356a*, 1998.

34. Russell, K.E., Nichols, T.C., Elwell, D.R., Bellinger, D.A., Rup, B.J., Keith, J.C., Leitermann, K., McCarthy, K.P., Schaub, R.G., Read, M.S. Maintenance of immune tolerance in hemophilia B dogs by subcutaneous administration of recombinant human factor IX (BeneFix™). *Blood 92(10, suppl 1): 554a*, 1998.

35. Herzog, R.W., Fields, P.A., Arruda, V.R., Elwell, D., Nichols, T.C., Couto, L.B., Hagstrom, J.N., High, K.A. Characterization of immune responses to factor IX in small and large animal models for gene therapy *Blood 92(10, suppl 1): 689a*, 1998.

36. Chao, H.J., Nichols, T., Bellinger, D.A., Elwell, D., Monahan, P.E., Samulski, R.J., Walsh, C.E. Persistent expression of canine FIX in the hemophilia B canine after direct intramuscular injection of rAAV vector. *Blood 92(10, suppl 1): 690a*, 1998.

37. Fischer, T.H., Russell, K.E., Merricks, E.P., White, G.C., Nichols, T.C., Read, M.S. Intracellular signaling capability is partially preserved in rehydrated, lyophilized platelets. *Blood 92(10, suppl 1): 65b*, 1998.

38. Merricks, E.P., Nichols, T.C., Russell, K.E., Read, M.S. Binding and internalization of fibrinogen and F-actin distribution in rehydrated lyophilized platelets. *Blood 92(10, suppl 1): 71b*, 1998.

39. Mustafa, R.L., Elwell, D.R., Russell, K.E., Nichols, T.C., Read, M.S. A role for whole blood clotting time as a sensitive screening test for F.VIII and F.IX replacement. *Blood 92(10, suppl 1): 96b*, 1998.

40. du Laney TV, Seaman WT, Read MS, Johnson TA, Baldwin AS, Nichols TC. The effects of calcium on NF- $\kappa$ B activation in endothelial cells in response to shear stress. *FASEB J 13:A855*, 1999.

41. Snyder R, Kay M, Nichols T, Miao C, Thompson A, Stafford D, Brinkhous K, Lozier J, Morgan R,

Donahue B. Long term expression of factor IX and factor VIII following rAAV-mediated gene delivery. Proceedings of the American Society of Gene Therapy 1999 Meetings, p 44a.

42. Nichols TC, Merricks EP, Raymer RA, Read MS. Automated whole blood tests for monitoring canine factor IX activity following gene therapy of hemophilia B. Thromb Haemost 1999 82:280(abSTRACT supplement for XVII Congress of the ISTH).

43. Nichols TC, Pipe SW, Kaufman RJ, McClintock DWD, Zollner R, Booth J, Schaub RG, Read MS. Inactivation-resistant human coagulation factor VIIIa (IR8) corrects canine hemophilia A coagulopathy. Thromb Haemost 1999 82:488(abSTRACT supplement for XVII Congress of the ISTH).

44. Miao CH, Chou S-H, Nichols TC, Thompson AR. Chimeric RNA/DNA hybrid dumbbells capped with compact trinucleotide loops more consistently corrects the factor IX point mutation in canine hemophilic fibroblasts. Blood 94 (Suppl 1): 373a, 1999.

45. Pipe SW, Nichols TC, McClintock DWD, Zollner R, Thomas J, Schaub R, Read MS, Saenko EL, Kaufman RJ. The conformation of the factor VIII light chain can modulate von Willebrand factor binding affinity without affecting cofactor activity in vitro and in vivo. Blood 94 (Suppl 1): 453a, 1999.

46. Fischer TH, Merricks EP, Raymer RA, Nichols TC, Read MS. Surface membrane integrity of rehydrated lyophilized platelets and the retention of critical proteins for stimulus-response coupling. Blood 94 (Suppl 1): 87b, 1999.

47. Herrmann R, Pye J, Bellinger D, Adams J, Elliott P, Pien C, Baldwin Jr, A, Nichols T. Proteasome inhibition reduces myocardial reperfusion injury through an NF- $\kappa$ B dependent pathway. Keystone Symposium: NF- $\kappa$ B Regulation and Function: From Basic Research to Drug Development, abstract number 321, p 100, February, 2000

48. Miao CH, Chou SH, Nichols TC, Thompson AR. Targeted gene repair in canine hemophilia fibroblasts by chimeric RNA/DNA hybrid dumbbells capped with compact trinucleotide loops. Molecular Therapy 1(abSTRACT supplement) :S291, 2000 Fewell JG, MacLaughlin FC, Mehta V, Gondo M, Nichol F, Nolan E, Read M, Nichols TC, Smith LC. Gene therapy for the treatment of hemophilia B using PINC<sup>TM</sup>-formulated plasmid delivered to muscle with electroporation. Molecular Therapy 1(abSTRACT supplement) :S287, 2000

49. Wang L, Nichols TC, Read MS, Bellinger DA, Verma IM. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated Gene therapy. Molecular Therapy 1(abSTRACT supplement) :S28, 2000

50. Herzog RW, Fields PA, Arruda VR, Armstrong E, Nichols TC, Couto LB, High KA. Characterization of B- and T- cell responses against factor IX in AAV vector-based gene therapy for canine hemophilia B. Molecular Therapy 1(abSTRACT supplement) :S27, 2000

51. Lozier JN, Nichols TC, Read MS, Bellinger DA, Morgan RA. Chapel Hill canine hemophilia A is associated with a fusion transcript. Blood 96:488a, 2000

52. Fang X, Zhang WW, Sobol RE, Gomperts E, Thompson AR, Wong WY, Kohn D, Rogers R, Fischer T, Nichols T, Murthy KK, Cobb EK, Fahs S, Montgomery RR, White G. Studies in non human primate and hemophilic dog models of a "gutless: adenovirus vector for treatment of hemophilia A. Blood 96:428a, 2000

53. Fewell JG, Bruce D, Florack V, Wilson E, Anscombe I, Nolan E, Read MS, Bellinger DA, Fischer TH, Nichols TC, Smith LC. Expression of Factor IX in mice and hemophilic B dogs following intramuscular injection of PINC<sup>TM</sup>-formulated plasmid with electroporation. Blood 96:803a, 2000

54. Nichols TC, McClintock DWD, Rogers RA, McManus IE, Merricks EP, Fischer TH, Schaub RG, Read MS. Effect of recombinant IL-11 and DDAVP on vWF and F.VIII in vWD dogs. Blood 96:636a, 2000

55. van den Berg HM, Zqaginga JJ, Kumar A, Eppihimer M, Schaub R, Fischer T, E M, Raymer R, Read M, Nichols T, Erhlich H. BeneFix<sup>TM</sup> induces agglutination of red cells: Is there a clinical relevance and can it be prevented. Blood 96:641a, 2000

56. Fischer T, Merricks E, Russell K, Raymer R, White G, Bode A, Nichols T, Read M. Intracellular Signalling in Rehydrated, Lyophilized Platelets. Brit J Haem 111:167-175, 2000

57. Fischer TH, Merricks EP, Raymer RA, Nichols TC, Bode AP. Multiple infusions of rehydrated, lyophilized platelets does not induce antiplatelet antibodies or thrombocytopenia in a canine model system. Blood 96:106b, 2000

58. Fischer TH, Bode AP, Merricks EP, Raymer RA, Nichols TC, Read MS. The development of rehydrated, lyophilized red blood cells as oxygen carriers for transfusion medicine. Blood 96:660a, 2000

59. Brodala N, Madianos P.N., Geva S, Offenbacher S, Beck JD, Fischer TH, Smith S, Bellinger, DA Baldwin AS, Nichols TC. Recurrent Porphyromonas gingivalis bacteremia induces atherosclerosis in

susceptible pigs. AAP-NIDCR Symposium, April 18-20, 2001, NIH, Bethesda MD.

60. Arruda VR, Schuettrumpf J, Robinson N, Powell S, Allen J, Ni D, Xiao W, Nichols T, Herzog R, High K. Improved muscle-directed gene transfer of factor IX for treatment of hemophilia B by use of novel AAV serotypes. *Molec Therapy* 3:S218, 2001.

61. Lozier J, Nichols TC, Read MS, Bellinger DA, Morgan RA. Hemophilia A in the Chapel Hill canine colony is due to a mutation that results in a fusion transcript. *Thromb and Haemost (Supl)* July 2001 Abstract P2922

62. Fischer TH, Merricks EP, Raymer RA, Bode AP, Read MS, Nichols TC. Multiple infusions of rehydrated, lyophilized platelets do not induce antiplatelet antibodies or thrombocytopenia in a canine model system. *Thromb and Haemost (Supl)* July 2001 Abstract P2694

63. Nichols TC, Fischer TH, Madden VJ, Sproul MT, Read MS, Merricks EP, Oakeley A, Anderson PW, Malouf NN. Expression of two calcium channels sheds new light on platelet calcium signaling. *Thromb and Haemost (Supl)* July 2001 Abstract OC109

64. Nichols TC, Read MS, Fischer TH, Schaub RG, Keith JC Jr, McCarthy K, Khor SP, Rup B, Leiterman K, Webb C, Warne N, Kadrichu NP, Egilmez-Reynolds N, Mohler M. Pharmacodynamics and pharmacokinetics of recombinant human factor IX (rF.IX) following oral inhalation in hemophilia B dogs. *Thromb and Haemost (Supl)* July 2001 Abstract OC 1007.

65. Fischer TH, Merricks EP, Raymer RA, Bode AP, Read MS, Nichols TC. Positive feedback-amplification for thrombus formation with rehydrated, lyophilized platelets. *Thromb and Haemost (Supl)* July 2001 Abstract P2698.

66. Kay MA, Nakai H, Nichols T, Mount J, Lothrop CD, Glader B, Manno CS, Arruda VR, Herzog RW, High KA. Safety and efficacy studies of AAV-mediate, liver-directed gene therapy for hemophilia B. *Thromb and Haemost (Supl)* July 2001 Abstract OC2491.

67. Lozier JN, Dutra A, Pak E, Zhou N, Zheng Z, Nichols TC, Bellinger DA, Read MS, Morgan RA. Evidence for a canine homologue to human F8A in and near the canine factor VIII gene: A possible mediator of an inversion in the Chapel Hill hemophilia A dog colony. *Blood* 98:39a, 2001

68. Olsen EHN, MacManus IE, Raymer RA, Merricks EP, Fischer TH, Fahs SA, Montgomery RR, Keith JC Jr, Schaub RG, Nichols TC. Existence of a DDAVP releasable vWF pool during IL-11 treatment in vWF+/- and normal (vWF+/+) dogs. *Blood* 98:41a, 2001

69. Fischer TH, Merricks EP, Nichols TC, Raymer RR, Hayes PM, Pearce LB, Bode AP, Manning JE. The co-infusion of rehydrated, lyophilized platelets with HBOC-201 for hemostasis in dilutional thrombocytopenia. *Blood* 98:538a, 2001

70. Arruda VR, Schuettrumpf J, Xiao W, Nichols TC, Robinson N, Ni D, Powell S, Allen J, Herzog RW, High KA. Alternate AAV serotypes results in enhanced factor IX expression in murine and canine models of hemophilia B. *Blood* 98:745a, 2001

71. Arruda VR, Schuettrumpf J, Nichols TC, Herzog RW, Haskins M, Couto LB, Stedman H, High KA. Correction of canine hemophilia B phenotype by intravascular delivery of AAV vector to skeletal muscle. *Blood* 98: 781a, 2001

72. Olsen EHN, Raymer R, Dillow A, Pendharkar S, Merricks E, Fischer TH, McCarthy K, Keith JC Jr, Schaub RG, Nichols TC. Pharmacodynamic effects of RefactoAF and Refacto in hemophilia A dogs. *Blood* 98: 76b, 2001

73. Brodala N, Madianos P, Geva S, Offenbacher S, Beck J, Fischer T, Smith S, Bellinger DA, Nichols TC. Recurrent Porphyromonas gingivalis bacteremia induces atherosclerosis in susceptible pigs. *Ann Periodontol* 2001;6:63-64

74. Brodala N, Madianos P, Champagne C, Offenbacher S, Beck J, Fischer T, Bellinger D, Nichols TC. Transient bacteremia in pigs increases CRP levels and promotes atherogenesis. *J Dent Res* 2001;81 (Spec Iss A); A 400, abstr. 3233

75. Wang L, Nichols TC, Read MS, Bellinger DA, Verma IM, Wilson JM. High level expression of canine FIX in hemophilia B dogs after readministration of AAV2/5 vectors. *Molecular Therapy*. 2002;5(Abstract supplement):S83

76. Arruda VR, Stedman H, Nichols TC, Haskins M, Schuettrumpf J, Herzog RW, Liu YL, Wagner K, Couto L, High KA. Sustained correction of hemophilia B phenotype following intravascular delivery of AAV vector to skeletal muscle. *Molecular Therapy*. 2002;5(Abstract Supplement):S157

77. Chao H, Monahan PE, Elia JR, Camp AS, Nichols TC, Bellinger DA, Samulski RJ, Walsh CE.



Intramuscular delivery of AAV1 vectors resulted in sustained expression of therapeutic levels of FIX in hemophilia B dogs. *Blood*. 2002;100:19a

78. Xu L, Sands MS, Nichols TC, Gao C, Sands MS, Cai SR, Raymer RA, Ponder KP. Retroviral vector-mediated gene therapy for hemophilia B mice and dog. *Blood*. 2003;100:20a

79. Fischer TH, Newton ME, Bode AP, Merricks EP, Nichols TC, Hayes PM, Sheonfisch MH. Evidence that lyophilized red bloodcells exhibit non-pathological range of deformability for normal microcirculation times. *Blood*. 2002;100:287a

80. Olsen EHN, Raymer RA, Dillow A, Keith JC Jr, Schaub RG, Merricks EP, Fischer TH, Nichols TC. Reduction of Bethesda Inhibitors by immunomodulation in hemophilia A dogs receiving ReFacto. *Blood*. 2002;100:91b

81. Brodala N, Madinaos PN, Offenbacher S, Beck JD, Fischer T, Bellinger DA, Baldwin AS, Nichols TC. Porphyromonas gingivalis bacteremia induces systemic inflammation and atherosclerosis in pigs. *J Perio* 2002; 73 (8): 969-970, Winner Balint Orban Memorial Competition, American Association of Periodontology Meeting.

82. Sarkar R, Tetreault R, Gao G-P, Wang L, Bell P, Chandler R, Bellinger DA, Nichols TC, Wilson JM, Kazazian HH. AAV 8 Serotype: Total Correction of Hemophilia A Mice and Partial Correction in Dogs with Canine FVIII. *Molecular Therapy*. 2003;7(Abstract supplement):S26

83. Wang L, Gao G-P, Bell P, Sanmiguel J, Li Y, Nichols TC, Verma IM, Wilson JM. Gene Therapy for Hemophilia B by Novel Serotypes of AAV Vectors. *Molecular Therapy*. 2003;7(Abstract supplement):S26

84. Ehrhardt A, Xu H, Dillow AM, Bellinger DA, Nichols TC, Kay MA. A Gene Deleted Adenoviral Vector Results in Phenotypic Correction of Canine Hemophilia B without Liver Toxicity or Thrombocytopenia. *Molecular Therapy*. 2003;7(Abstract supplement):S26

85. Olsen EHN, McCain AS, Merricks EP, Fischer TH, Dillon IM, Raymer RA, Fahs SA, Montgomery RR, Keith JC Jr, Schaub RG, Nichols TC. Comparative response of plasma VWF in dogs to up-regulation of VWF mRNA by interleukin-11 versus Weibel-Palade body release by desmopressin (DDAVP). *Journal of Thrombosis and Haemostasis* 2003;1: OC347

86. Sarkar R, Tetreault R, Gao G-P, Wang L, Bell P, Chandler R, Nichols TC, Wilson JM, Kazazian HH. Hemophilia A: Total Correction in Mice and Partial Correction in Dogs with Canine FVIII using a new AAV serotype. *Journal of Thrombosis and Haemostasis* 2003;1: OC048

87. Fahs SA, Nichols TC, Bellinger DA, Montgomery RR. Cloning and expression of full length recombinant porcine von Willebrand factor. *Journal of Thrombosis and Haemostasis* 2003;1: OC277

88. Fischer TH, Russell KE, Merricks EP, Nichols TC, Bode AP. The development of pro-hemostatic lyophilized platelets with minimized risk for intravascular coagulation. *Journal of Thrombosis and Haemostasis* 2003;1: OC155

89. McCormack WM, Ubhayakar K, Mane V, Guenther M, Nichols TC, Ng P, Palmer D, Beaudet A, Lee B. Phenotypic Correction of Canine Hemophilia A with a Helper-dependent Adenoviral Encoding Canine FVIII. *American Society of Human Genetics*, abstracts Nov 2003.

90. Sarkar R, Tetreault R, Gao GP, Wang L, Bell P, Chandler R, Bellinger D, Nichols TC, Wilson JM, Kazazain HH. Gene Therapy of Hemophilia A: Total correction of hemophilia A mice and partial correction of hemophilia A dogs with canine FVIII cDNA using the AAV8 serotype. *American Society of Human Genetics*, abstracts Nov 2003.

91. Xu L, Nichols TC, Sarkar R, McCorquodale S, Bellinger D, Ponder KP. Retroviral Vector-Mediated Neonatal Gene Therapy for Hemophilia A Mice and Dogs. *Blood* 2003;102:53a

92. Haberichter SL, Merricks EP, Fahs SA, Christopherson PA, Nichols TC, Montgomery RR. Re-Establishment of VWF-Dependent Weibel-Palade Bodies in VWD Endothelial Cells. *Blood* 2003;102:88a.

93. McCormack WM, Ubhayakar K, Nichols TC, Lee B, Ng P, Palmer D, Mane V, Guenther M. Phenotypic Correction of Canine Hemophilia A with a Helper-Dependent Adenoviral Vector Encoding Canine FVIII. *Blood* 2003;102:251a

94. Xu L, Nichols TC, Sarkar R, McCorquodale S, Bellinger DA, Ponder KP. Retroviral vector mediated neonatal gene therapy results in long-term and therapeutic levels of canine factor VIII expression in hemophilia A mice and dogs. *Molecular Therapy*. 2004;9(Abstract supplement):S34

95. Arruda V, Scallan C, Jian H, Couto L, Herzog RW, Nichols TC, Pierce G, High KA. Comparison of the efficacy on gene transfer by AAV vectors delivered by distinct routes of administration to the liver of hemophilia B dogs. *Molecular Therapy*. 2004;9(Abstract supplement):S103

96. McCormack WM, Bertin TK, Ubhayakar K, Guenther M, Mane VP, Ng P, Nichols TC, Finegold MJ, Palmer D, Beaudet A, Lee BH. Vector genome loss does not account for decline of plasma cFVIII protein in hemophilic dogs that demonstrate long term clinical correction following helper-dependent adenoviral gene therapy. *Molecular Therapy*. 2004;9(Abstract supplement):S159
97. Wang L, Louboutin J-P, Nichols TC, Wilson JM. Novel pseudotyped AAV vectors for hemophilia B gene therapy. *Molecular Therapy*. 2004;9(Abstract supplement):S161
98. Brunetti-Pierri N, Palmer D, Nichols TC, Beaudet AL, Ng P. Phenotypic correction of a hemophilia B dog following systemic administration of a helper-dependent Ad vector encoding canine factor IX. *Molecular Therapy*. 2004;9(Abstract supplement):S163
99. Xu L, Nichols TC, McCorquodale S, Dillow A, Merricks EP, Ponder KP. DDAVP-induced increase of factor VIII activity in blood is likely due to release of factor VIII that is synthesized by endothelial cells. *Blood*. 2004;104:abstract #692.
100. Arruda VR, Stedman HH, Schuettrumpf J, Jiang H, Pierce G, Nichols TC, High KA. novel method of regional intravenous delivery of AAV vector to skeletal muscle results in correction of canine hemophilia B phenotype. *Blood*. 2004;104:abstract #3179
101. Xu L, Haskins ME, Nichols TC, Mei M, O'Donnell P, Bellinger DA, McCorquodale S, Ponder KP. Tolerance after Neonatal Gene Transfer of a Human Factor IX-Expressing Retroviral Vector May Involve Clonal Deletion in C3H Mice and Is Effective in Hemophilia B Dogs *Molecular Therapy*. 2005;10(Abstract supplement):S32
102. Arruda V, Stedman H, Jian H, Pierce G, Schuettrumpf J, Freguia CF, Baila S, Gopal K, Nichols TC, High K. Correction of Hemophilia B Phenotype by Novel Method of Regional Intravenous Delivery of AAV Vector to Skeletal Muscle of Hemophilia B Dogs *Molecular Therapy*. 2005;10(Abstract supplement):S603
103. Brunetti-Pierri N, Nichols T, Palmer D, McCorquodale S, Merricks E, Beaudet A, Ng P. Long-Term Phenotypic Correction of Canine Hemophilia B Following Systemic Administration of Helper Dependent Adenoviral Vector *Molecular Therapy*. 2005;10(Abstract supplement):S607
104. Mingozi F, Sabatino D, Nichols T, McCorquodale S, Arruda V, High K. Long Term Persistence of Canine Factor IX-Specific Th1 Lymphocytes in Regional Lymph Nodes after AAV1-Mediated Intramuscular Gene Transfer in a Hemophilia B Dog *Molecular Therapy*. 2005;10(Abstract supplement):S609
105. Wang L, Calcedo R, Nichols TC, Verma IM, Wilson JM. Sustained Correction of Disease in Nave and AAV2-Pretreated Hemophilia B Dogs Using Pseudotyped AAV Vectors *Molecular Therapy*. 2005;10(Abstract supplement):S1081
106. Merricks EP, Ezban M, Persson E, Raymer RA, Dillow A, McCorquodale S, Nichols TC. Modified Whole Blood Clotting Time Assay Detects Recombinant Human FVIIa and rFVIIa Analog NN1731 in Canine Hemophilia a Blood in a Dose-Dependent Fashion. *Journal of Thrombosis and Haemostasis* 2005; Volume 3, Supplement 1: P1362
107. Hebbel RP, Milbauer L, Rone M, Lillicrap D, Voorberg J, Nichols TC. Use of Engineered Autologous BOC for Gene Therapy of Canine Hemophilia A. □ *Blood*. 106; Abstract #1281. November 16, 2005
108. Hui DJ, Mingozi F, Sabatino DE, McCorquodale S, Dillow A, Nichols TC, Arruda VR, High KA. Characterization of the Immune Response to Canine Factor IX Following AAV-Mediated Intravascular Gene Delivery to Skeletal Muscle in Hemophilia B Dogs. *Blood*. 106, Abstract #1297 November 16 2005
109. Scull CM, Kuruvilla R, Fischer TH, Nichols TC. Gene Transfer to Macrophages with Nanoparticle-Loaded Platelets. *Blood*. 106; Abstract #3043 November 16, 2005
110. Fischer TH, Wolberg AS, Bode AP, Ramer KJ, Nichols TC. Interaction of Recombinant Factor VIIa with Rehydrated, Lyophilized Platelets. *Blood*. 106, Abstract #3994, November 16, 2005□
111. Hui DJ, Mingozi F, Sabatino DE, Dillow A, McCorquodale S, Nichols TC, Arruda VR, High KA. T Cell Responses to Canine Factor IX and AAV Capsid Antigens in Hemophilia B Dogs after Intravascular Gene Delivery to Skeletal Muscle. *Molecular Therapy*. 2006;12(Abstract supplement):S1086
112. Ehrhardt A, Xu H, Dillow AM, Yant SR, Nichols TC, Kay MA. Transposition from a Gene-Deleted Adenoviral Vector Results in Phenotypic Correction in a Canine Model for Hemophilia B. □□ *Molecular Therapy*. 2006;12(Abstract supplement):S11.
113. Sabatino D, Lange AM, Mucci M, Sarkar R, Dillow AM, Nichols TC, Arruda V, Kazazian HH. Long Term Dose Dependent Correction of Hemophilia A Dogs Using AAV-8 and AAV-9 FVIII Gene Transfer. *Blood* 2006 (abstract supplement) :S999
114. Jankowitz RG, Chapman H, Merricks E, Kloos M, Dillow A, Nichols TC, Ragni MV. Recombinant



human IL-11 (rhIL-11), Neumega) Increases VWF Activity in Type 1 von Willebrand Disease. Blood 2006 (abstract supplement):S1003

115. Jankowitz RG, Chapman H, Merricks E, Kloos M, Dillow A, Nichols TC, Ragni MV. Recombinant IL-11 Increases VWF and VWF MRNA in Type 1 VWD. Abstract N° O-T-062, XXI ISTH, July 2007.

116. D. Viuff D, Ezban M, Lind V, Dillow A, Raymer R, Merricks E, Nichols T. Effect of rFVIIIa and NN1731 (rFVIIa analogue) on Thromboelastography (TEG) in Whole blood obtained from Hemophilia A dogs. Abstract N° P-W-113, XXI ISTH, July 2007

## PATENTS

1. Purified and isolated platelet calcium channel nucleic acids and polypeptides and therapeutic and screening methods using same. US Provisional Patent Application Serial No. 60/258,169. Inventors - Malouf N, Nichols, TC, and Merricks EM.
2. Freeze-dried red blood cells. (Filed 8/02, PCT App. NO PCT/US002/27898. Inventors Fischer T, Bode A, Nichols, TC, and Read MS. Assignee – UNC-CH and Ecu, Licensed to Hemocellular Therapeutics, Inc
3. Delivery of therapeutic agents with rehydrated lyophilized platelets. (Filed 6/03, US Provisional Patent Application Ser. No. 60.471,005). Inventors – Nichols TC, Bode A, Read MS, and Fischer T. Summary This patent relates to using lyophilized platelets to deliver therapeutics. Assignee – UNC-CH and Ecu, Licensed to Hemocellular Therapeutics, Inc.

## TEACHING RECORD AND RESPONSIBILITIES

a. Attending in the cardiac catheterization laboratory: I attended in the cardiac catheterization laboratory for 17 years teaching medical students, radiology students, cardiovascular technologists, medicine housestaff, and cardiology fellows. This work often included providing consultation with referring attendings inside and outside UNC. In the cardiac catheterization laboratory, I was responsible for teaching cardiology fellows all aspects of cardiac catheterization, hemodynamic physiology, patient selection for surgery, balloon and stent angioplasty, and valvuloplasty.

b. Attending on the in-patient cardiology ward and consult service. This assignment requires the attending to mentor and supervise cardiology fellows, housestaff from Internal Medicine and several other Departments and medical students on the in-patient cardiology service. The attending and the fellow also see in-patient cardiology consults when the consult service is unavailable (each weekend, holidays, nights).

c. Cardiovascular Radiology lectures to the Radiology housestaff: One to three lectures per year to the radiology residents on cardiovascular radiographic anatomy and pathology 1997- 2000.

e. Graduate students on whose thesis committee I currently serve or have served:

Department of Pathology	Date Completed
1. Alyssa A Gullledge	1999
2. Tracey C Dawson	1999
3. Gavin Gordin	2000
4. Jen Wemhoff	2001
Oral Biology	
1. Yong Liu	pending

f. Pathology 213 Mechanisms of Disease, Unit Director for section entitled "Vascular Disease." This is a required course for Pathology graduate students. I have responsible for giving and scheduling lectures and administering and grading the exam for the past 7 years.

g. Mentor for Research Trainees supported on the NIH Training Grant in Experimental Cardiology.

I have been responsible for recruiting and training pre and post doctoral research trainees (list available upon request)

h. Research conferences/seminars at UNC (selected)

Department	Date	Title of Seminar
Department Pathology	November 1997	Genetically determined susceptibility to atherosclerosis in vWD pigs.

**i. Department of Medicine Morbidity and Mortality Conference**

- (i) Morbidity and Mortality conference discussant for "Uremic Pericarditis" March 7, 1995
- (ii) CPC Discussant July 30, 1996, in a case of thrombosed prosthetic aortic valve.
- (iii) CPC Discussant April 27, 1999, in a case of constrictive pericarditis.

**j. AHEC conferences (recent)**

<u>Location</u>	<u>Date</u>	<u>Title of Seminar</u>
Moore Regional Hospital	Feb 8, 1996	Coronary Atherectomy
Wake/Dix	April 13, 1999	Atherosclerosis in 1999
Moses Cone	Spring 2000	Atherosclerosis Update
Mountain AHEC	Spring 2002	Lipids and Inflammation in Atherosclerosis
Moses Cone	Spring 2003	Inflammation and Atherosclerosis
Wilmington	Spring 2006	Atherosclerosis and Periodontitis
Wake/Dix	Spring 2007	Atherosclerosis in Insulin Resistant Pig

**Summary of Attending Responsibilities That Include Teaching from 2000 through 2006**

	<u>2000-2001</u>	<u>2001-2002</u>	<u>2002-2003</u>	<u>2003-2004</u>	<u>2004-2005</u>	<u>2005-2006</u>
1. In-Patient Cardiology Ward and Consults						
	2 months	3 months	3 months	3 months	3 months	3 months
2. Cardiac Catheterization Laboratory Night Call (25-33.3% of total attending call)						
	3 months	3 months				
3. Cardiac Catheterization Laboratory Day Time						
	1 day/week	1 day/week				
4. Cardiology Clinic		1/2 day/wk	1/2 day/wk	1/2 day/wk	1/2 day/month	1/2 day/month
5. ECG reading	1 day/month	1 day/month	1 day/month	1 day/month	1 day/month	1 day/month

**SELECTED INVITED SEMINARS AND GRAND ROUNDS PRESENTED AT OTHER INSTITUTIONS, NATIONAL OR INTERNATIONAL MEETINGS 7/1/96 – 2005:**

<u>Department/Meeting Name</u>	<u>Location</u>	<u>Date</u>	<u>Role</u>
Department of Reproductive Medicine	NCSU Vet School	11/97	Increased Suceptibility to Atherosclerosis in VWD pigs
70 th Scientific Meetings AHA	Orlando, FL	11/97	Vascular Biology Abstract Session Moderator
National Hemophilia Foundation Gene Therapy Workshop	Scripps Inst La Jolla, CA	11/98	Title: Coagulation assays in the monitoring of gene therapy of hemophilia A and hemophilia B in dogs
National Hemophilia Foundation Gene Therapy Workshop	Washington D.C.	3/00	Title: Absence of circulating F.IX antigen in the Chapel Hill strain of hemophilia B dogs
National Hemophilia Foundation	Salk Institute	4/01	Title: Summary of Gene Therapy in

## EXHIBIT A

Nichols, Timothy C.

Gene Therapy Workshop	La Jolla, CA		Hemophilia A and Hemophilia B dogs
American Acad of Periodontology NIDCR	Bethesda, MD	4/01	Title: Role of NF-kappaB in Inflammation, Periodontitis, and Atherogenesis
American Society of Hematology	Orlando, FL	12/01	Vascular Biology Abstract Session Moderator
Hematology Grand Rounds	Univ. Pittsburg	11/02	Title: Preclinical gene therapy studies and new approaches to treatments for hemophilia and vWD
National Hemophilia Foundation Gene Therapy Workshop	Salk Institute La Jolla, CA	4/03	Title: Sensitivity of Coagulation Assays Used to Monitor Gene Therapy of Hemophilia A and Hemophilia B dogs
2003 Scientific Subcommittees Scientific & Standardization Committee: <i>Porphyromonas gingivalis</i> induces Animal, Cellular & Molecular Models International Society Thrombosis & Haemostasis	Birmingham, England	7/03	Title: Recurrent bacteremia with systemic inflammation and atherosclerosis in normocholesterolemic pigs
Hematology Grand Rounds	Univ. of Penn Philadelphia PA	3/04	Title: Molecular basis for new treatments for hemophilia and vWD
National Hemophilia Foundation Gene Therapy Workshop	Univ. of Penn Philadelphia PA	4/05	Title: Molecular Defect and Cytokine-Induced Gene Expression in Canine VWD
2005 Scientific Subcommittees Scientific & Standardization Committee: Animal, Cellular & Molecular Models International Society Thrombosis & Haemostasis	Sydney, Australia	7/05	Title: Recurrent bacteremia with <i>Porphyromonas gingivalis</i> induces atherosclerosis in normo and hypercholesterolemic pigs
UNC SOM Frontiers in Medicine Complications of Diabetes Mellitus Clinical Challenges and Research Advances	Chapel Hill	12/05	Atherosclerosis in insulin resistant familial hypercholesterolemic pigs

## ORGANIZATION OF NATIONAL OR INTERNATIONAL MEETINGS

<u>Meeting Name</u>	<u>Location</u>	<u>Date</u>	<u>Title of Talk/Session/Symposium</u>
7 <sup>th</sup> Annual Symposium of the Center for Thrombosis and Hemostasis	Chapel Hill	May 2000	Program Organizer for conference entitled: "Etiology and Treatment of Coronary Arterial Thrombosis: Basic Science and New Clinical Approaches"
XVIII Congress International Society Of Thrombosis and Hemostasis	Paris	July 2001	Program Organizer
XIX Congress International Society Of Thrombosis and Hemostasis	Birmingham England	July 2003	Program Organizer

XX Congress International Society    Sydney    July 2005    Program Organizer  
Of Thrombosis and Hemostasis    Australia

UNC SOM Frontiers in Medicine    Chapel Hill    Dec 2005    Program Organizer  
Complications of Diabetes Mellitus  
Clinical Challenges and Research Advances

### Grants / Other Support

**Timothy Nichols, M.D.**

#### ACTIVE

2 R24-HL63098 ( <u>Nichols TC</u> , PI) NIH/NHLBI Maintenance of Animal Models of Human Hemophilia and vWD  The major goals of this project are to produce and maintain hemophilic and von Willebrand Disease animals for performing independent and collaborative research studies.	07/01/03 - 06/30/08 Annual Direct Costs \$499,957	20%
<u>OVERLAP: none.</u>		
R01 HL69364 (Clemmons DR, PI; <u>Nichols TC</u> Co-I) NIH/NHLBI Atherosclerosis in Insulin-Resistant, Hyperlipidemic Pigs.  The major goals of this project are to develop and characterize of insulin-resistant atherosclerotic pigs.	09/30/01-08/31/06 Annual Direct Costs \$367,325	20%
<u>OVERLAP: none.</u>		
R01 (Ponder K, Washington Univ, PI; <u>Nichols TC</u> , Co-I) NIH/NHLBI Gene Therapy Blood Protein Deficiencies.  The major goals of this project are to optimize strategies for gene therapy of hemophilia utilizing liver-directed retroviral vectors.	02/01/02 – 12/31/05 Annual Direct Costs \$38,682	5%
<u>OVERLAP: none.</u>		
2P01 HL64190, (High K, Univ. of Penn. PI) NIH/NHLBI Gene Therapy for Hemophilia  Core C: Canine Core Role for <u>Nichols TC</u> : Canine Core Director, subcontract at UNC The major goals of this project are to utilize novel AAV vectors to treat hemophilia.	4/1/05-3/31/10 Annual Direct Costs: \$113,000	10%
<u>OVERLAP: none.</u>		

U01DE13940 (Offenbacher S, PI; <u>Nichols TC</u> , Co-I) NIH/NIDCR A Periodontal Program to Prevent Cardiovascular Events  The major goals of this project are to conduct a pilot clinical trial to determine the role of periodontitis on cardiovascular events.	07/15/01 – 07/14/04 (continued)	0%
---	---------------------------------	----

OVERLAP: none.

P20 Sartor B, P.I. Non-invasive Assessment of Inflammation  SubProject PI <u>Nichols TC</u> , SubProject Title: Subproject: Identification of Molecular Targets for Noninvasive Detection of Inflammation in Atherosclerosis in FH Pigs	07/1/05 – 06/30/06 \$50,000	5%
---	--------------------------------	----

OVERLAP: none.

P20 Sartor B, P.I. Non-invasive Assessment of Inflammation  SubProject PIs Gallippi C, <u>Nichols TC</u> , Fischer T. SubProject Title: Novel Ultrasound Probes for Molecular Imaging of Vascular Inflammation in Atherogenesis	09/1/05 – 08/31/06 \$50,000	5%
---	--------------------------------	----

OVERLAP: none.

STTR Clemmons DR, P.I. The Development of Novel Methods for inhibiting atherosclerosis in diabetes.  The major goals of this project are to develop and test novel strategies for inhibiting atherosclerosis in pig models	03/1/06 – 02/28/07 \$70,0201 to UNC	5%
---	--	----

OVERLAP: none.

#### FUNDED – START DATE PENDING

SBIR (Hackett PB & McIVOR S, U MN, PI; Nichols, TC: Co-I) NIH Sleeping Beauty Mediated Gene Therapy for Hemophilia  The major goals of this project are to develop transposon mediated gene therapy for hemophilia.	11/01/05 to 10/31/06 Annual Direct Costs requested for UNC: \$120,182 Start date pending.	20%
---	---	-----

OVERLAP: none.

**EXHIBIT A**

Nichols, Timothy C.

SBIR (Velandar W, U Nebraska PI; <u>Nichols TC</u> : Co-I) NIH cGMP Recombinant Human Factor IX in hemophilia B therapy  The major goals of this project are to test recombinant F.IX made in pig mammary glands. <u>OVERLAP: none.</u>	04/01/05-03/31/10 Annual Direct Costs requested for UNC: \$141,938 Start date pending	15%
--	---	-----

**PENDING**

R01 Wang, Univ of Penn, P.I.; Nichols, TC, Co-I NIH Pseudotyped AAV Vector for Hemophilia B Gene Therapy  The major goals of this project are to utilize novel AAV vectors to treat hemophilia. <u>OVERLAP: none.</u>	7/1/06-6/30/11 Annual Direct Costs requested for UNC: \$75,477	10%
--	---	-----

STTR Selzman C. PI, <u>Nichols TC</u> CoI NF-kappaB Inhibition to Prevent Myocardial Reperfusion Injury.  The major goals of this project are to test NF-kappaB inhibitors in myocardial reperfusion injury <u>OVERLAP: none.</u>	9/1/06 – 8/30/07 Annual Direct Costs requested for UNC: \$106,037	10%
---	--	-----

**PROFESSIONAL SERVICE**School of Medicine

1. Medical School Admissions Committee Secondary Reviewer, September 1998 - 1999

UNC-CH

1. Chair, search committee, for assistant professor (EPA 804), December 1990 through April 1991.
2. Search Committee for Director Division of Laboratory Animal Medicine 2002 and 2003
3. P20 Roadmap Executive Committee for P20 RR020764 Noninvasive approaches to assessing inflammation, Balfour Sartor PI, 2004 -
4. Executive Council of the Carolina Cardiovascular Biology Center Scientific Advisory Committee Center for Carolina Cardiovascular Biology Center, WC Patterson, Director, 2005 -

UNC Hospitals

1. Housestaff Council, Chairman, 1981-1982, North Carolina Memorial Hospital
2. Executive Committee, Member, 1981-1982, North Carolina Memorial Hospital
5. Housestaff Faculty Liaison Committee, Member, 1978-1982, North Carolina Memorial Hospital

North Carolina

1. Reviewer: North Carolina American Heart Association Research Committee Grant Reviewer 1988-93.
2. UNC-CH director of American Heart Association Summer High School Fellowship Program 1992 –1999

National and International

1. NIH Study Section: NHLBI Program Project Grant Reviewer 2003
2. Co-chair Animal, Cellular & Molecular Models Subcommittee of the Scientific & Standardization Committee for the International Society Thrombosis & Haemostasis 2001 - current

**OTHER ADMINISTRATIVE ACTIVITIES**

Associate Director, C.V. Richardson Cardiac Catheterization Laboratory, 1986-1994

Acting Director, C.V. Richardson Catheterization Laboratory, 1987-88.

Associate Director Francis Owen Blood Research Laboratory 1995 - to 1999

Director Francis Owen Blood Research Laboratory (FOBRL) 1999 –

Please see description of FOBRL on next page.

**SCIENTIFIC ADVISORY BOARD MEMBERSHIPS**

1. Cell Based Delivery, Providence Rhode Island
2. Wyeth Research, Cambridge MA
3. Colgate Research, New York NY

## CHARACTERIZATION OF $\text{Ca}^{2+}$ AND $\text{K}^{+}$ CURRENTS IN THE HUMAN JURKAT T CELL LINE: EFFECTS OF PHYTOHAEMAGGLUTININ

By GILLES DUPUIS\*, JOSÉE HÉROUX\* AND MARCEL D. PAYET††

*From the \*Departments of Biochemistry and †Physiology and Biophysics,  
Faculty of Medicine, University of Sherbrooke, Sherbrooke, Quebec, Canada J1H 5N4*

*(Received 1 June 1988)*

### SUMMARY

1. Inward and outward currents were recorded in the human Jurkat T cell line using the whole-cell configuration of the patch-clamp technique.

2. The transient outward current was activated at membrane potentials positive to  $-60$  mV. The activation time constant–voltage relationship decreased from 17 ms to 2 ms for membrane potentials ranging from  $-40$  to  $+40$  mV. The inactivation phase could be fitted by a single-exponential function and the inactivation time constant decreased from 250 ms to 150 ms for membrane potentials ranging from  $-20$  to  $+100$  mV.

3. The steady-state inactivation–voltage relationship showed a mid-point potential of  $-32 \pm 2.6$  mV, and the slope factor was  $10.8 \pm 1.8$  mV ( $n = 3$ ).

4. The calcium ionophore A23187 provoked a decrease in the amplitude of the outward current, suggesting a dependence of this current on the cytosolic concentration of  $\text{Ca}^{2+}$ .

5. The  $\text{K}^{+}$  outward current was blocked by tetraethylammonium (TEA, Michaelis–Menten constant ( $K_m$ ), 6 mM) and by the calcium channel blockers  $\text{Ni}^{2+}$ ,  $\text{Co}^{2+}$ ,  $\text{Mn}^{2+}$  and  $\text{Cd}^{2+}$ .

6. Forty per cent ( $n = 120$ ) of the patched Jurkat cells displayed an inward current. In a physiological medium containing  $\text{Ca}^{2+}$  (2.2 mM), the inward current threshold voltage was  $-60$  mV, the maximum current was observed at  $-40$  mV and the zero current voltage was positive to  $+20$  mV. At negative membrane potentials, the time required to reach 50% of the maximum amplitude was 60 ms and grew shorter with increasing depolarization, reaching a value of 5 ms at  $-5$  mV. The inactivation of the inward current was very slow and the time constant varied from 1200 ms at  $-35$  mV to approximately 250 ms for potentials positive to  $-10$  mV.

7. The current availability had a value of one for potentials negative to  $-50$  mV and zero for potentials positive to  $-15$  mV. The mid-point potential was  $-31 \pm 3.4$  mV and the slope factor was  $3.3 \pm 0.2$  mV ( $n = 3$ ).

8. The inward channels were permeable to  $\text{Sr}^{2+}$ , but were blocked by classical  $\text{Ca}^{2+}$  channel inhibitors such as  $\text{Co}^{2+}$ ,  $\text{Mn}^{2+}$  and  $\text{Ni}^{2+}$ .

9. *Phaseolus vulgaris* phytohaemagglutinin (PHA), an inducer of interleukin-2 production in Jurkat cells, increased the inward current amplitude by  $32 \pm 20\%$

† To whom reprint requests should be addressed.



## EXHIBIT B

136

G. DUPUIS, J. HÉROUX AND M. D. PAYET

( $n = 4$ ). This increase was concomitant with a decrease ( $45 \pm 12\%$ ) in the amplitude of the outward current, but only when the current was carried by  $\text{Ca}^{2+}$ . In the case of cells that did not show a  $\text{Ca}^{2+}$  inward current, the amplitude of the outward current was increased by  $17.6 \pm 13\%$  ( $n = 5$ ) at  $-20$  mV.

10. Because PHA stimulation of interleukin-2 production by Jurkat cells depends on an increase in  $[\text{Ca}^{2+}]_i$ , we suggest that this response depends, at least in part, on the stimulation of voltage-dependent  $\text{Ca}^{2+}$  channels.

### INTRODUCTION

The addition of stimulants such as mitogens, monoclonal antibodies or antigens to lymphocytes cultured *in vitro* results in the perturbation of a series of metabolic processes and cell division (MacDonald & Nabholz, 1986; Cambier & Ransom, 1987; Linch, Wallace & O'Flynn, 1987). Significant changes in the rate of cation transport are amongst the earliest detectable events and such changes are related to subsequent lymphocyte proliferation (Kaplan, 1978; Deutsch & Price, 1982; Owens & Kaplan, 1982). Ionic channels must therefore play a determining role in triggering the cascade of events leading to mitosis. The patch-clamp technique (Hamill, Marty, Neher, Sakmann & Sigworth, 1981) has been used to obtain evidence suggesting that a transient outward  $\text{K}^+$  flux may play a key role in cellular response, including lymphocyte activation (DeCoursey, Chandy, Gupta & Cahalan, 1984; Fukushima, Hagiwara & Henkart, 1984; Matteson & Deutsch, 1984; Cahalan, Chandy, DeCoursey & Gupta, 1985). In addition, the use of fluorescent calcium chelators (Tsien, Pozzan & Rink, 1982) has demonstrated that an increase in  $[\text{Ca}^{2+}]_i$  is an essential part of the triggering signal of lymphocyte stimulation (Weiss, Imboden, Shoback & Stobo, 1984; Weiss, Imboden, Hardy, Manger, Terhorst & Stobo, 1986; Alcover, Ramarli, Richardson, Chang & Reinherz, 1987; Gelfand, Mills, Cheung, Lee & Grinstein, 1987). Michell (1975) originally proposed that  $\text{Ca}^{2+}$  channels may be responsible for  $\text{Ca}^{2+}$  entry into the cells, and unitary inward currents, of which the probability of opening is increased by lectins, have recently been recorded (Kuno, Goronzy, Weyand & Gardner, 1986; Kuno & Gardner, 1987). However, macroscopic  $\text{Ca}^{2+}$  inward currents in human T cells have not been clearly characterized yet, nor has the effect of phytohaemagglutinin (PHA) on this current been studied.

In the present report, we have used the whole-cell configuration of the patch-clamp technique to investigate the electrical properties of leukemic human Jurkat T cells (Schneider, Schwenk & Bornkmann, 1977) and the effect of PHA, a mitogenic lectin that induces IL-2 production in these cells (Gillis & Watson, 1980; Dupuis & Bastin, 1988). Our results show the existence of a voltage-dependent  $\text{K}^+$  channel characterized by a rapid activation and a slow inactivation. The properties of this channel are similar to those described for the well-known delayed rectifier  $\text{K}^+$  current of nerve and muscle cells. The current amplitude of the  $\text{K}^+$  channel is decreased in the presence of the  $\text{Ca}^{2+}$  ionophore A23187. We also present data that suggest the presence of a voltage-dependent inward current that can be conclusively attributed to  $\text{Ca}^{2+}$  ions. PHA consistently increased the inward current with a concomitant decrease in outward  $\text{K}^+$  current. Our data suggest that the previously reported increase in PHA-dependent  $[\text{Ca}^{2+}]_i$  in Jurkat cells (Weiss *et al.* 1986) is due, at least

## EXHIBIT B

### $\text{Ca}^{2+}$ AND $\text{K}^{+}$ CURRENTS IN JURKAT T CELLS

137

in part, to voltage-dependent  $\text{Ca}^{2+}$  channels, whereas outward  $\text{K}^{+}$  current is indirectly mediated through a  $[\text{Ca}^{2+}]_i$  increase during the early phase of stimulation. In support of this interpretation, PHA increased slightly the outward current in Jurkat cells that did not show a  $\text{Ca}^{2+}$  current, in agreement with reports of Cahalan *et al.* (1985) and Decoursey *et al.* (1984) in the case of peripheral blood T cells.

## METHODS

### Materials

Bovine serum albumin (BSA), antibiotics and poly-L-lysine were purchased from Sigma Chemical Co. (St Louis, Mo, USA). Fetal bovine serum and culture media came from Flow Laboratories (Montreal). Gey's balanced salt solution (GBSS) and RPMI 1640 medium were from Gibco (Grand Island Biologicals, Grand Island, NY, USA). PHA from *Phaseolus vulgaris* (red kidney bean) was prepared in our laboratory (Dupuis & Bastin, 1988). It showed one Coomassie Brilliant Blue-positive band by sodium dodecylsulphate-polyacrylamide gel electrophoretic analysis ( $M_r$  33000).

### Cell cultures

Jurkat 77 6·8 cells were kindly provided by Dr. K. A. Smith (Dartmouth Medical School, Hanover, NH, USA) and maintained in RPMI 1640 medium containing penicillin (100 units/ml), streptomycin (100  $\mu\text{g}/\text{ml}$ ) and garamycin (40  $\mu\text{g}/\text{ml}$ ). The medium was supplemented with 10% heat-inactivated (56 °C for 20 min) fetal bovine serum.

### Patch-clamp experiments

These were performed with Jurkat 77 6·8 cells resting in a Petri dish that had been coated 24 h earlier with poly-L-lysine (0·1 mg/ml) dissolved in GBSS and washed with GBSS and BSA (1%). The bath solution (GBSS) contained (mM): NaCl, 120;  $\text{CaCl}_2$ , 2·12; KCl, 5;  $\text{MgCl}_2$ , 2·2;  $\text{MgSO}_4$ , 0·6; D-glucose, 5·6; HEPES, 39; at pH 7·4. Experiments were carried out at 20 °C. The patch electrodes were filled with (mM): KCl, 120; NaCl, 20;  $\text{CaCl}_2$ , 1; EGTA, 11; HEPES, 5; at pH 7·3. Where appropriate, KCl was replaced by an equimolar concentration of CsCl to suppress outward current. The pipette resistance (Pyrex glass, Corning No. 7740) ranged from 4 to 8 M $\Omega$ , and the seal resistance varied between 10 and 50 G $\Omega$ . Once the seal was established, the cell membrane was ruptured by applying negative pressure. Series resistance was corrected empirically until the rigging point was attained. Experiments were performed using an Axopatch 1-B amplifier. Currents were low-pass filtered (1 kHz) and digitalized on-line via a PDP 11/23 computer. After whole-cell configuration was achieved, the system was left for 10–15 min to allow the voltage dependency of various parameters to stabilize. The cells were then stimulated at a low rate (1 stimulus/30 s) to avoid accumulation of inactivation. The leak current was subtracted from the current-voltage curves.

## RESULTS

### Whole-cell currents

One example of currents, recorded from a single Jurkat T cell maintained in GBSS, is illustrated in Fig. 1A. In this case, the holding potential (HP) was  $-80$  mV. As shown in the figure, a membrane potential less negative than  $-40$  mV activated an inward current which was followed by an outward current that increased with further membrane depolarization. The current-voltage relationship, measured at the peak of either the inward or the outward currents, is shown in Fig. 1B. The threshold voltage was observed at approximately  $-40$  mV, whereas the maximum current was obtained at a potential of  $-20$  mV. The current is directed outward for potentials positive to  $+5$  mV. These results indicated that outward as well as inward currents could be recorded in the human Jurkat T cell line.

## EXHIBIT B

G. DUPUIS, J. HÉROUX AND M. D. PAYET




Fig. 1. Global current measured by patch clamp in a Jurkat T cell. *A*, dependency of inward and outward currents on membrane potential. Responses were recorded as a function of depolarizing pulses at  $-70$ ,  $-20$ ,  $-10$ ,  $0$ ,  $10$ ,  $20$ ,  $40$  and  $50$  mV. The HP was  $-80$  mV. Depolarizing pulses were applied at 30 s intervals. *B*, current-voltage relationship in Jurkat cells. The current amplitude was measured at the inward and outward peak values.

#### Outward current

The outward current was studied in cells that showed no inward current. From an HP of  $-80$  mV, the outward current began to be activated for membrane potentials positive to  $-60$  mV. Data shown in Fig. 2*A* indicate that the current was rapidly activated and then was slowly inactivated to a non-zero steady state. The current-

## EXHIBIT B

### $Ca^{2+}$ AND $K^+$ CURRENTS IN JURKAT T CELLS

139

voltage relationship is shown in Fig. 2*B*. In this case, the amplitude was measured at the peak of the outward current after subtracting the leak current.

#### *Kinetics of activation*

Current traces plotted on an expanded time scale showed that the activation phase was sigmoidal and that the rate of activation increased with membrane depolarization (Fig. 3*A*, inset). Kinetic analysis of this current was performed for various




Fig. 2. Outward  $K^+$  current in Jurkat T cells. *A*, time course profile of the  $K^+$  current in a single cell. Depolarizing pulses of 2.8 s duration were applied at 1 min intervals from  $-80$  mV to  $+40$  mV, by 10 mV increments. The current was recorded 10 min after the whole-cell configuration patch was established. *B*, current-voltage relationship for the outward  $K^+$  current, after subtracting the leak current. The HP was  $-80$  mV.

voltage values. The activation phase was fitted using the following equation (Hodgkin & Huxley, 1952),

$$I_t = I_{\max}(1 - e^{-t/\tau_n})^x, \quad (1)$$

where  $I_{\max}$  is the maximum  $K^+$  current,  $\tau_n$  is the activation time constant and,  $x$  is the exponent of the activation process. We found that the best fit of the experimental data was for  $x = 4$ . Figure 3*A* shows results obtained with four different Jurkat cells.

## EXHIBIT B

G. DUPUIS, J. HÉROUX AND M. D. PAYET




Fig. 3. Kinetics of the outward K<sup>+</sup> current in a Jurkat T lymphocyte. *A*, activation phase: the activation phase is illustrated in the inset. The time constant of the activation phase ( $\tau_n$ ) is plotted as a function of the membrane potential. Each point is the mean of four different experiments. The bars represent s.e.m. *B*, inactivation phase: the inactivation phase was fitted with a single-exponential function. The time constant ( $\tau_i$ ) is plotted as a function of the membrane potential. The values were obtained from the tail current (■) and from the inactivation phase of the current (▲). Each point is the mean of four to five experiments. The bars represent s.e.m. Inset: fitted curves obtained using the following equation,

$$I_t = I_{\max}(1 - e^{-t/\tau_n})e^{-t/\tau_i} + I_l,$$

where  $I_{\max}$  is the maximum current at a given potential,  $\tau_n$  and  $\tau_i$  are the time constants of the activation and inactivation process, and  $I_l$  is a time-independent leak current.

## EXHIBIT B

### $\text{Ca}^{2+}$ AND $\text{K}^+$ CURRENTS IN JURKAT T CELLS

141

It was found that  $\tau_n$  was voltage-dependent and decreased from 17 ms at  $-40$  mV to 2 ms at  $+40$  mV.

#### *Kinetics of inactivation*

As shown in Fig. 2A, the outward current was inactivated on sustained membrane depolarization. The inactivation phase of the current was fitted by a single-exponential function and the inactivation time constant ( $\tau_i$ ) was plotted for various




Fig. 4. Inactivation of the outward  $\text{K}^+$  current in a Jurkat T cell. *A*, time-dependent accumulation of the current elicited by a depolarizing pulse to 0 mV from an HP of  $-80$  mV. The pulse was applied every 10 s. *B*, voltage dependence of the steady-state inactivation. The current elicited by a pulse to  $+10$  mV was recorded for various HPs that were maintained for 2 min to allow for the equilibrium to be reached. The normalized peak current is plotted as a function of the HP. The continuous line is fitted to the experimental data using eqn (2), where the values for  $V_{\infty}$  and  $k$  are  $-35$  mV and  $13$  mV, respectively.

membrane potentials. Results from these experiments are shown in Fig. 3B ( $\blacktriangle$ ). In the case of potentials ranging between  $-20$  and  $+100$  mV,  $\tau_i$  decreased from 250 ms to 150 ms. The deactivation time constant of the tail current was obtained by stepping the membrane potential from  $-80$  mV to  $-10$  mV with a brief pulse, followed by a test pulse applied at various levels. The decay of the tail current was

## EXHIBIT B

142

G. DUPUIS, J. HÉROUX AND M. D. PAYET

fitted by a single-exponential function. The time constant of the tail current ( $\tau_{\text{tail}}$ ) was plotted as a function of the test pulse voltage as shown in Fig. 3B (■).

The inactivation of the outward current was measured as a function of time intervals between stimulation or under steady-state conditions. The accumulation of the conductance inactivation was tested by stepping the membrane to +10 mV from an HP of -80 mV, at a frequency of 1 stimulation/10 s. Under these experimental




Fig. 5. Zero current voltage of the outward  $K^+$  current in a Jurkat T cell. *A*, the tail currents were obtained by stepping the membrane potential to +20 mV and then repolarizing to different levels. *B*, current-voltage relationship for the tail current. The current amplitude is plotted as a function of the repolarizing potential. The zero current voltage was estimated to be -61 mV.

conditions, the current amplitude decreased rapidly, as shown in Fig. 4*A*. The voltage dependence of the steady-state inactivation of the outward current was determined by varying the HP and recording the current at a constant membrane potential that brought about full current activation. The time interval between each sweep was 2 min. The inactivation-voltage curve obtained under these conditions is shown in Fig. 4*B*. The curve (continuous) was traced according to the Boltzmann equation,

$$j_{\infty} = 1/[1 + \exp(V - V_k)/k], \quad (2)$$

## EXHIBIT B




Fig. 6. Effect of the A23187 ionophore on  $\text{K}^+$  current in a Jurkat T lymphocyte. *A*, responses to a depolarizing voltage at  $-10$  mV were recorded (1) before and (2) 12 min after the addition of A23187 ( $1 \mu\text{M}$ ). The HP was  $-80$  mV. *B*, current-voltage relationship of the  $\text{K}^+$  current before (■) and after (▼) the addition of A23187 ( $1 \mu\text{M}$ ). Depolarizing pulses were applied from an HP of  $-80$  mV. *C*, blockage of the outward current by TEA. TEA was added, at various concentrations, to Jurkat cells bathed in GBSS. The current was measured after attaining steady state (5 min). Cells bathed in GBSS (1, control) and in the presence of TEA (mM): 1 (2) 5, (3), 9 (4) and 13 (5). The HP was  $-80$  mV and the membrane potential was  $-20$  mV. *D*, blockage of the outward current 2 min after the addition of  $\text{Ni}^{2+}$  ( $1$  mM). The HP was  $-80$  mV and the membrane potential was  $+20$  mV.

where  $V$  is the membrane potential,  $V_k$  is the mid-point potential, and  $k$  is the slope factor. The values of the different parameters were obtained by a non-linear least-squares method. Using three different cells, these values were  $-32 \pm 2.6$  and  $10.8 \pm 1.8$  mV, respectively.

### Zero current voltage

The zero current voltage of the outward current was not easily determined from the current-voltage relationship (Fig. 1*B*), and the tail current method was used. Figure 5*A* shows tail currents observed when cells were placed in GBSS containing  $5.4$  mM-KCl. From an HP of  $-80$  mV, a brief pulse to  $+10$  mV elicited an outward current, after which the cell was plotted as a function of the repolarizing voltage and



## EXHIBIT B

144

G. DUPUIS, J. HÉROUX AND M. D. PAYET

the results are shown in Fig. 5B. It was estimated that the zero current voltage had a value of  $-61$  mV. An average of  $-61.3 \pm 3.5$  mV was found ( $n = 3$ ).

### Sensitivity to $\text{Ca}^{2+}$

Several groups have reported the sensitivity of  $\text{K}^+$  channels to variations in  $\text{Ca}^{2+}$  concentrations in a number of somatic cells (Meech, 1978). We therefore asked the




Fig. 7. Slow inward current in Jurkat T cells. The current was recorded with CsCl-filled pipettes in order to block the outward current. The external medium contained  $2.2$  mM- $\text{CaCl}_2$ . *A*, current traces obtained for depolarizing pulses from  $-80$  mV to  $+20$  mV, in  $10$  mV increments. The HP was  $-80$  mV. *B*, current-voltage relationship for the slow inward current. The current starts to be activated at  $-60$  mV and zero current voltage is found at  $+25$  mV. The HP was  $-80$  mV. *C*, tail currents were obtained by stepping the membrane potential to  $+10$  mV and then applying a repolarizing pulse from  $-10$  mV to  $+30$  mV, in  $5$  mV increments. *D*, current-voltage relationship for the tail current.

question whether this was the case for Jurkat cells.  $[\text{Ca}^{2+}]_i$  was increased by incubating the cells with the well-known ionophore A23187 and the results are shown in Fig. 6A. A significant decrease in the current amplitude was evident after  $10$  min of incubation. Similar results were obtained with six different patched cells, where the current amplitude was decreased by  $31 \pm 16\%$ . Current-voltage relationships in the case of cells incubated in the presence ( $\blacktriangledown$ ) or absence ( $\blacksquare$ ) of A23187 are shown in Fig. 6B. At  $0$  mV, the amplitude of the current was decreased by approximately  $34\%$ .

## EXHIBIT B

### $\text{Ca}^{2+}$ AND $\text{K}^+$ CURRENTS IN JURKAT T CELLS

145

The possibility of a direct effect of A23187 on  $\text{K}^+$  current was assessed by incubating the cells in a  $\text{Ca}^{2+}$ -free medium. In this instance, the current amplitude was not affected or was slightly increased (data not shown).

#### Channel blocking

Various concentrations of tetraethylammonium (TEA) were used to block the outward current. Figure 6C shows the sensitivity of the  $\text{K}^+$  current to TEA, after a




Fig. 8. Kinetics of the slow inward current in a Jurkat T cell. *A*, activation phase of the slow inward current plotted on an expanded time scale. The HP was  $-80$  mV. *B*, time to half-peak plotted as a function of the membrane potential. Values are the mean of four different experiments. The bars represent s.e.m. *C*, inactivation phase of the slow inward current. Membrane potentials were stepped from  $-40$  to  $-25$  mV in 5 mV increments. The HP was  $-80$  mV. *D*, time constant of inactivation ( $\tau_i$ ) plotted as a function of the membrane potential. Values are the mean of six different experiments. The bars represent s.e.m.

5 min perfusion following steady state. In this cell, the TEA concentration required to reach 50% inhibition was 6 mM. Three other experiments gave similar results. In addition, the outward  $\text{K}^+$  current was rapidly blocked by incubating Jurkat cells (2 min) in the presence of  $\text{Ni}^{2+}$  (Fig. 6D), a specific  $\text{Ca}^{2+}$  channel inhibitor (Tsien, Hess, McCleskey & Rosenberg, 1987). Similar results were obtained in the case of other inhibitors such as  $\text{Co}^{2+}$  ( $n = 4$ ),  $\text{Mn}^{2+}$  ( $n = 3$ ) or  $\text{Cd}^{2+}$  ( $n = 7$ ); these data are not shown.

## EXHIBIT B

146

G. DUPUIS, J. HÉROUX AND M. D. PAYET

### *Inward current*

A voltage-dependent inward current was recorded in 40 % of Jurkat cells ( $n = 120$ ), whether outward current was present or inhibited by using  $\text{Cs}^+$ -loaded pipettes.

### *Current-voltage relationships and reversal potential*

These experiments were carried out on cells incubated in the presence of  $\text{Ca}^{2+}$  (2.2 mM) and with pipettes filled with CsCl (130 mM) in order to block the outward




Fig. 9. Voltage dependence of the steady-state inactivation of the inward current in a Jurkat T cell. *A*, the membrane potential was stepped to  $-10$  mV and the HP was varied. The normalized peak currents are plotted *versus* the HPs. The continuous line was drawn according to the Boltzmann function, where  $V_k = -31$  mV and  $k = 2.8$  mV. *B*, blocking effect of  $\text{Cd}^{2+}$  (1 mM) on the slow inward current. Tracings represent experiments carried out before (1) and 2 min after (2) addition of  $\text{Cd}^{2+}$ . *C*, currents recorded with cells placed in GBSS containing  $\text{Sr}^{2+}$  (2.2 mM). Membrane potentials were varied from  $-80$  mV to  $-10$  mV, in 5 mV increments. The HP was  $-80$  mV.

current. A family of current traces obtained for various depolarizations from an HP of  $-80$  mV is shown in Fig. 7*A*. Tracings show an obvious rapid current activation and a slow inactivation that is a function of time. The current-voltage relationship shows that the threshold voltage was near  $-60$  mV, whereas the peak of the maximum current was found at approximately  $-40$  mV and the zero current voltage was positive to  $+20$  mV (Fig. 7*B*).

The tail current method was used to determine the zero current voltage, as described above in the case of the outward current. Results are shown in Fig. 7*C*. The amplitude of the tail current was plotted as a function of the repolarizing voltage and had a value of zero at  $+23.6$  mV (Fig. 7*D*). Six similar experiments gave a mean value of  $19.0 \pm 4.1$  mV.

## EXHIBIT B

### $\text{Ca}^{2+}$ AND $\text{K}^{+}$ CURRENTS IN JURKAT T CELLS

147

#### *Kinetics of the inward current*

Figure 8A shows current traces on an expanded time scale. In the case of negative membrane potentials, the current activates very slowly and activation becomes faster with depolarization. An estimate of the activation rate was obtained by determining the time needed to reach 50% of the maximum amplitude (rise time to half-maximum current,  $t_{1/2}$ ) at a given membrane potential (Cahalan *et al.* 1985). The results are shown in Fig. 8B ( $n = 4$ ). When the membrane potential was negative ( $-50$  mV),  $t_{1/2}$  was 60 ms and grew shorter with increasing depolarization. For instance, at  $-5$  mV  $t_{1/2}$  was 5 ms.

Inactivation of the inward current was very slow and was completed only after approximately 2–3 s, as shown in Fig. 8C. The inactivation phase of the current was fitted with a single-exponential function and the inactivation time constant  $\tau_i$  was plotted as a function of the membrane potential (Fig. 8D).

#### *Steady-state inactivation*

Steady-state inactivation experiments were performed by changing the HP and measuring the inward current elicited by stepping the membrane to  $-10$  mV. For each HP studied, there was a waiting period of 2 min to allow the system to reach equilibrium. The normalized peak currents were plotted against HP values and the results are shown in Fig. 9A. The curve (continuous) was drawn according to the Boltzmann equation, using the parameters  $V_k = -31$  mV and  $k = 2.84$  mV. From three experiments we found that  $V_k$  had a value of  $-31 \pm 3.4$  mV and  $k$  had a value of  $3.3 \pm 0.2$  mV.

#### *Channel blockers and selectivity*

Inorganic ions are known to block the inward  $\text{Ca}^{2+}$  current in a variety of cells (Tsien *et al.* 1987). In the case of Jurkat cells, we observed that  $\text{Co}^{2+}$  (3 mM) and  $\text{Mn}^{2+}$  (3 mM) completely inhibited the inward current after 2–3 min of incubation (data not shown). In Fig. 9B we present data on the inhibition of the inward current by  $\text{Cd}^{2+}$  (1 mM). Clearly, the inward current was totally inhibited after a 2 min incubation period.

It is well established that  $\text{Ca}^{2+}$  channels are permeable to divalent cations such as  $\text{Sr}^{2+}$  (Tsien *et al.* 1987). Substitution of  $\text{Ca}^{2+}$  for an equimolar concentrations of  $\text{Sr}^{2+}$  did not change the kinetics or the amplitude of the inward current in Jurkat cells (Fig. 9C). These observations suggest that, in the case of Jurkat cells,  $\text{Ca}^{2+}$  channels appear to be equally permeable to  $\text{Ca}^{2+}$  and  $\text{Sr}^{2+}$  ions.

#### *Effects of PHA on the inward and the outward currents*

Since we had observed that the outward current amplitude decreased when  $[\text{Ca}^{2+}]_i$  was augmented (Fig. 6) and since PHA induces increased  $[\text{Ca}^{2+}]_i$  (Weiss *et al.* 1986) in Jurkat cells, we investigated the possibility that the effect of the lectin on the outward current amplitude may involve  $\text{Ca}^{2+}$  channels. Experiments were performed on the global ionic current and results are shown in Fig. 10. In the case of control experiments (absence of PHA, cells in GBSS containing  $2.2$  mM- $\text{Ca}^{2+}$ ) a membrane

## EXHIBIT B

G. DUPUIS, J. HÉROUX AND M. D. PAYET




Fig. 10. Representative examples of the effects of PHA on the inward and outward currents of Jurkat T cells. *A*, effect of PHA on the global current. Jurkat T cells were bathed in GBSS medium containing  $\text{Ca}^{2+}$  (2.2 mM): (1) current traces obtained under control (absence of PHA) conditions. Membrane potentials were varied from  $-40$  mV to  $+30$  mV, in 10 mV increments. The HP was  $-80$  mV, (2) currents recorded in the same cell after addition of PHA ( $10 \mu\text{g/ml}$ ), (3) current-voltage relationships for the global current before (■) and after (□) the addition of PHA ( $10 \mu\text{g/ml}$ ). *B*, effect of PHA on the global current of a Jurkat T lymphocyte bathed in GBSS containing  $\text{Sr}^{2+}$  (2.2 mM): (1) current traces obtained under control (absence of lectin) conditions. Membrane potential was varied from  $-80$  mV to  $+30$  mV, in 10 mV increments. The HP was  $-80$  mV, (2) currents recorded in the same cell after the addition of PHA ( $10 \mu\text{g/ml}$ ), (3) current-voltage relationships for the global current before (■) and after (▲) the addition of PHA ( $10 \mu\text{g/ml}$ ).

## EXHIBIT B

### $\text{Ca}^{2+}$ AND $\text{K}^{+}$ CURRENTS IN JURKAT T CELLS

149




Fig. 11. Effects of PHA on the outward current in a Jurkat cell. *A*, the outward current was recorded in a Jurkat T cell that did not display any inward current. Data are presented for the control (absence of PHA) and experimental conditions (PHA, 10  $\mu\text{g/ml}$ ). The HP was  $-80$  mV, and membrane potentials were 10, 20, 30 and 40 mV, respectively. *B*, current-voltage relationships before (▲) and after (■) addition of PHA (10  $\mu\text{g/ml}$ ). Effects of PHA on the inward current in a Jurkat cell. *C*, experiments were carried out under conditions in which the outward current was blocked (CsCl in the patch electrode). The upper part of the panel represents control conditions (absence of PHA) and the lower part experimental conditions (PHA, 10  $\mu\text{g/ml}$ ). The HP was  $-80$  mV and the membrane was depolarized to  $-50$ ,  $-40$ ,  $-30$  and  $-20$  mV. *D*, current-voltage relationships before (■) and after (▲) addition of PHA (10  $\mu\text{g/ml}$ ). The leak current was subtracted.

potential positive to  $-50$  mV elicited inward currents from an HP of  $-80$  mV (Fig. 10A1). When the potential was more positive than  $-20$  mV, outward currents were recorded, as shown in Fig. 10A. Addition of PHA (10  $\mu\text{g/ml}$ ) induced two obvious major changes in the current trace pattern: an increase in the inward current amplitude and a decrease in the outward current amplitude (Fig. 10A2). These changes are summarized in Fig. 10A3 where the respective current-voltage relationships are illustrated. In studies with eight different cells, the outward current was decreased by  $45 \pm 12\%$ .

## EXHIBIT B

150

G. DUPUIS, J. HÉROUX AND M. D. PAYET

Similar experiments using a  $\text{Ca}^{2+}$ -free,  $\text{Sr}^{2+}$ -containing medium showed that the  $\text{Sr}^{2+}$  current was increased by the lectin, while the outward current was not affected (Fig. 10B1 and B2). The current-voltage relationship showed an increase in the range of voltage where the current was inward, but no changes were detected in the outward portion of the curve (Fig. 10B3).

Moreover, the effect of PHA was assessed in cells which did not display an inward current. In these cases ( $n = 5$ ), the outward current was increased by  $17.6 \pm 13\%$  at  $-20$  mV (Fig. 11A and B). The inactivation time constant  $\tau_i$  decreased for all of the voltage ranges studied, with specific decreases of  $-38.5 \pm 9$  and  $-23 \pm 4\%$  at 0 and  $+40$  mV, respectively.

Figure 11C shows the current traces obtained in patched Jurkat cells at various membrane potentials from an HP of  $-80$  mV. In this case, the external GBSS medium contained  $2.2$  mM- $\text{CaCl}_2$  and pipettes were filled with CsCl ( $120$  mM). After addition of PHA ( $10$   $\mu\text{g}/\text{ml}$ ), the amplitude of the current increased significantly as shown in Fig. 11C. The current-voltage relationship is shown in Fig. 11D. Kinetic analysis of the inactivation phase of the  $\text{Ca}^{2+}$  current showed that PHA had no effect on  $\tau_i$  ( $n = 4$ , data not shown).

### DISCUSSION

The present study demonstrates the presence, in the Jurkat T cell line, of an outward  $\text{K}^+$  current as well as an inward  $\text{Ca}^{2+}$  current that shows time- and voltage-dependent kinetics.

#### $\text{K}^+$ channels

The outward  $\text{K}^+$  current presents activation and inactivation kinetics similar to those previously observed for human peripheral T lymphocytes (DeCoursey *et al.* 1984; Matteson & Deutsch, 1984; Cahalan *et al.* 1985; Bregestovski, Redkozubov & Alexeev, 1986), murine T cells (DeCoursey, Chandy, Gupta & Cahalan, 1987) and murine cytotoxic (Fukushima *et al.* 1984) and helper (Lee, Sabath, Deutsch & Prystowsky, 1986) T lymphocytes.

$\text{K}^+$  channels activated by  $[\text{Ca}^{2+}]_i$  have been found in neurones and in many excitable cells (Meech, 1978). However, some types of  $\text{K}^+$  channels such as those found in human T lymphocytes (Bregestovski *et al.* 1986) or in murine B cells (Choquet, Sarthou, Primi, Cazenaven & Korn, 1987) are blocked by an increase in  $[\text{Ca}^{2+}]_i$ . This also appears to be the case for Jurkat cells as evidenced by the effect of the calcium ionophore A23187 (Fig. 6) or ionomycin (not shown). PHA also reduces the outward  $\text{K}^+$  current with a concomitant increase of the  $\text{Ca}^{2+}$  current (Fig. 11). In contrast, the lectin increased the  $\text{Sr}^{2+}$  current but this did not affect the  $\text{K}^+$  current. We thus postulate that the PHA-dependent decreased  $\text{K}^+$  current observed in Jurkat cells is due to a lectin-dependent increase in  $[\text{Ca}^{2+}]_i$ . This proposition is based on (1) the fact that PHA increases  $[\text{Ca}^{2+}]_i$  in Jurkat cells (Weiss *et al.* 1986), (2) an observable increase in  $\text{Ca}^{2+}$  current in these cells (Fig. 11), (3) the effect of ionophores on the  $\text{K}^+$  current (Fig. 6) and (4) the lack of effect of PHA on cells that did not display any inward current. In keeping with this last result, we have found that PHA increased the outward current in cells that did not display an inward current

## EXHIBIT B

### $\text{Ca}^{2+}$ AND $\text{K}^{+}$ CURRENTS IN JURKAT T CELLS

151

(Fig. 10A and B). These observations are in agreement with those of Cahalan *et al.* (1985) who reported that PHA increased the amplitude of the peak conductance by altering the external surface potential (DeCoursey *et al.* 1984). However, Schlichter, Sidell & Hagiwara (1986) have suggested that this phenomenon is not an essential event in the T cell response to PHA.

The potency of TEA to block the delayed outward  $\text{K}^{+}$  current in somatic cells depends on the type of  $\text{K}^{+}$  channels involved. For instance, the concentration needed for 50% inhibition has been found to be 8–16 mM in the case of type n  $\text{K}^{+}$  channels, whereas it is 50–100  $\mu\text{M}$  in the case of type l  $\text{K}^{+}$  channels (DeCoursey *et al.* 1987). In the present study, our data suggest that Jurkat cells possess type n  $\text{K}^{+}$  channels.

#### $\text{Ca}^{2+}$ channels

The existence of  $\text{Ca}^{2+}$  channels in lymphoid cells was originally proposed by Michell (1975), but the presence of such channels could not be recorded in human (Matteson & Deutsch, 1984; Cahalan *et al.* 1985) or in cloned murine T lymphocytes (Fukushima *et al.* 1984). However, macroscopic as well as unitary voltage-independent  $\text{Ba}^{2+}$  currents have been observed in cloned human helper T lymphocytes (Kuno *et al.* 1986) and unitary  $\text{Ca}^{2+}$  currents have been reported in Jurkat cells (Kuno & Gardner, 1987) and in T lymphocyte tumour cell markers reconstituted in bilayer phospholipid membranes (Pecht, Corcia, Liuzzi, Alcover & Reinherz, 1987).

Our results show conclusively the presence of voltage-dependent  $\text{Ca}^{2+}$  channels in approximately 40% of the Jurkat cells studied. It is of note to mention that MacCumber & Tucker (1987) have reported that 50% of peripheral human lymphocytes respond to PHA by increasing  $[\text{Ca}^{2+}]_i$ . This observation may be related to the frequency of  $\text{Ca}^{2+}$  currents observed in the present study.

At a holding potential of  $-80$  mV and in the presence of external  $\text{Ca}^{2+}$  (2.2 mM), the current starts to be activated at a voltage positive to  $-60$  mV, the maximum current is found near  $-40$  mV and the zero current voltage is observed between  $+20$  and  $+30$  mV. This low value for the zero current voltage could be due to an outward current of monovalent cations ( $\text{Cs}^{+}$ ) flowing through the  $\text{Ca}^{2+}$  channels, as reported by Fukushima & Hagiwara (1985).

Recently, various types of  $\text{Ca}^{2+}$  channels have been described and they differ in voltage thresholds, steady-state inactivation curves, kinetics and response to pharmacological agents (Nowycky, Fox & Tsien, 1985). Although the current found in Jurkat T cells shows a slow kinetic pattern similar to that of the long-lasting (L-type) channel, the threshold voltage was more negative than that of a typical L-type channel. Further work using channel agonists or antagonists is obviously required to classify the  $\text{Ca}^{2+}$  channel observed in Jurkat cells.

The observation that a voltage-dependent  $\text{Ca}^{2+}$  is present in the leukemic Jurkat T cell line whereas it has not been previously reported in peripheral blood T lymphocytes, may suggest that calcium channels are too small in number to be detected as macroscopic current in normal T cells. In addition, cell transformation may be accompanied by an increase in the number of  $\text{Ca}^{2+}$  channels (Fukushima & Hagiwara, 1983).



## EXHIBIT B

152

G. DUPUIS, J. HÉROUX AND M. D. PAYET

### *Effects of PHA on ionic currents in Jurkat cells*

PHA is known to stimulate T lymphocyte from various species to undergo blast transformation and mitosis (Gelfand *et al.* 1987). One of the earliest events that is associated with PHA-dependent lymphocyte stimulation is an increase in  $[Ca^{2+}]_i$  and a depolarization of the plasma membrane (Gelfand *et al.* 1987).

With respect to changes in  $[Ca^{2+}]_i$ , Tsien *et al.* (1982) initially reported that PHA brings about an approximately twofold increase in  $[Ca^{2+}]_i$  in porcine lymphocytes. Similar results have been reported by Gelfand, Cheung & Grinstein (1986) in the case of human peripheral T cells and by Weiss *et al.* (1986) in Jurkat T cells. The source of  $Ca^{2+}$  involved in such increases has been established. The largest contribution comes from extracellular  $Ca^{2+}$  that is responsible for the sustained increase in  $[Ca^{2+}]_i$  (Oettgen, Terhorst, Cantley & Rosoff, 1985; Alcover *et al.* 1987; Imboden & Weiss, 1987), whereas,  $Ca^{2+}$  mobilization from intracellular stores, probably as a result of inositol 1,4,5-trisphosphate ( $InsP_3$ ) release, accounts for the early rise in  $[Ca^{2+}]_i$  (Berridge & Irvine, 1984). It has been postulated that lymphocyte  $Ca^{2+}$  channels involved in the cytosolic increase of this ion may be regulated directly by the T cell antigen-receptor complex (Oettgen *et al.* 1985) or indirectly by  $InsP_3$  (Kuno & Gardner, 1987). Alternatively, Cahalan *et al.* (1985) have suggested that  $Ca^{2+}$  entry into lymphocytes could proceed via  $K^+$  channels. However, reports by Gelfand *et al.* (1986) and data presented in this study do not agree with this hypothesis (Fig. 10). Our observations suggest that cytosolic increases in  $Ca^{2+}$  concentration previously observed in Jurkat cells (Weiss *et al.* 1986) may, at least in part, be mediated via voltage-dependent calcium channels. Whether PHA acts directly on such channels or whether the action is mediated through a second messenger such as  $InsP_3$  (Kuno & Gardner, 1987) remains to be determined.

We thank Dr K. A. Smith for providing the Jurkat 77 6·8 cells. The work was supported by grants from the Medical Research Council of Canada (M. D. P. and G. D.), the Centre de Recherches Cliniques du C.H.U.S. and 'Challenger 87' summer training programme (J. H.). M. D. P. is a holder of a 'Chercheur Boursier' scholarship from the Fonds de la Recherche en Santé du Québec. We would also like to thank Lyne Bilodeau for technical assistance. This work is dedicated to Dr J. P. Caillé, *in memoriam*.

### REFERENCES

- ALCOVER, A., RAMARLI, D., RICHARDSON, N. E., CHANG, H.-C. & REINHERZ, E. L. (1987). Functional and molecular aspects of human T lymphocyte activation via T3-Ti and T11 pathways. *Immunological Reviews* **95**, 5–35.
- BERRIDGE, M. J. & IRVINE, R. F. (1984). Inositol trisphosphate, a novel second messenger in cellular signal transduction. *Nature* **312**, 315–321.
- BREGESTOVSKI, P., REDKOZUBOV, A. & ALEXEEV, A. (1986). Elevation of intracellular calcium reduces voltage-dependent potassium conductance in human T cells. *Nature* **319**, 776–778.
- CAHALAN, M. D., CHANDY, K. G., DECOURSEY, T. E. & GUPTA, S. (1985). A voltage-gated potassium channel in human T lymphocytes. *Journal of Physiology* **358**, 197–237.
- CAMBIER, J. C. & RANSOM, J. T. (1987). Molecular mechanisms of transmembrane signaling in B lymphocytes. *Annual Review of Immunology* **5**, 175–199.
- CHOQUET, D., SARTHOU, P., PRIMI, D., CAZENAVE, P.-A. & KORN, H. (1987). Cyclic AMP-modulated potassium channels in murine B cells and their precursors. *Science* **235**, 1211–1214.

## EXHIBIT B

### $Ca^{2+}$ AND $K^{+}$ CURRENTS IN JURKAT T CELLS

153

- DECOURSEY, T. E., CHANDY, K. G., GUPTA, S. & CAHALAN, M. D. (1984). Voltage-gated  $K^{+}$  channels in human T lymphocytes: a role in mitogenesis. *Nature* **307**, 465–468.
- DECOURSEY, T. E., CHANDY, K. G., GUPTA, S. & CAHALAN, M. D. (1987). Two types of potassium channels in murine T lymphocytes. *Journal of General Physiology* **89**, 379–404.
- DEUTSCH, C. & PRICE, M. (1982). Cell calcium in human peripheral blood lymphocytes and the effect of mitogen. *Biochimica et biophysica acta* **687**, 211–218.
- DUPUIS, G. & BASTIN, B. (1988). Lectin interactions with the Jurkat leukemic T-cell line: quantitative binding studies and interleukin-2 production. *Journal of Leukocyte Biology* **43**, 238–247.
- FUKUSHIMA, Y. & HAGIWARA, S. (1983). Voltage-gated  $Ca^{2+}$  channel in mouse myeloma cells. *Proceedings of the National Academy of Sciences of the USA* **80**, 2240–2242.
- FUKUSHIMA, Y. & HAGIWARA, S. (1985). Currents carried by monovalent cations through calcium channels in mouse neoplastic B lymphocytes. *Journal of Physiology* **358**, 255–284.
- FUKUSHIMA, Y., HAGIWARA, S. & HENKART, M. (1984). Potassium current in clonal cytotoxic T lymphocytes from the mouse. *Journal of Physiology* **351**, 645–656.
- GELFAND, E. W., CHEUNG, R. K. & GRINSTEIN, S. (1986). Mitogen-induced changes in  $Ca^{2+}$  permeability are not mediated by voltage-gated  $K^{+}$  channels. *Journal of Biological Chemistry* **261**, 11520–11523.
- GELFAND, E. W., MILLS, G. B., CHEUNG, R. K., LEE, J. W. W. & GRINSTEIN, S. (1987). Transmembrane ion fluxes during activation of human T lymphocytes: role of  $Ca^{2+}$ ,  $Na^{+}/H^{+}$  exchange and phospholipid turnover. *Immunological Reviews* **95**, 59–87.
- GILLIS, S. & WATSON, J. (1980). Biochemical and biological characterization of lymphocyte regulatory molecules. V. Identification of an interleukin 2 producing human leukemia T cell line. *Journal of Experimental Medicine* **152**, 1709–1719.
- HAMILL, O. P., MARTY, A., NEHER, E., SAKMANN, B. & SIGWORTH, F. J. (1981). Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. *Pflügers Archiv* **391**, 85–100.
- HODGKIN, A. L. & HUXLEY, A. F. (1952). Quantitative description of membrane current and its application to conduction and excitation in nerve. *Journal of Physiology* **117**, 500–544.
- IMBODEN, J. B. & WEISS, A. (1987). The T-cell antigen receptor regulates sustained increases in cytoplasmic free  $Ca^{2+}$  through extracellular  $Ca^{2+}$  influx and ongoing intracellular  $Ca^{2+}$  mobility. *Biochemical Journal* **247**, 695–700.
- KAPLAN, J. G. (1978). Membrane cation transport and the control of proliferation of mammalian cells. *Annual Review of Physiology* **40**, 19–41.
- KUNO, M. & GARDNER, P. (1987). Ion channels activated by inositol 1,4,5-trisphosphate in plasma membrane of human T lymphocytes. *Nature* **326**, 301–304.
- KUNO, M., GORONZY, J., WEYAND, C. M. & GARDNER, P. (1986). Single-channel and whole-cell recordings of mitogen-regulated inward currents in human cloned helper T lymphocytes. *Nature* **323**, 269–273.
- LEE, S. C., SABATH, D. E., DEUTSCH, C. & PRYSTOWSKY, M. B. (1986). Increased voltage-gated potassium conductance during interleukin 2-stimulated proliferation of a mouse helper T lymphocyte clone. *Journal of Cell Biology* **102**, 1200–1208.
- LINCH, D. C., WALLACE, D. L. & O'FLYNN, K. (1987). Signal transduction in human T lymphocytes. *Immunological Reviews* **95**, 137–159.
- MACCUMBER, M. W. & TUCKER, R. W. (1987). Studies of intracellular free calcium in human lymphocytes using Fura 2 and digital image analysis. *Annals of the New York Academy of Science* **494**, 230–232.
- MACDONALD, H. R. & NABHOLZ, M. (1986). T-cell activation. *Annual Review of Cell Biology* **2**, 231–253.
- MATTESON, D. R. & DEUTSCH, C. (1984). K channels in T lymphocytes: a patch clamp study using monoclonal antibody adhesion. *Nature* **307**, 468–471.
- MEECH, R. W. (1978). Calcium-dependent potassium activation in nervous tissues. *Annual Review of Biophysics and Bioengineering* **7**, 1–18.
- MICHELL, R. H. (1975). Inositol phospholipids and cell surface receptor function. *Biochimica et biophysica acta* **415**, 81–147.
- NOWYCKY, M. C., FOX, A. P. & TSIEN, R. W. (1985). Three types of neuronal calcium channels with different calcium agonist sensitivity. *Nature* **316**, 440–443.

## EXHIBIT B

154

G. DUPUIS, J. HÉROUX AND M. D. PAYET

- OETTGEN, H. C., TERHORST, C., CANTLEY, L. C. & ROSOFF, P. M. (1985). Stimulation of the T3-T cell receptor complex induces a membrane-potential-sensitive calcium influx. *Cell* **40**, 583-590.
- OWENS, T. & KAPLAN, J. G. (1982). Increased cationic fluxes in stimulated lymphocytes of the mouse: response of enriched B- and T-cell subpopulations to B- and T-cell mitogens. *Canadian Journal of Biochemistry* **58**, 831-839.
- PECHT, I., CORCIA, A., LIUZZI, M. P. T., ALCOVER, A. & REINHERZ, E. L. (1987). Ion channels activated by specific Ti or T3 antibodies in plasma membranes of human T cells. *EMBO Journal* **6**, 1935-1939.
- SCHLICHTER, L., SIDELL, N. & HAGIWARA, S. (1986). K channels are expressed early in human T-cell development. *Proceedings of the National Academy of Sciences of the USA* **83**, 5623-5629.
- SCHNEIDER, U., SCHWENK, H.-U. & BORNKMAN, G. (1977). Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. *International Journal of Cancer* **19**, 621-626.
- TSIEN, R. W., HESS, P., MCCLESKEY, E. W. & ROSENBERG, R. L. (1987). Calcium channels: mechanisms of selectivity, permeation, and block. *Annual Review of Biophysics and Biophysical Chemistry* **16**, 265-290.
- TSIEN, R. Y., POZZAN, T. & RINK, T. J. (1982). T-cell mitogens cause early changes in cytoplasmic free  $\text{Ca}^{2+}$  and membrane potential in lymphocytes. *Nature* **295**, 68-71.
- WEISS, A., IMBODEN, J., HARDY, K., MANGER, B., TERHORST, C. & STOBO, J. (1986). The role of the T3/antigen receptor complex in T-cell activation. *Annual Review of Immunology* **4**, 593-619.
- WEISS, A., IMBODEN, J., SHOBACK, D. & STOBO, J. (1984). Role of T3 surface molecules in human T cell activation: T3-dependent activation results in an increase in cytoplasmic free calcium. *Proceedings of the National Academy of Sciences of the USA* **81**, 4169-4173.



Annual Reviews  
www.annualreviews.org/aronline

*Annu. Rev. Immunol.* 1995. 13:623-653  
Copyright © 1995 by Annual Reviews Inc. All rights reserved

## POTASSIUM AND CALCIUM CHANNELS IN LYMPHOCYTES

*Richard S Lewis*

Department of Molecular and Cellular Physiology, Stanford University  
School of Medicine, Stanford, California 94305

*Michael D Cahalan*

Department of Physiology and Biophysics, University of California, Irvine,  
California 92717

**KEY WORDS:** ion channels, lymphocyte activation, patch-clamp, ion transport, signal transduction

### ABSTRACT

Over the past decade, a variety of ion channels have been identified and characterized in lymphocytes by use of the patch-clamp technique. This review discusses biophysical and regulatory aspects of lymphocyte potassium and calcium channels with the aim of understanding the role of these channels in lymphocyte functions. Lymphocytes express both voltage-dependent potassium [K(V)] channels and calcium-activated potassium [K(Ca)] channels, and each is upregulated as cells progress toward division following mitogenic stimulation. The genes encoding two K(V) channels, Kv1.3 (type  $\pi$ ) and Kv3.1 (type I), have been cloned. Mutational analysis is revealing functionally important regions of these channel proteins. Exogenous expression studies and the use of highly specific channel blockers have helped to establish the roles of type  $\pi$  K(V) channels in sustaining the resting membrane potential, in regulating cell volume, and in enabling lymphocyte activation. Blockade of K(V) and K(Ca) channels effectively inhibits the antigen-driven activation of lymphocytes, probably by inducing membrane depolarization and thereby diminishing calcium influx. A prolonged rise in intracellular calcium ( $[Ca^{2+}]_i$ ) is a required signal for lymphocyte activation by antigen or mitogens. Single-cell fluorescence measurements have revealed underlying  $[Ca^{2+}]_i$  oscillations that are linked closely to the opening and closing of  $Ca^{2+}$  and  $K^+$  channels. Sustained  $Ca^{2+}$  signaling and oscillations depend absolutely on plasma-membrane  $Ca^{2+}$  channels that are activated by the depletion of intracellular calcium stores. Under physiological conditions these channels

623

0737 0507/05/0410 062306E 00



open as a consequence of store depletion induced by inositol 1,4,5-trisphosphate ( $IP_3$ ), but they can also be activated experimentally by several agents that empty the stores without generating  $IP_3$ , such as the microsomal  $Ca^{2+}$ -ATPase inhibitor thapsigargin. The intricate causal relationships among ion channels, membrane potential,  $[Ca^{2+}]_i$ , and lymphokine gene expression can now be pursued at the single-cell level with patch-clamp recording, calcium-dependent dyes, reporter genes, and fluorescence video techniques. These approaches will help to clarify the essential roles of ion channels in the molecular pathways subserving activation and other lymphocyte behaviors.

## INTRODUCTION

Ion channels and fluxes have long been suspected to play a role in lymphocyte signal transduction, but only relatively recently have specific channel types been defined at biophysical or molecular levels. Unlike nerve and muscle cells, lymphocytes lack electrical excitability, and yet patch-clamp studies have revealed a surprisingly complex biophysical phenotype, with multiple  $K^+$ ,  $Ca^{2+}$ , and  $Cl^-$  channels expressed in patterns that are regulated differentially according to cell subset and state of activation. By controlling ion fluxes across the plasma membrane, channels mediate changes in intracellular ion concentrations and membrane potential in response to a variety of stimuli. The properties and possible functions of many of these channels have been reviewed (1–10). This review focuses on recent developments in understanding the properties and functional roles of  $K^+$  and  $Ca^{2+}$  channels in lymphocytes. Substantial progress has been made in this area by the application of molecular biological and patch-clamp techniques together with single-cell fluorescence measurements of intracellular  $Ca^{2+}$  concentration ( $[Ca^{2+}]_i$ ) and reporter gene expression. We specifically address several outstanding issues concerning the functional roles of channels in lymphocytes, including 1) the requirement of  $K^+$  channels for T cell activation; 2) the identity of the mitogen-stimulated  $Ca^{2+}$  channel and its mode of regulation; and 3) the means by which  $K^+$  channels and  $Ca^{2+}$  channels may interact to influence cell-activation events.

## POTASSIUM CHANNELS IN LYMPHOCYTES

### *Molecular Cloning of Voltage-Gated $K^+$ Channels in Lymphocytes*

Several types of voltage-gated  $K^+$  [ $K(V)$ ] channels have been intensively studied in lymphocytes through patch-clamp studies of a variety of immature and mature T cells, B cells, and lymphoid cell lines. For convenience, these have been named types *n* (for prevalence in *normal* human T cells) (11, 12), *n'* (similar to type *n*) (13), and *l* (*large* conductance and abundance in T cells from autoimmune *lpr* mice) (14). The three channel types share two fundamental

K<sup>+</sup> AND CA<sup>2+</sup> CHANNELS IN LYMPHOCYTES 625

properties: they are opened by membrane depolarization, and they are K<sup>+</sup>-selective. However, they differ in their voltage sensitivity, their tendency to inactivate during prolonged depolarization, their kinetic behavior, their single-channel conductance, and their sensitivities to a range of pharmacological agents. The distinguishing features of these channels have been reviewed previously in detail (7, 8); the characteristics most relevant to this review are summarized in Table 1.

The molecular cloning of ion-channel genes from different cell types and species has revealed an ever-increasing complexity of the K(V) channel superfamily. Sequence analysis provides a convenient and logical means of grouping the channels into families according to their similarity to several K<sup>+</sup>-channel genes originally identified in *Drosophila*: *Shaker* (Kv1), *Shab* (Kv2), *Shaw* (Kv3), and *Shal* (Kv4) (for reviews, see 8, 15). Below we summarize the results of cloning and expression studies that have identified the genes encoding the type *n* (Kv1.3) and *l* (Kv3.1) channels in lymphocytes (for review, see 9). These results establish a basis for identifying residues that are

Table 1 Potassium and calcium channels in lymphocytes<sup>a</sup>

Name	Conductance (pS)	Activation (midpoint)	Blockers	Expression (resting)	Expression (proliferating)
K(V) <i>n</i> (Kv1.3)	10–18	voltage (–40 mV)	TEA (mM) CTX, NTX, MTX, KTX (nM)	human T (++) mouse T, B (+)	human T (+++) mouse T, B (+++) Jurkat (++)
K(V) <i>n'</i>	18	voltage (–30 mV)	TEA (mM) CTX (nM)	mouse T (++)	
K(V) <i>l</i> (Kv3.1)	27	voltage (0 mV)	TBA (μM)	mouse T (++)	Louckes (++)
K(Ca) mini	2–8	Ca <sup>2+</sup> <sub>i</sub> (400 nM)	TEA (mM) apamin (pM)	mouse T (?)	Jurkat (+++)
K(Ca) midi	11–35	Ca <sup>2+</sup> <sub>i</sub> (300 nM)	TEA (mM) CTX (nM)	human T (+) mouse B (+)	human T (+++) mouse B (++) Jurkat (+)
Ca <sup>2+</sup>	0.01–0.03	Ca <sup>2+</sup> store depletion	Ni <sup>2+</sup> (mM) econazole, SKF 96365 (μM)	human T (+++)	Jurkat (+++)

<sup>a</sup>Summary of characteristics, including the channel gene (if known), single-channel conductance, mode of activation, selected pharmacological blockers, and expression levels in resting and proliferating cells. Approximate potencies of blockers are indicated in ranges from mM to pM. Expression levels are approximate: +, 5–50 channels per cell; ++, 100–500 per cell; +++, > 500 per cell; and ?, expression level unknown. See text for references and abbreviations.

## 626 LEWIS &amp; CAHALAN

critical in determining biophysical properties and pharmacological profiles. For clarity, the terms *n* and *l* are used below to refer to studies of native channels, while the Kv nomenclature is used in reference to exogenously expressed K<sup>+</sup> channels.

**Kv1.3 ENCODES THE *n*-TYPE CHANNEL IN LYMPHOCYTES** Genes encoding the *n* channel were isolated by low-stringency screening of rat or mouse genomic DNA libraries with probes derived from homospecific homologs of the *Shaker* gene (Kv1.1) (16, 17), or by screening a human Jurkat T cell cDNA library with a probe made from the rat brain *Shaker* homolog, RCK1 (18). The resulting clones, classified as Kv1.3, are all very similar. Northern analysis shows that the Kv1.3 transcript is highly expressed in rat thymus (16), and the polymerase chain reaction (PCR) has been used to detect Kv1.3 mRNA in the EL4 T cell line (19). Furthermore, mRNA derived in vitro from the rat, mouse, or human Kv1.3 genes, when expressed in *Xenopus* oocytes, encodes K<sup>+</sup> channels whose biophysical and pharmacological signature closely resembles that of native type *n* channels in lymphocytes (16, 18–20). Similar results were obtained after transient transfection of CTLL-2 cells (a murine cytotoxic T cell line that does not normally express either detectable K<sup>+</sup> currents or Kv1.3 mRNA) with a Kv1.3-containing plasmid (21). Their voltage dependence, rates of opening and closing, single-channel conductance, inactivation properties, and blockade by different compounds including tetraethylammonium (TEA) and charybdotoxin (CTX) were indistinguishable from native channels (Table 1).

Site-directed mutagenesis of the Kv1.3 gene provides a powerful tool to explore structure-function relationships for the type *n* channel. Thus far, the channel's pharmacological sensitivity and inactivation behavior have been studied most extensively. A relationship between the sites that govern blockade by TEA and inactivation was first inferred from the ability of partially blocking doses of TEA to slow the rate of inactivation (22). Similarly, protonation of his401 in the Kv1.3 channel decreases both TEA sensitivity (23) and the inactivation rate (24), and mutation of this histidine to a tyrosine reduces the extent of inactivation approximately fivefold (24). These results suggest that a histidine located near the outer pore region determines how the *n* channel inactivates and binds TEA. One speculation is that each of the four channel subunits contributes a histidine to create a Ca<sup>2+</sup> binding site (24), which is consistent with biophysical evidence that Ca<sup>2+</sup> binds to a site near the extracellular mouth of the *n* channel pore to cause or enhance inactivation (25).

**Kv3.1 ENCODES THE TYPE *l* K<sup>+</sup> CHANNEL** The *Shaw*-related Kv3.1 gene was first cloned by homology from rat and mouse libraries (26, 27). Heterologous expression in oocytes produced a K<sup>+</sup> current with similarities to type *l* channels in terms of the voltage dependence of opening, single-channel conductance, sensitivity to TEA, and insensitivity to CTX (26, 27; see Table 1). Further



studies showed that the kinetics of inactivation and deactivation (channel closing following the end of a depolarizing stimulus) were also indistinguishable from native *I* channels (28). The extremely close similarities between native *I* channels and Kv3.1 expressed in oocytes suggest that the *I* channel exists in lymphocytes as a homomultimer of four identical Kv3.1 subunits rather than as a heteromultimer containing another Kv3 subfamily member (28). Kv3.1 has also been expressed through transient transfection of CTLL-2 cells, in which it produces a conductance with *I*-type characteristics (21). Finally, Kv3.1 coding sequences have been detected using PCR in two cell types that express functional type *I* K<sup>+</sup> channels: a human B-lymphoma line, Louckes, and CD4<sup>+</sup>CD8<sup>+</sup> T cells from *lpr* mice (28).

**ADDITIONAL VOLTAGE-GATED K<sup>+</sup> CHANNELS IN LYMPHOCYTES** Electrophysiological and molecular biological evidence exists for additional K(V) channels in T cells, but these are less abundant than *n*- and *I*-type channels and hence have not received as much attention. A channel classified as type *n'*, similar to type *n* but non-inactivating, is expressed by murine CD4<sup>+</sup>CD8<sup>+</sup> thymocytes (13, 29); its molecular basis is not yet understood (Table 1). Indirect evidence for a CTX-insensitive K<sup>+</sup> channel in rat thymocytes is based on the inability of CTX to fully inhibit the regulatory volume decrease (RVD) induced by hypoosmotic solutions, a process that requires K<sup>+</sup> efflux and is completely inhibited by less selective K<sup>+</sup>-channel blockers (30; for reviews, see 1, 31, 32). Interestingly, one study of single K<sup>+</sup> channels in membrane patches revealed at least two types of K<sup>+</sup> channels in human T cells that appear to be distinct from types *n* and *I* (33), one of which has properties that could explain the CTX-insensitive RVD activity observed in rat thymocytes (30). Several hypotheses have been advanced to explain the molecular origins of additional K<sup>+</sup> channels in lymphocytes, including alternative splicing (although alternative splicing of mammalian Kv1.3 mRNA is not believed to occur—17), expression of additional K<sup>+</sup> channel genes such as Isk (18), heteromultimer formation, and modulation of channel properties by another channel subunit (34), by channel clustering (35, but see 9), or by posttranslational modifications.

### *Acute Mechanisms of K(V) Channel Modulation*

The functioning of K(V) channels in lymphocytes is subject to both acute and long-term modulation. Acute mechanisms are of particular interest, as physiological stimuli including antigen, neurotransmitters, and hormones act through lymphocyte receptors both to generate increases in second messengers such as Ca<sup>2+</sup> and cAMP and to activate protein kinases (36–39). Results thus far have varied widely among different groups, due in part to the use of different lymphocyte subtypes and protocols, and to the fact that the behavior of K(V) channels is strongly influenced by such experimental factors as temperature and intracellular dialysis during whole-cell recording (11, 12, 40–42). Studies





of modulation using cloned and modified Kv1.3 gene products may ultimately provide a more uniform basis for comparisons.

**EFFECTS OF CALCIUM** There is widespread agreement that intracellular  $\text{Ca}^{2+}$  exerts an inhibitory effect on  $n$ -type  $\text{K}^+$  channels in both T and B lymphocytes, although multiple mechanisms appear to exist. Bregestovski et al (43) were the first to describe  $\text{Ca}^{2+}$ -dependent inhibition of  $\text{K}^+$  channels in excised patches and in whole-cell recordings from human T cells. Similar inhibition has been observed in cell-attached patch recordings from intact T cells treated with the  $\text{Ca}^{2+}$  ionophore ionomycin, demonstrating that the effect does not require the dilution of cellular constituents that occurs during excised-patch and whole-cell experiments (44). The  $n$ -type  $\text{K}^+$  current in murine B cells and their precursors is inhibited by micromolar levels of  $\text{Ca}^{2+}$  in the recording pipette, primarily through a several-fold increase in the rate of inactivation (45). A subsequent detailed study of divalent ion interactions with the type  $n$   $\text{K}^+$  channel in Jurkat T cells found comparable effects and concluded that  $\text{Ca}^{2+}$  causes or accelerates inactivation by binding to a site located within the channel pore (25). Taken together, these results suggest that the inhibition by  $\text{Ca}^{2+}$  is unlikely to involve a kinase, phosphatase, or other diffusible cytosolic molecule.

A different type of  $\text{Ca}^{2+}$ -dependent inhibition has been observed in oocytes coinjected with mRNA for Kv1.3 and 5-HT<sub>2</sub> receptors (46–48). In these cells, 5-HT elicits a rise in  $[\text{Ca}^{2+}]_i$  through the activation of phospholipase C (PLC) and production of inositol 1,4,5-trisphosphate ( $\text{IP}_3$ ), and inhibits the  $\text{K}^+$  current by 70–80%. Similar results were produced by directly injecting  $\text{IP}_3$  or  $\text{Ca}^{2+}$ , and the 5-HT effect was slowed or blocked by injection of  $\text{Ca}^{2+}$  chelators, suggesting that it is mediated through a rise in  $[\text{Ca}^{2+}]_i$ . However, unlike the  $\text{Ca}^{2+}$ -dependent inhibition described above for lymphocytes, 5-HT-induced inhibition in oocytes is nearly irreversible and does not involve a change in the rate of channel inactivation. A similar long-lasting inhibition of type  $n$  channels by  $\text{Ca}^{2+}$  has not been reported in lymphocytes, although 5-HT binding to 5-HT<sub>1</sub> and 5-HT<sub>3</sub> receptors increases the maximum  $\text{K}^+$  conductance and accelerates inactivation in a pre-B cell line (49). The different effects of  $\text{Ca}^{2+}$  on  $\text{K}^+$  channels in oocytes as opposed to lymphocytes may reflect differences in the biochemical microenvironment or in the expression of auxiliary channel subunits. In this regard, a 41-kDa  $\beta$  subunit of Kv1 channels has been described that appears to play an important role in the inactivation process (50), and a protein of this size is associated with the type  $n$  channel in T cells (34).

**EFFECTS OF PHORBOL ESTERS** Phorbol esters, potent activators of protein kinase C (PKC), lack acute effects on type  $n$   $\text{K}^+$  current in human peripheral blood T cells (12), but they do appear to inhibit  $n$  channels in Jurkat T cells (51) and Kv1.3 channels expressed in oocytes (47, 48). The primary sequence of Kv1.3 contains a highly conserved intracellular consensus site for PKC

phosphorylation (34). A biochemical study has shown that the native type *n* channel from unstimulated Jurkat cells is phosphorylated exclusively on serines, and that cell extracts contain a relatively high PKC activity that can phosphorylate the channel in vitro (34). That PKC may be responsible for the resting phosphorylation of *n* channels in vivo is consistent with evidence that the K<sup>+</sup> current in Jurkat cells increases gradually during whole-cell recordings made with anti-PKC antibody or alkaline phosphatase in the recording pipette (51). The discrepancy between phorbol ester effects on Jurkat cells and human peripheral blood T cells remains unexplained. Nevertheless, these results raise the possibility that antigenic stimulation may inhibit *n* channels by generating diacylglycerol (DG) and activating PKC; thus, two downstream messengers of the antigen receptor, Ca<sup>2+</sup> and DG, may act in concert to limit the number of open K(V) channels during lymphocyte activation.

**EFFECTS OF cAMP** The inhibitory effects of cAMP on T cell activation (37) have prompted several groups to investigate its actions on K<sup>+</sup> channels. A full spectrum of effects has been reported, ranging from channel inhibition, to no effect, to activation. Choquet et al (45) found that intracellular application of cAMP almost completely eliminated the type *n* K<sup>+</sup> current in murine B cell blasts and pre-B cell lines, and similar findings were later reported in Jurkat T cells treated with 8-Br-cAMP or the cAMP agonist PGE<sub>2</sub> (51). The effect in Jurkat cells was blocked by inhibitors of protein kinase A (PKA), suggesting a phosphorylation-dependent mechanism (51). As in the case of phorbol esters, the effects of cAMP in Jurkat cells do not extend in a consistent way to *n* channels in human peripheral T cells. Several studies found no effect of cAMP applied through the recording pipette or of bath-applied permeant cAMP analogs (43, 44, 52, but see 53), even at 37°C (40). Pahapill & Schlichter (44) addressed this discrepancy in a study of K<sup>+</sup> channels in cell-attached patches. Several agents that elevate cAMP levels induced a slow rise in K<sup>+</sup> channel activity at the resting potential. It is unknown whether these channels are modified *n* channels or are previously "silent" channels activated by cAMP. It should be noted that in another study PGE<sub>2</sub> failed to activate K<sup>+</sup> channels in cell-attached patches (40). The question remains why cAMP appears to inhibit K<sup>+</sup> channels in some cases and to activate them in others. Recent biochemical studies suggest that the actions of cAMP on the type *n* channel may be complex. In vitro PKA phosphorylates not only the Jurkat *n* channel, but also a 40-kDa protein with which it coprecipitates (34). This protein is similar in size to the recently characterized  $\beta$  subunit believed to accelerate the inactivation of Kv1 channels (50), and by analogy it may have a similar action on *n* channels in lymphocytes. Thus, a more complete biochemical characterization of native *n* channels and their associated subunits in different lymphocyte subtypes may shed light on the diversity of cAMP effects that have been described.

**EFFECTS OF TEMPERATURE** Several properties of type *n* channels are profoundly temperature-dependent, implying that caution must be exercised when extrapolating from results obtained at room temperature to predict  $K^+$ -channel behavior under physiological conditions (40, 41). Increased temperature affects the overall activity of *n* channels in several ways: 1) It increases the single-channel conductance; 2) it accelerates activation, inactivation, and deactivation kinetics; 3) it shifts the voltage dependence of inactivation and activation in opposite directions, thereby increasing by two- to threefold the number of channels active at the resting potential; and 4) it speeds the recovery from inactivation. The net effect of these changes is to increase significantly the activity of  $K^+$  channels at 37°C relative to room temperature (40, 41). This information will be essential in developing a realistic quantitative model of  $K^+$ -channel activity in lymphocytes under physiological conditions. Such modeling may provide the ultimate test of hypotheses regarding the functional roles of  $K^+$  channels and their modulation in the intact lymphocyte.

### *Ca<sup>2+</sup>-Activated K<sup>+</sup> Channels*

The existence of  $Ca^{2+}$ -activated  $K^+$  [ $K(Ca)$ ] channels in lymphocytes was first inferred from observations that  $Ca^{2+}$  ionophores increased the membrane  $K^+$  permeability (measured with radioactive isotopes) and evoked membrane hyperpolarization (30, 54–56; for review, see 1, 57). Subsequent patch-clamp studies identified  $K(Ca)$  channels in rat thymocytes (58, 59), human and mouse B cells (58, 60, 61), and human T cells (62, 63). The current consensus is that at least two types of  $K(Ca)$  channels, readily distinguished by their different conductances and pharmacological profiles, are expressed in a lineage-specific pattern in lymphocytes (Table 1). A small-conductance (2–8 pS) “mini” channel appears to be absent from human T cells (63, but see 64), is rare in B cells (60), but is quite abundant in Jurkat cells (several hundred/cell) (62). This channel is effectively blocked by apamin but is insensitive to CTX (62). A larger, 10–35 pS “midi” channel is relatively more abundant in B cells (60), thymocytes (58), and peripheral blood T cells (63) and is rare in Jurkat (62). In contrast to the mini- $K(Ca)$  channel, this larger channel is insensitive to apamin but is half-blocked by 3 nM CTX (60, 62, 63). Neither channel exhibits significant voltage dependence, unlike the large-conductance “maxi”- $K(Ca)$  channel found in other cell types (65); instead, each is highly sensitive to intracellular  $Ca^{2+}$ . The calcium dependence of both channels has been measured in whole-cell recordings by intracellular perfusion with buffered  $Ca^{2+}$  solutions and by simultaneous patch-clamp and  $[Ca^{2+}]_i$  measurements. Both channels are activated by  $[Ca^{2+}]_i > 200$ –300 nM, and activation by  $Ca^{2+}$  is cooperative, with a Hill coefficient of  $\approx 4$  (62, 63), suggesting that multiple  $Ca^{2+}$ -binding sites are involved in channel opening. The genes for these channels have not yet been cloned.



### *K<sup>+</sup> Channel Expression During Development and Activation*

**T LYMPHOCYTES** The surface density of K<sup>+</sup> channels in the plasma membrane of T lymphocytes is regulated in intriguing ways during development and during activation of mature cells by mitogens (for reviews, see 8, 29). Developmental regulation of K(V) channels is most pronounced in murine lymphocytes. Immature thymocytes (CD4<sup>-</sup> CD8<sup>-</sup> or CD4<sup>+</sup> CD8<sup>+</sup>) express hundreds of type *n* channels per cell. As the developmental lineage diverges, *n* channels are either downregulated ~10-fold in CD4<sup>+</sup> CD8<sup>-</sup> cells (helper phenotype) or supplanted with a mixture of ~20–200 *n'* and *l* channels in most CD4<sup>-</sup> CD8<sup>+</sup> cells (cytotoxic/suppressor subset) (13). Mitogenic activation causes both classes of mature murine T cells to revert to the immature pattern of channel expression, i.e. hundreds of *n* channels per cell (66, 67). In contrast, resting human T cells express *n* channels at a level similar to that of immature or activated T cells of mice, and activation increases channel abundance only by a factor of ~2–3 (12, 63, 68). However, the expression of K(Ca) channels in human T cells is profoundly upregulated by mitogens, increasing from ~20 per resting cell to >500 channels per cell in T cell blasts treated with phytohemagglutinin (PHA) (63). Thus, the relative contribution of K(Ca) channels to maintaining the membrane potential may be greatly enhanced in activated cells and perhaps in memory cells. Type *l* K(V) channels have been found only in CD4<sup>-</sup>CD8<sup>+</sup> thymocytes and peripheral T cells from mice (at low levels) and at high levels in CD4<sup>-</sup>CD8<sup>-</sup> T cells from a variety of autoimmune mice such as *lpr*, *gld*, NOD, and EAE (for review, see 8). Type *l* channels have not been detected in human T cells but are present in a human Burkitt's lymphoma cell line, Louckes (69).

Recent evidence suggests that the expression of K(V) channels during T cell activation is regulated through a posttranscriptional mechanism. Following mitogenic stimulation, Kv1.3 mRNA levels remain constant or decrease in murine and human T cells as the number of channels increases (18, 20). A number of posttranscriptional mechanisms could explain the increase in K<sup>+</sup>-channel density, including an increased rate of translation, stimulated insertion of presynthesized channels, or unmasking of previously "silent" channels. Transcriptional control mechanisms cannot be ruled out, however, as several Kv1.3 transcripts have been detected [~9.9, 4.4, and ~3 kb (18, 20)], and the expression of the smaller two transcripts increases with time in activated Jurkat cells (18). The relative translational efficiency of the different transcripts is not known.

**B LYMPHOCYTES** Independent regulation of K(V) and K(Ca) channels via different activation pathways has been demonstrated in B cells (61). Stimulation through the antigen receptor increases expression of both channels, while lipopolysaccharide (LPS) affects only K(V) channels. In each case, the surface density of the channels increases roughly 5–10-fold to hundreds per cell. Inhibitors of RNA synthesis block the induction of K(Ca) channels by antigen,



indicating a requirement for gene transcription. The functional implications of differential regulation are unknown, but the induction of K(Ca) channels appears to be correlated with an inability to differentiate (61). LPS elevates the levels of K(V) channels and triggers differentiation into plasma cells, while anti- $\mu$  induces K(Ca) channels in LPS-pretreated cells and inhibits their ability to differentiate. Identification of a specific blocker for mid-K(Ca) channels in B cells would offer a means of testing this hypothesis.

### *K(V) Channels as a Pharmacological Target*

A prospective therapeutic intervention in immune disease is based on pharmacological inhibition of type  $n$   $K^+$  channels. These channels are blocked by a remarkable variety of agents, including classical  $K^+$  channel blockers [TEA and 4-aminopyridine (4-AP)],  $Ca^{2+}$ -channel antagonists (verapamil and dihydropyridines), K(Ca) channel blockers (quinine and cetiedil), calmodulin antagonists (trifluoperazine and chlorpromazine), and the steroid hormone progesterone (for reviews, see 2, 7, 8). Many of these compounds also inhibit lymphocyte activation (below); however, their rather low affinity ( $K_i = 10^{-5}$  to  $10^{-2}$  M) and specificity undermine their usefulness either as research probes for K(V) channel function or as therapeutic tools. The more recent identification of peptide toxins from scorpion venoms that block K(V) and K(Ca) channels with high affinity and specificity offers great promise. CTX blocks type  $n$  K(V) as well as K(Ca) channels with a  $K_i$  of  $\approx 10^{-9}$  M (60, 70, 71). Noxiustoxin (NTX) (64, 70), margatoxin (MTX) (72), and kaliotoxin (KTX) (61) are even more potent and are also selective for K(V) over K(Ca) channels. It is encouraging to note that low, therapeutic concentrations of calcium antagonists that also block  $n$  channels (verapamil, nifedipine, nimodipine, and diltiazem) significantly enhance the immunosuppressive effects of cyclosporin A (CsA) *in vitro* (73). Thus,  $K^+$ -channel blockers may synergize with low doses of CsA *in vivo* to increase the survival of organ grafts while minimizing the nephrotoxicity and hypertension associated with conventional CsA therapy. To this end, several pharmaceutical companies are currently attempting to develop K(V) blocking agents of high affinity and specificity using both toxins and organic compounds. The success of this approach may be aided by the restricted tissue distribution of Kv1.3 mRNA, which is expressed abundantly in thymus and spleen, at a low level in fibroblasts, brain, and kidney, and not detectably in liver or heart (16, 19).

### *Functional Roles for $K^+$ Channels in Lymphocytes*

**CONTROL OF MEMBRANE POTENTIAL** The membrane potential ( $V_m$ ) exerts powerful effects on lymphocyte activation (see below). Based on measurements of radiolabeled and fluorescent membrane potential probes, the resting potential of quiescent T cells from humans and mice is  $-50$  to  $-70$  mV (56, 64, 74, 75; for review, see 1). In human T cells, the resting potential results

primarily from a K<sup>+</sup>-diffusion potential contributed by *n*-type K<sup>+</sup> channels. It has been estimated that on average only several *n* channels are open in resting T cells, and that this can account for the resting K<sup>+</sup> efflux (11, 41). This conclusion agrees well with the observation that the resting potential of T cells slowly fluctuates by  $\approx 8$  mV, presumably due to the opening and closing of single K<sup>+</sup> channels (76). The extremely high input resistance of resting T cells makes it possible for such a small number of open channels to determine the membrane potential and creates a substantial reserve of dormant K<sup>+</sup> channels to "protect" against depolarization. High-affinity blockers provide definitive pharmacological evidence for the role of *n* channels in setting the resting potential. CTX, margatoxin, and NTX depolarize resting human T cells (30, 64), and although CTX also blocks K(Ca) channels, its effect on  $V_m$  is no greater than that of the more selective K(V) blockers (64).

In murine T cells, the contribution of K(V) channels to establishing the resting potential correlates well with their level of expression (75). Type *n* channels play a dominant role in immature thymocytes or activated peripheral T cells, both of which express hundreds of channels per cell. In contrast,  $V_m$  in mature resting T cells (with  $\approx 10$  *n* channels/cell) is determined largely by the electrogenic activity of the Na<sup>+</sup>/K<sup>+</sup> ATPase. Blocking the pump with ouabain, low temperature, or removal of K<sub>o</sub><sup>+</sup> depolarizes these cells, whereas moderate changes in the transmembrane K<sup>+</sup> gradient have little effect (75). The Na<sup>+</sup>/K<sup>+</sup> pump's contribution to  $V_m$  may explain why CTX does not depolarize rat thymocytes (55), cells that express low numbers of type *n* channels (M Cahalan, unpublished observation).

K(Ca) channels do not appear to contribute significantly to  $V_m$  in resting lymphocytes but exert a powerful influence when [Ca<sup>2+</sup>]<sub>i</sub> is elevated. [Ca<sup>2+</sup>]<sub>i</sub> in resting lymphocytes is 50–100 nM (1), well below the measured threshold for activating K(Ca) channels (200–300 nM) (58, 62, 63). K(Ca) channels are silent in cell-attached recordings from intact resting lymphocytes except during a brief period immediately after establishing the membrane-pipette seal, when a [Ca<sup>2+</sup>]<sub>i</sub> spike often occurs (58, 59). The rise in [Ca<sup>2+</sup>]<sub>i</sub> elicited by mitogens or Ca<sup>2+</sup> ionophores is sufficient to activate K(Ca) channels in both whole-cell and cell-attached configurations (58, 59, 62, 63). Thus activated, K(Ca) channels cause a membrane hyperpolarization that is prevented or reversed by CTX (55, 59, 77) or quinine (56), both of which block K(Ca) channels in patch-clamp studies (60, 63).

**REGULATION OF CELL VOLUME** When exposed to hypoosmotic solutions, T cells swell rapidly, then shrink over several minutes back to approximately their normal size. This regulatory volume decrease (RVD) response is mediated by the stimulated efflux of K<sup>+</sup> and Cl<sup>−</sup>, which drives osmotically obligated water from the cell (1). A model for RVD in T cells has been proposed in which cell swelling activates Cl<sup>−</sup> channels (78), eliciting an efflux of Cl<sup>−</sup> that depolarizes



## 634 LEWIS &amp; CAHALAN

the membrane and thereby opens type *n* K(V) channels (31, 32). Several types of evidence support a role for type *n* channels in RVD. First, the density of *n* channels in several types of lymphocytes correlates with the ability to volume regulate (75, 79). Second, a series of pharmacological reagents block *n* channels and inhibit RVD with the same relative order of potency (reviewed in 31, 32). Finally, increasing the expression of type *n* channels by mitogenic stimulation of murine T cells (79) or by transfection of Kv1.3 into the K<sup>+</sup>-channel and RVD-deficient CTLL-2 cell line (21) confers the ability to volume regulate. Significantly, *l* channels expressed by CTLL-2 cells after transfection with Kv3.1 did not fulfill this role (21). These results present compelling evidence for the roles of swelling-activated Cl<sup>-</sup> channels and type *n* K<sup>+</sup> channels in RVD, as Cl<sup>-</sup> channels can only depolarize the cell to a maximum of  $\approx -35$  mV (the estimated equilibrium potential for Cl<sup>-</sup>), above the activation threshold for *n* channels ( $-60$  mV) but well below that of type *l* channels ( $-10$  mV). K(Ca) channels normally do not appear to be involved in RVD but can assume this function in murine T cells treated with ionomycin (75).

**ACTIVATION OF LYMPHOCYTES** Two types of circumstantial evidence support a role for K<sup>+</sup> channels in the activation of lymphocytes. First, as described above, T and B cell mitogens stimulate an increase in the density of K(V) and K(Ca) channels, and the density of K<sup>+</sup> channels in thymocyte subsets is positively correlated with proliferative activity. Second, pharmacological studies suggest a requirement for functional K<sup>+</sup> channels in the activation of T and B cells. A variety of chemically distinct K(V) channel blockers, including TEA, 4-AP, quinine, verapamil, diltiazem, cetiedil, trifluoperazine, and chlorpromazine, inhibit activation, gene expression, killing by cytotoxic T cells and NK cells, lymphokine secretion, and proliferation (4, 80–82). The discovery that K<sup>+</sup>-channel blockers can inhibit proliferation has since been extended to a variety of cell types outside the immune system (reviewed in 83, 84).

The interpretation of results obtained with K<sup>+</sup>-channel blockers is complicated by the fact that some of these compounds have effects on proteins other than K(V) channels. For example, TEA and quinine also block K(Ca) channels, and trifluoperazine is a potent inhibitor of calmodulin. The identification of high affinity, specific K<sup>+</sup>-channel blockers from scorpion venoms has allowed more definitive studies of K<sup>+</sup>-channel functions in intact cells. Deutsch and colleagues first demonstrated that nanomolar concentrations of CTX effectively inhibit PHA- or antigen-driven T cell activation *in vitro* (71). The inhibition appears to result from suppression of IL-2 transcription, as the level of IL-2 mRNA and secreted IL-2 are both reduced in CTX-treated cultures (85), and normal proliferation can be restored by supplying exogenous IL-2 (71). Because CTX blocks K(V) and K(Ca) channels with similar potency, it cannot be used to distinguish their functional roles. Lin et al (86) addressed this

point using the selective K(V)-channel blockers, margatoxin (MTX) and nox-iustoxin (NTX); like CTX, both peptides block mitogen-induced proliferation, the mixed lymphocyte response, and the secretion of IL-2 and  $\gamma$ -IFN. Moreover, MTX inhibits IL-2 secretion at lower concentrations than does CTX, consistent with its higher affinity for the type *n* K<sup>+</sup> channel. These results provide the strongest available evidence for a role of K(V) channels in mitogenesis. However, even though CTX and NTX block activation with equal efficacy (86), it should be noted that the effects of these peptides do not rule out a role for K(Ca) channels downstream from events involving K(V) channels. At present the absence of a selective blocker for K(Ca) channels precludes a test of this possibility.

Considerable evidence suggests that functional K<sup>+</sup> channels are required during T cell activation to maintain a membrane potential that promotes Ca<sup>2+</sup> influx. A negative membrane potential enhances Ca<sup>2+</sup> entry by optimizing the electrochemical driving force for Ca<sup>2+</sup> movement through Ca<sup>2+</sup> channels; in addition, indirect effects of V<sub>m</sub> on the activity of the Ca<sup>2+</sup> channels themselves have also been suggested (87–89). Several types of evidence support a V<sub>m</sub>-mediated link between K<sup>+</sup> channels, Ca<sup>2+</sup> influx, and cell activation. High affinity K<sup>+</sup>-channel antagonists like CTX, NTX, and MTX depolarize human T cells (30, 64) and inhibit T cell activation induced by Ca<sup>2+</sup>-dependent pathways (anti-CD2 or anti-CD3) but not Ca<sup>2+</sup>-independent ones (anti-CD28+ PMA, or IL-2) (86). The immunosuppressive effects of CTX *in vitro* can be mimicked by an equivalent depolarization invoked directly by elevated [K<sup>+</sup>]<sub>o</sub> (85). Furthermore, depolarization inhibits the [Ca<sup>2+</sup>]<sub>i</sub> rise induced by T cell mitogens (88, 90–93), whereas hyperpolarization by the potassium ionophore valinomycin reverses the effect of K<sup>+</sup>-channel blockade on [Ca<sup>2+</sup>]<sub>i</sub> (87).

While these studies suggest that K(V) channels are needed to enhance Ca<sup>2+</sup> entry, several unresolved discrepancies remain. First, Gelfand & Or (77) found that CTX had no effect on either the mitogen-induced [Ca<sup>2+</sup>]<sub>i</sub> rise or activation of human lymphocytes, even though it effectively blocked RVD. Second, even doses of CTX more than tenfold greater than the K<sub>i</sub> for K<sup>+</sup>-channel blockade inhibit activation by only 50–60% (71, 85, 86). This may be due to the fact that CTX evokes a maximal depolarization of only 20–25 mV (30, 64), implying that CTX-insensitive K<sup>+</sup> or Cl<sup>−</sup> channels also contribute to the resting potential, particularly when *n* channels are blocked. Contributions of CTX-insensitive mechanisms to membrane potential might also explain the lack of CTX effects observed by Gelfand & Or (77). Finally, in the study by Lin et al (86), although CTX did not affect the long-lasting plateau level of [Ca<sup>2+</sup>]<sub>i</sub>, it inhibited activation significantly even when added hours after the mitogen, *i.e.* well into the plateau phase. In this regard, it should be noted that [Ca<sup>2+</sup>]<sub>i</sub> oscillations may be important in controlling lymphocyte activation (94), and





these would not be detected in the population  $[Ca^{2+}]_i$  measurements discussed above. Blockade of K(V) and K(Ca) channels with CTX and apamin effectively inhibits PHA-triggered  $[Ca^{2+}]_i$  oscillations in Jurkat cells, but it has only a small effect ( $\approx 25\%$  decrease) on the average  $[Ca^{2+}]_i$  of the cell population (62). Thus, further studies of the effects of channel antagonists on  $[Ca^{2+}]_i$  at the single-cell level may better define the role of K(V) channels in  $Ca^{2+}$  signaling and lymphocyte activation.

### CALCIUM CHANNELS IN LYMPHOCYTES

A rise in  $[Ca^{2+}]_i$  is an essential triggering signal for many of the events associated with lymphocyte activation. These events include changes in motility and cell shape occurring soon after T cells contact antigen-presenting cells (95, 96), transcription of genes for lymphokines such as IL-2 (97–99), cell killing by cytotoxic T cells (100, 101), apoptosis of self-reactive T cells during development in the thymus (102, 103), and induction of tolerance to self-antigens in mature peripheral T cells (104, 105). In the past several years, substantial progress has been made in understanding many of the key molecular events upstream and downstream of the  $Ca^{2+}$  signal. Binding of antigen (or mitogens) to the TCR activates multiple tyrosine kinases and leads to the phosphorylation and activation of phospholipase  $C\gamma 1$  (for reviews, see 39, 106). Once activated, the enzyme cleaves phosphatidylinositol 4,5-bisphosphate ( $PIP_2$ ) to generate the second messengers  $IP_3$  and diacylglycerol (DG).  $IP_3$  evokes a rise in  $[Ca^{2+}]_i$ , which in combination with DG activates PKC. The elevation of  $[Ca^{2+}]_i$  appears to be necessary and, together with PKC, sufficient to drive many events in T cell activation (for reviews, see 36, 97).  $Ca^{2+}$  exerts much of its influence through the activation of transcription factors that control the production of lymphokines such as IL-2 (99, 107). Additional signaling molecules such as ras operate within parallel pathways to play critical roles in T cell activation, but these are beyond the scope of this review (107, 108).

Because of its central role in lymphocyte activation, an intense effort has been focused on defining the underlying basis of the  $Ca^{2+}$  signal. The first phase of the  $[Ca^{2+}]_i$  rise is generally understood to be mediated by  $IP_3$  binding to its receptor in the endoplasmic reticulum (ER) membrane and opening a  $Ca^{2+}$  channel that releases stored  $Ca^{2+}$  into the cytosol (109). The second phase, considerably less well understood, consists of a prolonged influx of  $Ca^{2+}$  across the plasma membrane. Because of the finite capacity of the ER  $Ca^{2+}$  store, intracellular release generates a transient signal that is neither necessary nor sufficient to drive activation (110, 111).  $Ca^{2+}$  influx and elevation of  $[Ca^{2+}]_i$  must be sustained for  $>30$  min to commit T cells to become activated and express the IL-2 gene (94, 107, 111). Considerable effort has been spent over the past few years to identify the  $Ca^{2+}$  channels that carry out this signaling function and to understand the mechanisms that regulate their activity.



### *Identification of Mitogen-Regulated Calcium Channels*

A great variety of channels have been proposed to mediate mitogenic Ca<sup>2+</sup> influx in lymphocytes, an indication of both the intense interest in elucidating this pathway and the technical difficulties inherent in doing so. Below, we consider many of the proposed mechanisms in the context of the characteristics of the Ca<sup>2+</sup> influx pathway, as inferred from [Ca<sup>2+</sup>]<sub>i</sub> measurements in intact cells (90, 93, 109, 112, 113). Based on these studies, any potential candidate for the mitogen-activated Ca<sup>2+</sup> channel should exhibit the following properties: 1) activation by mitogens or downstream messengers (e.g. IP<sub>3</sub>); 2) significant Ca<sup>2+</sup> permeability and an ability to carry Mn<sup>2+</sup>; 3) activity that is temporally correlated with increases in [Ca<sup>2+</sup>]<sub>i</sub>; 4) decreased Ca<sup>2+</sup> conductance upon depolarization; 5) feedback inhibition by intracellular Ca<sup>2+</sup>; and 6) inhibition by Ni<sup>2+</sup> and imidazole antimycotics such as SKF 96365. So far, these six criteria have been met only for depletion-activated Ca<sup>2+</sup> channels.

**DEPLETION-ACTIVATED CALCIUM CHANNELS** These channels were first described by Lewis & Cahalan (93) in Jurkat T cells using whole-cell recording and simultaneous [Ca<sup>2+</sup>]<sub>i</sub> imaging with fura-2. A small, highly selective Ca<sup>2+</sup> current appeared spontaneously during intracellular dialysis with solutions containing EGTA. The current displayed many of the properties expected for mitogenic Ca<sup>2+</sup> channels, including high permeability to Ca<sup>2+</sup>, a tight temporal link to changes in [Ca<sup>2+</sup>]<sub>i</sub>, inhibition by depolarization, evidence of Ca<sup>2+</sup>-dependent feedback inhibition, and blockade by Ni<sup>2+</sup> and Cd<sup>2+</sup>. In perforated-patch recordings, the current did not develop spontaneously but could be activated by PHA in an oscillatory manner. A calculation based on the lymphocyte volume demonstrated that the observed 1- to 10-pA Ca<sup>2+</sup> current was sufficiently large to account for the observed rate at which [Ca<sup>2+</sup>]<sub>i</sub> rises during oscillations in PHA-stimulated cells (≈100 nM/sec maximum) (93), even allowing for substantial binding of Ca<sup>2+</sup> by cytoplasmic buffers (114). The mode of regulation for these channels was unclear at the time; although activation by PHA could be explained through the action of IP<sub>3</sub>, activation by intracellular dialysis alone was unlikely to involve the same messenger. The ability of IP<sub>3</sub> to activate a similar Ca<sup>2+</sup> current in Jurkat cells was later shown directly by flash photolysis of intracellular caged IP<sub>3</sub> (115).

The key to understanding this Ca<sup>2+</sup> channel came from the capacitative Ca<sup>2+</sup> entry hypothesis originally proposed by Putney to explain receptor-mediated Ca<sup>2+</sup> influx in exocrine cells (116). According to this hypothesis, depletion of the ER Ca<sup>2+</sup> store generates a signal that activates Ca<sup>2+</sup> influx across the plasma membrane. Supporting evidence has accumulated rapidly since the isolation of compounds that block Ca<sup>2+</sup>-ATPases in the ER membrane and thereby unmask a passive Ca<sup>2+</sup> leak that empties the stores without generating IP<sub>3</sub>. Store depletion by several of these compounds, including thapsigargin (TG), tert-butylhydroquinone (tBHQ), and cyclopiazonic acid (CPA), activates

$\text{Ca}^{2+}$  influx in rat thymocytes and human T cells (113, 117–119), as does store depletion induced simply by prolonged incubation of cells in  $\text{Ca}^{2+}$ -free media (113, 120). Overlap between the depletion-activated and mitogen-activated  $\text{Ca}^{2+}$  entry mechanisms was first indicated by observations that TG depletes the same  $\text{Ca}^{2+}$  store that is mobilized by TCR ligation (112, 113, 117, 119), and that stimulation of the TCR fails to evoke an additional  $[\text{Ca}^{2+}]_i$  increase in cells pretreated with a maximal dose of TG (113, 119). In view of these results, Zweifach & Lewis (121) used perforated-patch recording to test whether the mitogen-regulated  $\text{Ca}^{2+}$  current is activated by store depletion, by comparing the  $\text{Ca}^{2+}$  currents activated by TG and PHA in Jurkat T cells. The two currents were identical in every property that was tested, including divalent ion selectivity, voltage-independence of gating, sensitivity to blockade by  $\text{Ni}^{2+}$ , and single-channel conductance. The single-channel conductance was estimated from noise analysis to be  $\approx 24$  fS in 110 mM  $\text{Ca}^{2+}_o$ ; this extremely small value and the channel's high  $\text{Ca}^{2+}$  selectivity readily distinguish it from  $\text{IP}_3$ -gated  $\text{Ca}^{2+}$  permeable channels previously described in T cells (see below; 122, 123). The simplest conclusion consistent with these results is that mitogen-activated  $\text{Ca}^{2+}$  channels in T cells are regulated by the depletion of  $\text{Ca}^{2+}$  stores, and that under physiological conditions of TCR stimulation,  $\text{IP}_3$  activates  $\text{Ca}^{2+}$  channels through store depletion rather than by a direct action on the  $\text{Ca}^{2+}$  channels themselves. This conclusion was later confirmed by Gardner and colleagues (124) in a comparison of whole-cell  $\text{Ca}^{2+}$  currents in Jurkat cells treated with TG, tBHQ, CPA, and intracellular  $\text{IP}_3$ ; in particular, the TG-induced current was not increased further by  $\text{IP}_3$ -mobilizing agents and vice versa, consistent with previous evidence that the two stimulus pathways converge upon the same channel (113, 119). Choquet and coworkers have recently described an apparently identical depletion-activated  $\text{Ca}^{2+}$  current in human peripheral blood T cells (125). Thus, present evidence favors the idea that stimulation of the TCR triggers an influx of  $\text{Ca}^{2+}$  through low conductance, voltage-independent  $\text{Ca}^{2+}$  channels that are controlled indirectly by  $\text{IP}_3$ -driven depletion of the intracellular  $\text{Ca}^{2+}$  stores.

Although additional  $\text{Ca}^{2+}$  entry pathways activated by the TCR may exist, most evidence argues otherwise. First, stimulation through the TCR fails to elevate  $[\text{Ca}^{2+}]_i$  or the  $\text{Ca}^{2+}$  current when added after an optimal dose of TG (113, 119, 124; but see 126). Second, antigen-unresponsive T cells from patients with a primary immunodeficiency lack the sustained mitogen-driven increase in  $[\text{Ca}^{2+}]_i$  in conjunction with an absence of depletion-activated  $\text{Ca}^{2+}$  current (125). Taken together, these findings suggest that depletion-activated  $\text{Ca}^{2+}$  channels play the major and perhaps the sole role in mediating the influx of  $\text{Ca}^{2+}$  essential for T cell activation.

**$\text{IP}_3$ -GATED CHANNELS** Kuno et al (122) were the first to report PHA-activated single-channel  $\text{Ca}^{2+}$  and  $\text{Ba}^{2+}$  currents in cell-attached patches from human

K<sup>+</sup> AND CA<sup>2+</sup> CHANNELS IN LYMPHOCYTES 639

T cells. Similar currents were observed in excised patches exposed to IP<sub>3</sub> on the intracellular face, leading to the conclusion that the channels were directly activated by this messenger (123). These channels fulfill several of the criteria for being mitogenic Ca<sup>2+</sup> channels: They are activated by cross-linking of the TCR as well as by IP<sub>3</sub>; they conduct current in the presence of isotonic Ca<sup>2+</sup> or Ba<sup>2+</sup>; they exhibit voltage-independent gating, and the current amplitude decreases with depolarization; and they are inhibited by micromolar [Ca<sup>2+</sup>]<sub>i</sub> and by Cd<sup>2+</sup> (122, 123, 128). Moreover, Khan et al (129) have detected IP<sub>3</sub>R-like immunoreactivity on the surface of human T cells by means of an antiserum generated against the cerebellar microsomal IP<sub>3</sub> receptor. Concanavalin A caps the immunoreactivity as well as Ca<sup>2+</sup> influx sites as inferred from elevated [Ca<sup>2+</sup>]<sub>i</sub> near the cap (129). However, several necessary criteria supporting a role of the IP<sub>3</sub> receptor in the influx of Ca<sup>2+</sup> remain untested. First, the single-channel currents appeared to have a low selectivity for Ca<sup>2+</sup> over monovalent ions (123), raising the question as to whether they have the capacity to conduct significant amounts of Ca<sup>2+</sup> under physiological conditions. A correlation of their activity with the increase in [Ca<sup>2+</sup>]<sub>i</sub> has not been demonstrated. Second, activity of IP<sub>3</sub>-gated channels has not been observed in whole-cell recordings, suggesting that the density of these channels is quite low. Even in the relatively noninvasive perforated-patch mode, electrical noise expected from the opening and closing of 8-pS IP<sub>3</sub>-gated channels was undetectable in PHA-treated cells (121). Although IP<sub>3</sub> activates a Ca<sup>2+</sup> current in whole-cell recordings from Jurkat cells (115), this appears to be identical to the depletion-activated Ca<sup>2+</sup> current (121, 124). Third, the correlation of IP<sub>3</sub>R-like immunoreactivity and gradients of [Ca<sup>2+</sup>]<sub>i</sub> in capped cells may be misleading. Apparent gradients often result from the uptake of fura-2 by organelles, which can be significant in human T cells (130) and could underlie the spatial non-uniformity of the total fura-2 concentration that was observed (129). Furthermore, con A caps a large number of membrane glycoproteins in T cells, including perhaps the depletion-activated Ca<sup>2+</sup> channel. For these reasons, it appears unlikely that plasma-membrane IP<sub>3</sub> receptors mediate significant Ca<sup>2+</sup> entry, and their physiological function in T cells remains unclear (124).

**OTHER POSSIBLE CALCIUM CHANNELS IN LYMPHOCYTES** Two lines of evidence suggest that voltage-dependent Ca<sup>2+</sup> channels are not expressed at a significant level in T cells. First, depolarization of resting Jurkat cells or human T cells with high [K<sup>+</sup>] (87, 88, 91–93, 131) or by current injection (132) fails to raise [Ca<sup>2+</sup>]<sub>i</sub> significantly; and second, several groups have failed to observe voltage-gated Ca<sup>2+</sup> currents under whole-cell recording conditions optimal for their detection in excitable cells (122, 133, 134). However, there are two reports of voltage-gated Ca<sup>2+</sup> currents in whole-cell recordings from T cell lines. In one case, a large, slowly inactivating inward current was activated at potentials above -60 mV in a subset of Jurkat 77 T cells (135), while in another a small,



rapidly inactivating inward current was reported in Jurkat, Molt-4, and HSB T cell lines (136). The second current was active transiently (duration < 10 msec) at potentials above -20 mV, while it was inactivated at potentials more positive than -90 mV; these properties appear to be inconsistent with a role in mediating a sustained rise in  $[Ca^{2+}]_i$  at physiological potentials of -50 to -80 mV. There is no direct evidence to show that either current is carried by  $Ca^{2+}$ , and although the size of both of these currents appears to be enhanced by stimulation of TCR, significant activity of the channels at physiological membrane potentials has not been demonstrated. Several experiments could clarify the existence and role of these channels in T cells: if they are to mediate mitogenic  $Ca^{2+}$  influx, then  $Ca^{2+}_o$  removal should eliminate the current, depolarization should increase  $[Ca^{2+}]_i$ , and holding the cell at potentials below the channel's threshold for activation should prevent the  $[Ca^{2+}]_i$  increase triggered by mitogens.

A  $Ca^{2+}$  entry pathway independent of the phosphatidylinositol cascade has been proposed based on the ability of mitogens to evoke  $Ca^{2+}$  influx in HPB-ALL cells without measurable production of inositol phosphates or release of intracellular  $Ca^{2+}$  (137). In lipid vesicles reconstituted from HPB-ALL plasma membrane, anti-CD3 mAb induced  $Ca^{2+}$  uptake to a greater extent than nonmitogenic control antibodies to CD2 or Thy 1.2; this was specifically inhibited by several conditions that reduce influx in intact HPB-ALL cells. It is not known whether this pathway can account for  $Ca^{2+}$  influx in intact HPB-ALL cells, nor whether it also exists in nontransformed cells. Another  $Ca^{2+}$  entry mechanism distinct from the TCR-triggered pathway has been reported in T cells from patients with multiple sclerosis.  $\gamma$ -interferon activates  $Ca^{2+}$  entry in these cells apparently through activation of protein kinase C (138). Patch-clamp studies may help to clarify the nature of these additional routes for  $Ca^{2+}$  entry.

CD20, a B cell plasma membrane phosphoprotein thought to play a role in B cell activation and cell-cycle progression, has been proposed to be a  $Ca^{2+}$  channel (139). The evidence for this is indirect, based largely on the appearance of an inwardly rectifying  $Ca^{2+}$  current and an increased resting  $Ca^{2+}$  permeability in cells transfected with CD20, and an acute increase in whole-cell conductance induced by an anti-CD20 mAb. Several key questions about the nature and function of CD20 remain. First, the increase in conductance induced by cross-linking CD20 is nonselective and thus distinct from the resting CD20-associated conductance. Second, the authors do not exclude the possibility that CD20 is a channel modulator rather than a channel itself. In fact, other work has shown that mAb binding to CD20 initiates tyrosine kinase activity and oncogene expression (140, 141), actions suggestive of a biochemical modulator. Finally, the mechanisms that control CD20-linked  $Ca^{2+}$  entry under physiological conditions are unknown, although a link to depletion-activated  $Ca^{2+}$  channels has been proposed (139).



### *Properties of Depletion-Activated Calcium Channels*

The evidence reviewed above strongly supports the conclusion that depletion-activated Ca<sup>2+</sup> channels underlie mitogenic Ca<sup>2+</sup> influx in T cells. Although their properties differ from those of voltage-gated Ca<sup>2+</sup> channels in electrically excitable cells, T cell Ca<sup>2+</sup> channels closely resemble Ca<sup>2+</sup> release-activated Ca<sup>2+</sup> (CRAC) channels originally described in rat mast cells by Hoth & Penner (142, 143). Patch-clamp studies indicate that these channels are present in a wide variety of cell types, including RBL cells, fibroblasts, thyrocytes, hepatocytes, HL-60 cells, and *Xenopus* oocytes (144–146); indirect evidence based on Ca<sup>2+</sup>-sensitive dyes suggests an even wider distribution (116). A complete understanding of the capacitative Ca<sup>2+</sup> entry pathway in lymphocytes and other cells will require cloning of the CRAC channel and other elements involved in its regulation. The unique nature of the channel and its mode of activation, a frustrating lack of high-affinity ligands, and an extremely widespread tissue distribution make its cloning a challenging goal. The defining properties of CRAC channels are reviewed below with particular emphasis on T cells and mast cells, in which they have been studied most extensively. This channel "fingerprint" may prove to be useful for the identification of these channels in other immune cells.

**ION SELECTIVITY** CRAC channels are extremely selective for Ca<sup>2+</sup> over monovalent cations, having a relative Ca<sup>2+</sup> permeability comparable to that of voltage-gated Ca<sup>2+</sup> channels (121, 124, 143). The divalent conductance sequence for the channel is Ca<sup>2+</sup> > Ba<sup>2+</sup> ≈ Sr<sup>2+</sup> >> Mn<sup>2+</sup>, with Ba<sup>2+</sup> and Sr<sup>2+</sup> carrying current about 50% as well as Ca<sup>2+</sup>. This sequence is unusual, as most voltage-gated Ca<sup>2+</sup> channels conduct Ba<sup>2+</sup> and Sr<sup>2+</sup> better than Ca<sup>2+</sup> (147).

**PHARMACOLOGY** No specific, high-affinity blockers of I<sub>CRAC</sub> (the current through CRAC channels) have been identified. A variety of organic antagonists of Ca(V) channels do not affect the current (124, 148), but imidazole antimycotics such as econazole and SKF 96365 inhibit capacitative Ca<sup>2+</sup> influx (149, 150) and I<sub>CRAC</sub> (148, 150). These compounds block with relatively low affinity (K<sub>i</sub> values of 0.6 μM for econazole and 4–12 μM for SKF 96365) and in mast cells block nonselective cation channels and chloride channels with similar potency (148). Divalent (Ni<sup>2+</sup>, Co<sup>2+</sup>, Cd<sup>2+</sup>, Mn<sup>2+</sup>) and trivalent (La<sup>3+</sup>) ions also inhibit I<sub>CRAC</sub> in the range of 0.1–5 mM (93, 121, 124, 143), but they block type *n* K(V) channels at similar concentrations (134, 135, 151) and therefore cannot be used to elucidate the function of CRAC channels in intact cells.

**UNITARY CONDUCTANCE AND LEVEL OF EXPRESSION** One hallmark of the CRAC channel is its extremely small single-channel conductance [10–24 fS in T cells (121) and <1 pS in mast cells (143)]. This conductance is ≈100-fold smaller than that of voltage-gated Ca<sup>2+</sup> channels, far too small for the single-



channel currents to be detected in membrane patches or even for whole-cell current noise to be visible by eye. In principle, the low transport rate predicted by the unitary conductance could be achieved by a single-ion transport mechanism like an ion exchanger.  $\text{Na}^+/\text{Ca}^{2+}$  exchange has in fact been proposed to underlie  $\text{Ca}^{2+}$  entry in T cells (152), but such a mechanism cannot explain observations that  $\text{Ca}^{2+}$  influx decreases with depolarization (93) and is insensitive to the removal of  $\text{Na}^{2+}_o$  (114, 153). The shape of its noise spectrum suggests that  $I_{\text{CRAC}}$  is carried by channels rather than by a single-ion transport mechanism, and based on the size of the unitary and whole-cell currents, a typical Jurkat cell may express > 10,000 CRAC channels (121).

**ACTIVATION AND INACTIVATION** The gating of depletion-activated  $\text{Ca}^{2+}$  channels is their least well-understood feature and perhaps the most important from a physiological viewpoint. CRAC channels are not opened directly by depolarization (93, 115, 121, 124, 142),  $\text{IP}_3$  (121, 124, 142), or  $\text{IP}_4$  (124, 142). Most attention has been focussed on the possibility of activation by a diffusible messenger released from intracellular  $\text{Ca}^{2+}$  stores, although activation by physical contact between proteins in the ER and plasma membranes or by stimulated insertion of new channels is also possible. One hypothesis is that  $\text{Ca}^{2+}$  entry in T cells is directly driven by  $\text{Ca}^{2+}$  released from intracellular stores (154–156), based in large part on the ability of high concentrations of intracellular  $\text{Ca}^{2+}$  buffers to abolish capacitative  $\text{Ca}^{2+}$  entry (154–156; but see 110). The strongest evidence against  $\text{Ca}^{2+}$ -dependent activation is that  $I_{\text{CRAC}}$  is induced in whole-cell recordings by intracellular dialysis with  $\text{Ca}^{2+}$  buffers that clamp  $[\text{Ca}^{2+}]_i$  to <10 nM, well below the resting level (93, 124, 142). In addition, TG or  $\text{IP}_3$  activates  $I_{\text{CRAC}}$  in advance of the  $[\text{Ca}^{2+}]_i$  rise in buffer-loaded cells (93, 115, 121, 124, 142). Thus, it appears that CRAC channels are opened by a signal other than  $\text{Ca}^{2+}$  itself, although modulatory roles for  $\text{Ca}^{2+}$  should not be excluded (see below).

The ability of several imidazole inhibitors of cytochrome P450 to inhibit capacitative  $\text{Ca}^{2+}$  entry originally led to the suggestion that a P450 metabolite is the activating messenger (157). However, a subsequent study has shown that chemical modification of these compounds can greatly reduce the anti-P450 activity without altering the inhibition of  $\text{Ca}^{2+}$  influx, suggesting that the imidazoles may block CRAC channels directly (158). A more recent candidate for the CRAC channel messenger is CIF ( $\text{Ca}^{2+}$  Influx Factor), a low-mol-wt phosphate-containing molecule present in Jurkat cell extracts (159). CIF activity is released from the microsomal fraction into the cytosol following depletion of  $\text{Ca}^{2+}$  stores, and when applied to several nonlymphoid cell types elicits a small, fluctuating  $[\text{Ca}^{2+}]_i$  rise without triggering intracellular  $\text{Ca}^{2+}$  release. These results are consistent with a role for CIF as the messenger that couples ER depletion to CRAC channel activation. Confirmation will require the demonstration that purified CIF activates  $I_{\text{CRAC}}$  when applied



intracellularly, for example through a patch pipette. The molecular identity of CIF is not known, although present data argue against a wide variety of known messengers (159). Other mechanisms involving small G proteins (160, 161), phosphatases (144), tyrosine kinases (162, 162a, 162b), nitric oxide (163), and cGMP (163, 164) have also been proposed to evoke capacitative Ca<sup>2+</sup> entry in various cells, but further experiments are needed to assign a specific action to these in lymphocytes.

Ca<sup>2+</sup> entering the cell through CRAC channels feeds back to inhibit the channel's activity in several ways. Rapid inactivation of the channels occurs over tens of msec (143, 165) and is driven by local intracellular Ca<sup>2+</sup> accumulation and binding to sites located probably on the channel itself (165). In addition, increased [Ca<sup>2+</sup>]<sub>i</sub> slowly inhibits I<sub>CRAC</sub> over tens of seconds (93, 115, 121, 166). Part of this slow inactivation process is due to uptake of Ca<sup>2+</sup> by stores, as it is blocked by TG (166). A second type of slow Ca<sup>2+</sup>-dependent inhibition appears to involve a protein phosphatase, as it is sensitive to okadaic acid, a phosphatase inhibitor (166; A Zweifach, R Lewis, unpublished observations). Slow activation and inactivation of I<sub>CRAC</sub> is likely to play a major role in generating oscillations of [Ca<sup>2+</sup>]<sub>i</sub> (93, 114, 130). In addition, negative feedback by Ca<sup>2+</sup> may act as an essential brake that prevents inappropriate or excessive increases in [Ca<sup>2+</sup>]<sub>i</sub>. These regulatory mechanisms may suggest useful therapeutic strategies for controlling lymphocyte responsiveness in vivo.

Receptor-mediated inhibition of capacitative Ca<sup>2+</sup> entry has been described in B cells. Cross-linking of Fcγ type II receptors (FcγRII) to membrane immunoglobulin (mIg) inhibits anti-μ-induced influx of Ca<sup>2+</sup> without preventing its release (167, 168). Because this treatment does not affect TG-induced Ca<sup>2+</sup> entry (168), it probably does not inactivate the CRAC channel or preempt its activation signal. It is possible that stimulation of FcγRII enhances pumping and reuptake of Ca<sup>2+</sup> by the stores and thereby prevents the activation of I<sub>CRAC</sub> by anti-μ (D Choquet, personal communication). Cross-linking of FcγRII to mIg in vivo may contribute to the inhibition of B cell activity during the late phases of the humoral immune response, when concentrations of circulating antibody are high (167).

### *Lymphocyte Signaling by Calcium Oscillations*

Single-cell measurements of [Ca<sup>2+</sup>]<sub>i</sub> with fluorescent dyes have revealed a remarkable degree of dynamic behavior that is undetectable in cell populations. A number of studies have shown that stimulation of the TCR by mitogens or antigen elicits pronounced [Ca<sup>2+</sup>]<sub>i</sub> oscillations in T cells and related cell lines (93, 95, 114, 169). In many cells, including antigen-stimulated B cells (170), [Ca<sup>2+</sup>]<sub>i</sub> oscillations appear to result from the repetitive release and reuptake of Ca<sup>2+</sup> by intracellular stores (171, 172). T cell oscillations are unusual in that they absolutely require Ca<sup>2+</sup> influx, which is believed to occur through CRAC channels (93, 114). In single Jurkat cells stimulated with PHA, I<sub>CRAC</sub> oscillates





in tandem with periodic changes in  $[Ca^{2+}]_i$  (93). A recent study suggests how the properties of CRAC channels may explain this behavior (130). Moderate release of stored  $Ca^{2+}$  by low doses of  $Ca^{2+}$ -ATPase inhibitors or a  $Ca^{2+}$  ionophore effectively induces  $[Ca^{2+}]_i$  oscillations in human T cells similar to those triggered by mitogens. Both  $Ca^{2+}$  influx and the content of intracellular stores fluctuate in oscillating cells, supporting an oscillation model based on cross-communication between  $Ca^{2+}$  stores and CRAC channels in the plasma membrane (130). According to this model, a small  $Ca^{2+}$  leak from the ER, e.g. induced by  $IP_3$ , causes partial depletion that activates a fraction of the cell's CRAC channels. The ensuing influx elevates  $[Ca^{2+}]_i$ , promoting store refilling and subsequent channel closure.  $Ca^{2+}$  pumps in the plasma membrane then reduce  $[Ca^{2+}]_i$  once more, enhancing efflux from the ER and triggering the next cycle. An essential element of any oscillation model is the presence of strong positive and negative feedback. K(Ca) channels may contribute feedback by generating membrane potential oscillations that would enhance  $Ca^{2+}$  influx during the rising phase (through hyperpolarization) and would diminish  $Ca^{2+}$  influx during the falling phase (as K(Ca) channels close and the membrane depolarizes). Membrane-potential oscillations of this kind have been seen to accompany  $[Ca^{2+}]_i$  oscillations in PHA-stimulated Jurkat cells (173).

What is the physiological function of  $[Ca^{2+}]_i$  oscillations in T cells? A recent study addressed this question using an IL-2 reporter gene to determine the calcium dependence of IL-2 gene expression in single murine T hybridoma cells (94). IL-2 transcriptional activity was monitored with a *lacZ* gene driven by the NF-AT (Nuclear Factor of Activated T cells) enhancer, and  $[Ca^{2+}]_i$  was elevated to steady levels using high doses of TG or allowed to fluctuate by stimulating with anti-CD3. In the presence of PMA, transcription was very sensitive to  $[Ca^{2+}]_i$ ; a threefold increase in steady state  $[Ca^{2+}]_i$  activated transcription in half the cells. In response to stimulation through the TCR, cells expressing *lacZ* tended to have larger and more frequent  $[Ca^{2+}]_i$  spikes than *lacZ*<sup>-</sup> cells. These results show at a single-cell level the dependence of gene expression on  $[Ca^{2+}]_i$  and suggest that  $[Ca^{2+}]_i$  oscillations may serve to enhance the efficiency of signaling from the TCR to the nucleus.

## TOWARD A MOLECULAR MECHANISM OF ANTIGEN-TRIGGERED CALCIUM SIGNALING

Progress over the past several years in understanding ion channels,  $Ca^{2+}$  regulation, and gene transcription in T cells suggests a model that links antigen recognition at the cell surface to the expression of specific genes in the nucleus through changes in  $[Ca^{2+}]_i$  and PKC activity (Figure 1).  $Ca^{2+}$ -dependent signaling in lymphocytes may be considered to occur in three phases. First, molecular events at the cell surface commence with the binding of the peptide-MHC complex to the antigen receptor and include the subsequent stimulation


K<sup>+</sup> AND CA<sup>2+</sup> CHANNELS IN LYMPHOCYTES 645

Figure 1 A cartoon of early events in T cell activation. Selected events from antigen binding to changes in ion channel activity to IL-2 gene expression are shown. Arrows labeled with + or - indicate stimulatory or inhibitory interactions, respectively.

of tyrosine kinases, phosphorylation and activation of PLC $\gamma$  1, and hydrolysis of PIP<sub>2</sub> to produce IP<sub>3</sub> and diacylglycerol (reviewed in 106, 107). During the second phase, IP<sub>3</sub> carries the activation signal to the ER, where it releases stored Ca<sup>2+</sup> through IP<sub>3</sub>-activated channels. Depletion of stores triggers the opening of Ca<sup>2+</sup> channels in the plasma membrane, leading to Ca<sup>2+</sup> entry. Type *n* K(V) channels ensure the proper initiation of Ca<sup>2+</sup> entry by maintaining the electrical gradient that helps drive Ca<sup>2+</sup> into the cell. As [Ca<sup>2+</sup>]<sub>i</sub> rises, K(Ca) channels open and may assume control of the membrane potential as K(V) channels undergo Ca<sup>2+</sup>-dependent inactivation. Delayed communication between the ER and plasma-membrane CRAC channels, together with positive and negative feedback provided by K(Ca) channels and Ca<sup>2+</sup>, may generate [Ca<sup>2+</sup>]<sub>i</sub> oscillations under moderate stimulation conditions. The third phase of signal transduction connects these cytoplasmic events with gene transcription in the nucleus and probably occurs concomitantly with the first and second phases described above (98, 99, 107). Activated by diacylglycerol in concert with increased [Ca<sup>2+</sup>]<sub>i</sub>, PKC stimulates de novo synthesis of the nuclear-targeted component of NF-AT (NF-AT<sub>n</sub>). In addition, the rise in [Ca<sup>2+</sup>]<sub>i</sub> drives the



## 646 LEWIS &amp; CAHALAN

$\text{Ca}^{2+}$ /calmodulin-dependent activation of the phosphatase calcineurin. De-phosphorylation of one or more substrates by calcineurin in turn promotes the translocation of a preexisting cytosolic NF-AT<sub>c</sub> subunit across the nuclear membrane, where it combines with NF-AT<sub>n</sub> to help drive expression of the IL-2 gene (for review, see 99, 107).

This model is certainly an oversimplification of the finely coordinated and complex sequence of parallel pathways engaged during T cell activation; it may, however, provide a useful framework for further studies of the roles of ion channels in shaping these events. As we attempt to describe the ionic signaling events that couple antigen recognition to the control of gene expression, important gaps in our understanding become apparent. The specific functions of  $\text{K}^+$  channels in lymphocytes are not yet fully understood, nor have the ramifications of  $\text{K}^+$ -channel diversity, modulation, and developmental regulation been explained. Basic features of depletion-activated  $\text{Ca}^{2+}$  channels are obscure; how are these channels controlled at a molecular level, and how does feedback regulation of their activity create  $[\text{Ca}^{2+}]_i$  oscillations? Finally, the meaning of  $[\text{Ca}^{2+}]_i$  oscillations is a mystery. Do oscillations encode specificity by selecting certain response pathways over others, or are they simply a means of enhancing the efficiency of signal transduction under conditions of weak antigenic stimulation? Application of increasingly sensitive techniques of molecular physiology will help us answer these questions and unravel the intricate web that connects ion channels, intracellular messengers, and gene transcription in lymphocytes.

## ACKNOWLEDGMENTS

We are grateful to Drs. Markus Hoth and Adam Zweifach for their comments on the manuscript and to Ruth Cahalan for her help with revisions. Work in the authors' laboratories was supported by National Institutes of Health grants GM47354 (RSL) and NS14609 and Gm41514 (MDC).

Any Annual Review chapter, as well as any article cited in an Annual Review chapter, may be purchased from the Annual Reviews Preprints and Reprints service.  
 1-800-347-8007; 415-259-5017; email arpr@class.org

## Literature Cited

1. Grinstein S, Dixon SJ. 1989. Ion transport, membrane potential, and cytoplasmic pH in lymphocytes: changes during activation. *Physiol. Rev.* 69:417-81
2. Lewis RS, Cahalan MD. 1990. Ion channels and signal transduction in lymphocytes. *Annu. Rev. Physiol.* 52:413-28
3. Cahalan MD, Lewis RS. 1990. Functional roles of ion channels in lymphocytes. *Semin. Immunol.* 2:107-17
4. Deutsch C. 1990.  $\text{K}^+$  channels and mitogenesis. *Prog. Clin. Biol. Res.* 334:251-71
5. Gardner P. 1990. Patch clamp studies of lymphocyte activation. *Annu. Rev. Immunol.* 8:231-52
6. Premack BA, Gardner P. 1991. Role of ion channels in lymphocytes. *J. Clin. Immunol.* 11:225-38
7. Gallin EK. 1991. Ion channels in leuko-

K<sup>+</sup> AND CA<sup>2+</sup> CHANNELS IN LYMPHOCYTES 647

Ann. Rev. Immunol. 1995.13:623-653. Downloaded from arjournals.annualreviews.org by University of North Carolina - Chapel Hill on 01/23/08. For personal use only.

- cytes. *Physiol. Rev.* 71:775-811
8. Cahalan MD, Chandy KG, Grissmer S. 1991. Potassium channels in development, activation, and disease in T lymphocytes. *Curr. Top. Membr.* 39:357-94
9. Chandy KG, Gutman GA, Grissmer S. 1993. Physiological role, molecular structure and evolutionary relationships of voltage-gated potassium channels in T lymphocytes. *Sem. Neurosci.* 5:125-34
10. Cahalan MD, Lewis RS. 1994. Regulation of chloride channels in lymphocytes. *Curr. Top. Membr.* 42:103-29
11. Cahalan MD, Chandy KG, DeCoursey TE, Gupta S. 1985. A voltage-gated potassium channel in human T lymphocytes. *J. Physiol.* 358:197-237
12. Deutsch C, Krause D, Lee SC. 1986. Voltage-gated potassium conductance in human T lymphocytes stimulated with phorbol ester. *J. Physiol.* 372:405-23
13. Lewis RS, Cahalan MD. 1988. Subset-specific expression of potassium channels in developing murine T lymphocytes. *Science* 239:771-75
14. DeCoursey TE, Chandy KG, Gupta S, Cahalan MD. 1987. Two types of potassium channels in murine T lymphocytes. *J. Gen. Physiol.* 89:379-404
15. Chandy KG, Gutman GA. 1995. Voltage-gated potassium channel genes. In *Ligand- and Voltage-gated Ion Channels*, ed. RA North, pp. 1-71. Boca Raton, FL: CRC. In press
16. Douglass J, Osborne PB, Cai YC, Wilkinson M, Christie MJ, Adelman JP. 1990. Characterization and functional expression of a rat genomic DNA clone encoding a lymphocyte potassium channel. *J. Immunol.* 144:4841-50
17. Chandy KG, Williams CB, Spencer RH, Aguilar BA, Ghanshani S, Tempel BL, Gutman GA. 1990. A family of three mouse potassium channel genes with intronless coding regions. *Science* 247:973-75
18. Attali B, Romey G, Honore E, Schmid-Alliana A, Mattei MG, Lesage F, Ricard P, Barhanin J, Lazdunski M. 1992. Cloning, functional expression, and regulation of two K<sup>+</sup> channels in human T lymphocytes. *J. Biol. Chem.* 267:8650-57
19. Grissmer S, Dethlefs B, Wasmuth JJ, Goldin AL, Gutman GA, Cahalan MD, Chandy KG. 1990. Expression and chromosomal localization of a lymphocyte K<sup>+</sup> channel gene. *Proc. Natl. Acad. Sci. USA* 87:9411-15
20. Cai YC, Osborne PB, North RA, Dootley DC, Douglass J. 1992. Characterization and functional expression of genomic DNA encoding the human lymphocyte type n potassium channel. *DNA Cell Biol.* 11:163-72
21. Deutsch C, Chen LQ. 1993. Heterologous expression of specific K<sup>+</sup> channels in T lymphocytes: functional consequences for volume regulation. *Proc. Natl. Acad. Sci. USA* 90:10036-40
22. Grissmer S, Cahalan M. 1989. TEA prevents inactivation while blocking open K<sup>+</sup> channels in human T lymphocytes. *Biophys. J.* 55:203-6
23. Kavanaugh MP, Varnum MD, Osborne PB, Christie MJ, Busch AE, Adelman JP, North RA. 1991. Interaction between tetraethylammonium and amino acid residues in the pore of cloned voltage-dependent potassium channels. *J. Biol. Chem.* 266:7583-87
24. Busch AE, Hurst RS, North RA, Adelman JP, Kavanaugh MP. 1991. Current inactivation involves a histidine residue in the pore of the rat lymphocyte potassium channel RGK5. *Biochem. Biophys. Res. Commun.* 179:1384-90
25. Grissmer S, Cahalan MD. 1989. Divalent ion trapping inside potassium channels of human T lymphocytes. *J. Gen. Physiol.* 93:609-30
26. Lunsau CJ, Williams JB, Marshall J, Levitan ES, Oliva C, Smith JS, Antkowiak J, Follander K, Stein RB, Swanson R, Kaczmarek LK, Burow SA. 1991. Alternative splicing contributes to K<sup>+</sup> channel diversity in the mammalian central nervous system. *Proc. Natl. Acad. Sci. USA* 88:3932-36
27. Yokoyama S, Imoto K, Kawamura T, Higashida H, Iwabe N, Miyata T, Numa S. 1989. Potassium channels from NG108-15 neuroblastoma hybrid cells: primary structure and functional expression from cDNAs. *FEBS Lett.* 259:37-43
28. Grissmer S, Ghanshani S, Dethlefs B, McPherson JD, Wasmuth JJ, Gutman GA, Cahalan MD, Chandy KG. 1992. The Shaw-related potassium channel gene, Kv3.1, on human chromosome 11, encodes the type I K<sup>+</sup> channel in T cells. *J. Biol. Chem.* 267:20971-79
29. Lewis RS, Cahalan MD. 1988. The plasticity of ion channels: parallels between the nervous and immune systems. *Trends Neurosci.* 11:214-18
30. Grinstein S, Smith JD. 1990. Calcium-independent cell volume regulation in human lymphocytes. Inhibition by charybdotoxin. *J. Gen. Physiol.* 95:97-120
31. Cahalan MD, Lewis RS. 1988. Role of potassium and chloride channels in volume regulation by T lymphocytes. In *Cell Physiology of Blood. Soc. Gen. Physiol. Ser.*, ed. RB Gunn, JC Parker.



- 43:281-301. New York: Rockefeller Univ. Press
32. Deutsch C, Lee SC. 1988. Cell volume regulation in lymphocytes. *Renal Physiol. Biochem.* 3-5:260-76
33. Lee SC, Levy DL, Deutsch C. 1992. Diverse  $K^+$  channels in primary human T lymphocytes. *J. Gen. Physiol.* 99:771-93
34. Cai YC, Douglass J. 1993. In vivo and in vitro phosphorylation of the T lymphocyte type  $n$  (Kv1.3) potassium channel. *J. Biol. Chem.* 268:23720-27
35. Honoré E, Attali B, Romey G, Lesage F, Barhanin J, Lazdunski M. 1992. Different types of  $K^+$  channel current are generated by different levels of a single mRNA. *EMBO J.* 11:2465-71
36. Weiss A, Imboden JB. 1987. Cell surface molecules and early events involved in human T lymphocyte activation. *Adv. Immunol.* 41:1-38
37. Coffey RG, Hadden JW. 1985. Neurotransmitters, hormones, and cyclic nucleotides in lymphocyte regulation. *Fed. Proc.* 44:112-17
38. Plaut M. 1987. Lymphocyte hormone receptors. *Annu. Rev. Immunol.* 5:621-69
39. Premack BA, Gardner P. 1992. Signal transduction by T-cell receptors: mobilization of Ca and regulation of Ca-dependent effector molecules. *Am. J. Physiol.* 263:C1119-40
40. Lee SC, Deutsch C. 1990. Temperature dependence of  $K^+$ -channel properties in human T lymphocytes. *Biophys. J.* 57:49-62
41. Pahapill PA, Schlichter LC. 1990. Modulation of potassium channels in human T lymphocytes: effects of temperature. *J. Physiol.* 422:103-26
42. Oleson DR, DeFelice LJ, Donahoe RM. 1993. A comparison of  $K^+$  channel characteristics in human T cells: perforated-patch versus whole-cell recording techniques. *J. Membr. Biol.* 132:229-41
43. Bregestovski P, Redkozubov A, Alexeev A. 1986. Elevation of intracellular calcium reduces voltage-dependent potassium conductance in human T cells. *Nature* 319:776-78
44. Pahapill PA, Schlichter LC. 1992. Modulation of potassium channels in intact human T lymphocytes. *J. Physiol.* 445:407-30
45. Choquet D, Sathou P, Frimi D, Cazenave P-A, Korn H. 1987. Cyclic AMP-modulated potassium channels in murine B cells and their precursors. *Science* 235:1211-14
46. Kavanaugh MP, Christie MJ, Osborne PB, Busch AE, Shen K-Z, Wu Y-N, Seeburg PH, Adelman JP, North RA. 1991. Transmitter regulation of voltage-dependent  $K^+$  channels expressed in *Xenopus oocytes*. *Biochem. J.* 277:899-902
47. Attali B, Honoré E, Lesage F, Lazdunski M, Barhanin J. 1992. Regulation of a major cloned voltage-gated  $K^+$  channel from human T lymphocytes. *FEBS Lett.* 303:229-32
48. Aiyar J, Grissmer S, Chandy KG. 1993. Full-length and truncated Kv1.3  $K^+$  channels are modulated by 5-HT<sub>1c</sub> receptor activation and independently by PKC. *Am. J. Physiol.* 265:C1571-78
49. Choquet D, Korn H. 1988. Dual effects of serotonin on a voltage-gated conductance in lymphocytes. *Proc. Natl. Acad. Sci. USA* 85:4557-61
50. Rettig J, Heinemann SH, Wunder F, Lora C, Parcej DN, Dolly JO, Pongs O. 1994. Inactivation properties of voltage-gated  $K^+$  channels altered by presence of  $\beta$  subunit. *Nature* 369:289-94
51. Payet MD, Dupuis G. 1992. Dual regulation of the  $n$  type  $K^+$  channel in Jurkat T lymphocytes by protein kinases A and C. *J. Biol. Chem.* 267:18270-73
52. Krause D, Lee SC, Deutsch C. 1988. Forskolin effects on the voltage-gated  $K^+$  conductance of human T cells. *Pflügers Arch.* 412:133-40
53. Soliven B, Nelson DJ. 1990. Beta-adrenergic modulation of  $K^+$  current in human T lymphocytes. *J. Membr. Biol.* 117:263-74
54. Tsien RY, Pozzan T, Rink TJ. 1982. T-cell mitogens cause early changes in cytoplasmic free  $Ca^{2+}$  and membrane potential in lymphocytes. *Nature* 295:68-71
55. Grinstein S, Smith JD. 1989.  $Ca^{2+}$  induces thapsigargin-sensitive membrane potential changes in rat lymphocytes. *Am. J. Physiol.* 257:C197-C206
56. Wilson HA, Chused TM. 1985. Lymphocyte membrane potential and  $Ca^{2+}$ -sensitive potassium channels described by oxonol dye fluorescence measurements. *J. Cell. Physiol.* 125:72-81
57. Rink TJ, Deutsch C. 1983. Calcium-activated potassium channels in lymphocytes. *Cell Calcium* 4:463-73
58. Mahaut-Smith MP, Schlichter LC. 1989.  $Ca^{2+}$ -activated  $K^+$  channels in human B lymphocytes and rat thymocytes. *J. Physiol.* 415:69-83
59. Mahaut-Smith MP, Mason MJ. 1991.  $Ca^{2+}$ -activated  $K^+$  channels in rat thymic lymphocytes: activation by concanavalin A. *J. Physiol.* 439:513-28
60. Partiseti M, Choquet D, Diu A, Korn H. 1992. Differential regulation of


 K<sup>+</sup> AND CA<sup>2+</sup> CHANNELS IN LYMPHOCYTES 649

- voltage- and calcium-activated potassium channels in human B lymphocytes. *J. Immunol.* 148:3361-68
61. Partiseti M, Korn H, Choquet D. 1993. Pattern of potassium channel expression in proliferating B lymphocytes depends upon the mode of activation. *J. Immunol.* 151:2462-70
  62. Grissmer S, Lewis RS, Cahalan MD. 1992. Ca<sup>2+</sup>-activated K<sup>+</sup> channels in human leukemic T cells. *J. Gen. Physiol.* 99:63-84
  63. Grissmer S, Nguyen AN, Cahalan MD. 1993. Calcium-activated potassium channels in resting and activated human T lymphocytes. *J. Gen. Physiol.* 102:601-30
  64. Leonard RJ, Garcia ML, Slaughter RS, Reuben JP. 1992. Selective blockers of voltage-gated K<sup>+</sup> channels depolarize human T lymphocytes: mechanism of the antiproliferative effect of charybdotoxin. *Proc. Natl. Acad. Sci. USA* 89:10094-98
  65. Latorre R, Oberhauser A, Labarca P, Alvarez O. 1989. Varieties of calcium-activated potassium channels. *Annu. Rev. Physiol.* 51:385-99
  66. McKinnon D, Ceredig R. 1986. Changes in the expression of potassium channels during mouse T cell development. *J. Exp. Med.* 164:1846-61
  67. DeCoursey TE, Chandy KG, Gupta S, Cahalan MD. 1987. Mitogen induction of ion channels in murine T lymphocytes. *J. Gen. Physiol.* 89:405-20
  68. Deutsch C, Price M, Lee S, King VF, Garcia ML. 1991. Characterization of high affinity binding sites for charybdotoxin in human T lymphocytes. Evidence for association with the voltage-gated K<sup>+</sup> channel. *J. Biol. Chem.* 266:3668-74
  69. Shapiro MS, DeCoursey TE. 1988. Two types of potassium channels in a lymphoma cell line. *Biophys. J.* 53:a530
  70. Sands SB, Lewis RS, Cahalan MD. 1989. Charybdotoxin blocks voltage-gated K<sup>+</sup> channels in human and murine T lymphocytes. *J. Gen. Physiol.* 93:1061-74
  71. Price M, Lee SC, Deutsch C. 1989. Charybdotoxin inhibits proliferation and interleukin 2 production in human peripheral blood lymphocytes. *Proc. Natl. Acad. Sci. USA* 86:10171-75
  72. Garcia-Calvo M, Leonard RJ, Novick J, Stevens SP, Schmalhofer W, Kaczorowski GJ, Garcia ML. 1993. Purification, characterization, and biosynthesis of margatoxin, a component of *Centruroides margaritatus* venom that selectively inhibits voltage-dependent potassium channels. *J. Biol. Chem.* 268:18866-74
  73. Marx M, Weber M, Merkel F, Meyer zum Büschenfelde KH, Köhler H. 1990. Additive effects of calcium antagonists on cyclosporin A-induced inhibition of T-cell proliferation. *Nephrol. Dial. Transplant.* 5:1038-44
  74. Deutsch CJ, Holian A, Holian SK, Daniele RP, Wilson DF. 1979. Transmembrane electrical and pH gradients across human erythrocytes and human peripheral lymphocytes. *J. Cell. Physiol.* 99:79-94
  75. Ishida Y, Chused TM. 1993. Lack of voltage sensitive potassium channels and generation of membrane potential by sodium potassium ATPase in murine T lymphocytes. *J. Immunol.* 151:610-20
  76. Maltsev VA. 1990. Oscillating and triggering properties of T cell membrane potential. *Immunol. Lett.* 26:277-82
  77. Gelfand EW, Or R. 1991. Charybdotoxin-sensitive, Ca<sup>2+</sup>-dependent membrane potential changes are not involved in human T or B cell activation and proliferation. *J. Immunol.* 147:3452-58
  78. Lewis RS, Ross PE, Cahalan MD. 1993. Chloride channels activated by osmotic stress in T lymphocytes. *J. Gen. Physiol.* 101:801-26
  79. Lee S, Price M, Prystowsky MB, Deutsch C. 1988. Volume response of quiescent and interleukin 2-stimulated T-lymphocytes to hypotonicity. *Am. J. Physiol.* 254:C286-96
  80. Chandy KG, DeCoursey TE, Cahalan MD, McLaughlin D, Gupta S. 1984. Voltage-gated potassium channels are required for human T lymphocyte activation. *J. Exp. Med.* 160:369-85
  81. Amigorena S, Choquet D, Teillaud JL, Korn H, Fridman WH. 1990. Ion channels and B cell mitogenesis. *Mol. Immunol.* 27:1259-68
  82. Schlichter L, Sidell N, Hagiwara S. 1986. Potassium channels mediate killing by human natural killer cells. *Proc. Natl. Acad. Sci. USA* 83:451-55
  83. Dubois J-M, Rouzaine-Dubois B. 1993. Role of potassium channels in mitogenesis. *Prog. Biophys. Mol. Biol.* 59:1-21
  84. Nilius B, Droogmans G. 1994. A role for K<sup>+</sup> channels in cell proliferation. *News Physiol. Sci.* 9:105-10
  85. Freedman BD, Price MA, Deutsch CJ. 1992. Evidence for voltage modulation of IL-2 production in mitogen-stimulated human peripheral blood lymphocytes. *J. Immunol.* 149:3784-94
  86. Lin CS, Boltz RC, Blake JT, Nguyen M, Talento A, Fischer PA, Springer MS, Sigal NH, Slaughter RS, Garcia ML, Kaczorowski GJ, Koo GC.



## 650 LEWIS &amp; CAHALAN

1993. Voltage-gated potassium channels regulate calcium-dependent pathways involved in human T lymphocyte activation. *J. Exp. Med.* 177:637-45
87. Randanampita C, Bismuth G, Debre P, Trautmann A. 1991. Nitrendipine-induced inhibition of calcium influx in a human T-cell clone: role of cell depolarization. *Cell Calcium* 12:313-23
88. Sarkadi B, Tordai A, Gárdos G. 1990. Membrane depolarization selectively inhibits receptor-operated calcium channels in human T (Jurkat) lymphoblasts. *Biochim. Biophys. Acta* 1027:130-40
89. Sarkadi B, Tordai A, Müller M, Gárdos G. 1990. Regulation of stimulus-induced calcium transport pathways in human T (Jurkat) lymphoblasts. *Mol. Immunol.* 27:1297-306
90. Gelfand EW, Cheung RK, Grinstein S. 1984. Role of membrane potential in the regulation of lectin-induced calcium uptake. *J. Cell. Physiol.* 121:533-39
91. Gray LS, Gnarr JR, Russell JH, Engelhard VH. 1987. The role of  $K^+$  in the regulation of the increase of intracellular  $Ca^{2+}$  mediated by the T lymphocyte antigen receptor. *Cell* 50:119-27
92. Oetgen HC, Terhorst C, Cantley LC, Rosoff PM. 1985. Stimulation of the T3-T cell receptor complex induces a membrane-potential-sensitive calcium influx. *Cell* 40:583-90
93. Lewis RS, Cahalan MD. 1989. Mitogen-induced oscillations of cytosolic  $Ca^{2+}$  and transmembrane  $Ca^{2+}$  current in human leukemic T cells. *Cell Regul.* 1:99-112
94. Negulescu PA, Shastri N, Cahalan MD. 1994. Intracellular calcium dependence of gene expression in single T lymphocytes. *Proc. Natl. Acad. Sci. USA* 91:2873-77
95. Donnadieu E, Cefal D, Tan YP, Paresys G, Bismuth G, Trautmann A. 1992. Imaging early steps of human T cell activation by antigen-presenting cells. *J. Immunol.* 148:2643-53
96. Donnadieu E, Bismuth G, Trautmann A. 1994. Antigen recognition by helper T cells elicits a sequence of distinct changes of their shape and intracellular calcium. *Curr. Biol.* 4:384-93
97. Gelfand EW. 1990. Cytosolic calcium changes during T- and B-lymphocyte activation: biological consequences and significance. *Curr. Top. Membr. Transp.* 35:153-77
98. Crabtree GR. 1989. Contingent genetic regulatory events in T lymphocyte activation. *Science* 243:355-61
99. Rao A. 1994. NF-ATp: a transcription factor required for the co-ordinate induction of several cytokine genes. *Immunol. Today* 15:274-81
100. Poenig M, Tsien RY, Schmitz-Verhulst A-M. 1987. Sequential activation and lethal hit measured by  $[Ca^{2+}]_i$  in individual cytolytic T cells and targets. *EMBO J.* 6:2223-32
101. Haverstick DM, Engelhard VH, Gray LS. 1991. Three intracellular signals for cytotoxic T lymphocyte-mediated killing. Independent roles for protein kinase C,  $Ca^{2+}$  influx, and  $Ca^{2+}$  release from internal stores. *J. Immunol.* 146:3306-13
102. McConkey DJ, Jondal M, Orrenius S. 1992. Cellular signaling in thymocyte apoptosis. *Semin. Immunol.* 4:371-77
103. Nakayama T, Ueda Y, Yamada H, Shores EW, Singer A, June CH. 1992. In vivo calcium elevations in thymocytes with T cell receptors that are specific for self ligands. *Science* 257:96-99
104. Schwartz RH. 1990. A cell culture model for T lymphocyte clonal anergy. *Science* 248:1349-56
105. Nghiem P, Ollick T, Gardner P, Schulman H. 1994. Interleukin-2 transcriptional block by multifunctional  $Ca^{2+}$ /calmodulin kinase. *Nature* 371:347-50
106. Weiss A, Littman DR. 1994. Signal transduction by lymphocyte antigen receptors. *Cell* 76:263-74
107. Crabtree GR, Clipstone NA. 1994. Signal transmission between the plasma membrane and nucleus of T lymphocytes. *Annu. Rev. Biochem.* 63:1045-83
108. Woodrow M, Clipstone NA, Cantrell DA. 1993. p21ras and calcineurin synergize to regulate the nuclear factor of activated T cells. *J. Exp. Med.* 178:1517-22
109. Imboden JB, Stobo JD. 1985. Transmembrane signalling by the T cell antigen receptor. Perturbation of the T3-antigen receptor complex generates inositol phosphates and releases calcium ions from intracellular stores. *J. Exp. Med.* 161:446-56
110. Gelfand EW, Cheung RK, Mills GB, Grinstein S. 1988. Uptake of extracellular  $Ca^{2+}$  and not recruitment from internal stores is essential for T lymphocyte proliferation. *Eur. J. Immunol.* 18:917-22
111. Goldsmith MA, Weiss A. 1988. Early signal transduction by the antigen receptor without commitment to T cell activation. *Science* 240:1029-31
112. Llopis J, Chow SB, Kass GEN, Gahn A, Orrenius S. 1991. Comparison between the effects of the microsomal  $Ca^{2+}$  translocase inhibitors thapsigargin and


 K<sup>+</sup> AND CA<sup>2+</sup> CHANNELS IN LYMPHOCYTES 651

- 2,5-di-(*t*-butyl)-1,4-benzohydroquinone on cellular calcium fluxes. *Biochem. J.* 277:553-56
113. Mason MJ, Mahaux-Smith MP, Grinstein S. 1991. The role of intracellular Ca<sup>2+</sup> in the regulation of the plasma membrane Ca<sup>2+</sup> permeability of unstimulated rat lymphocytes. *J. Biol. Chem.* 266:10872-79
  114. Donnadieu E, Bismuth G, Trautmann A. 1992. Calcium fluxes in T lymphocytes. *J. Biol. Chem.* 267:25864-72
  115. McDonald TV, Premack BA, Gardner P. 1993. Flash photolysis of caged inositol 1,4,5-trisphosphate activates plasma membrane calcium current in human T cells. *J. Biol. Chem.* 268:3889-96
  116. Putney JW Jr. 1990. Capacitative calcium entry revisited. *Cell Calcium* 11:611-24
  117. Gouy H, Cefai D, Christensen SB, Debré P, Bismuth G. 1990. Ca<sup>2+</sup> influx in human T lymphocytes is induced independently of inositol phosphate production by mobilization of intracellular Ca<sup>2+</sup> stores. A study with the Ca<sup>2+</sup> endoplasmic reticulum-ATPase inhibitor thapsigargin. *Eur. J. Immunol.* 20:2269-75
  118. Mason MJ, Garcia-Rodriguez C, Grinstein S. 1991. Coupling between intracellular Ca<sup>2+</sup> stores and the Ca<sup>2+</sup> permeability of the plasma membrane. Comparison of the effects of thapsigargin, 2,5-di-(*tert*-butyl)-1,4-hydroquinone, and cyclopiazonic acid in rat thymic lymphocytes. *J. Biol. Chem.* 266:20856-62
  119. Sarkadi B, Tordai A, Homolya L, Scharff O, Gárdos G. 1991. Calcium influx and intracellular calcium release in anti-CD3 antibody-stimulated and thapsigargin-treated human T lymphoblasts. *J. Membr. Biol.* 123:9-21
  120. Montero M, Alvarez J, Garcia-Sancho J. 1990. Uptake of Ca<sup>2+</sup> and refilling of intracellular Ca<sup>2+</sup> stores in Ehrlich-ascites-tumour cells and in rat thymocytes. *Biochem. J.* 271:535-40
  121. Zweifach A, Lewis RS. 1993. Mitogen-regulated Ca<sup>2+</sup> current of T lymphocytes is activated by depletion of intracellular Ca<sup>2+</sup> stores. *Proc. Natl. Acad. Sci. USA* 90:6295-99
  122. Kuno M, Goronzy J, Weyand CM, Gardner P. 1986. Single-channel and whole-cell recordings of mitogen-regulated inward currents in human cloned helper T lymphocytes. *Nature* 323:269-73
  123. Kuno M, Gardner P. 1987. Ion channels activated by inositol 1,4,5-trisphosphate in plasma membrane of human T-lymphocytes. *Nature* 326:301-4
  124. Premack BA, McDonald TV, Gardner P. 1994. Activation of Ca<sup>2+</sup> current in Jurkat T cells following the depletion of Ca<sup>2+</sup> stores by microsomal Ca<sup>2+</sup>-ATPase inhibitors. *J. Immunol.* 152:5226-40
  125. Partiseti M, Le Deist F, Hivroz C, Fischer A, Korn H, Choquet D. 1994. The calcium current activated by T cell receptor and store depletion in human lymphocytes is absent in a primary immunodeficiency. *J. Biol. Chem.* 269:32327-35
  126. Chow SC, Kass GEN, Orrenius S. 1993. Two independently regulated Ca<sup>2+</sup> entry mechanisms coexist in Jurkat T cells during T cell receptor antigen activation. *Biochem. J.* 293:395-98
  127. Deleted in proof
  128. Gardner P, Alcover A, Kuno M, Moinjeon P, Weyand CM, Goronzy J, Reinherz EL. 1989. Triggering of T-lymphocytes via either T3-Ti or T11 surface structures opens a voltage-insensitive plasma membrane calcium-permeable channel: requirement for interleukin-2 gene function. *J. Biol. Chem.* 264:1066-76
  129. Khan AA, Steiner JP, Klein MG, Schneider MF, Snyder SH. 1992. IP<sub>3</sub> receptor: localization to plasma membrane of T cells and cocapping with the T cell receptor. *Science* 257:815-18
  130. Dolmetsch R, Lewis RS. 1994. Signaling between intracellular Ca<sup>2+</sup> stores and depletion-activated Ca<sup>2+</sup> channels generates [Ca<sup>2+</sup>]<sub>i</sub> oscillations in T lymphocytes. *J. Gen. Physiol.* 103:365-88
  131. Gelfand EW, Cheung RK, Grinstein S. 1986. Mitogen-induced changes in Ca<sup>2+</sup> permeability are not mediated by voltage-gated K<sup>+</sup> channels. *J. Biol. Chem.* 261:11520-23
  132. Lewis RS, Cahalan MD. 1988. Voltage-dependent calcium signalling in single T lymphocytes. *Soc. Neurosci. Abstr.* 14:298
  133. DeCoursey TE, Chandy KG, Gupta S, Cahalan MD. 1984. Voltage-gated K<sup>+</sup> channels in human T lymphocytes: a role in mitogenesis? *Nature* 307:465-68
  134. Matteson DR, Deutsch C. 1984. K channels in T lymphocytes: a patch clamp study using monoclonal antibody adhesion. *Nature* 307:468-71
  135. Dupuis G, Héroux J, Payet MD. 1989. Characterization of Ca<sup>2+</sup> and K<sup>+</sup> currents in the human Jurkat T cell line: effects of phytohaemagglutinin. *J. Physiol.* 412:135-54





## 652 LEWIS &amp; CAHALAN

136. Denzmore JJ, Szabo G, Gray LS. 1992. A voltage-gated calcium channel is linked to the antigen receptor in Jurkat T lymphocytes. *FEBS Lett.* 312:161-64
137. O'Riordan C, Rosoff PM. 1993. Reconstitution of a T cell receptor-stimulated plasma membrane calcium transporter: lack of dependence on inositol phosphates. *Cell Calcium* 14:119-33
138. Martino G, Clementi E, Brambilla E, Moiola L, Corni G, Meldolesi J, Grimaldi LM. 1994.  $\gamma$  interferon activates a previously undescribed  $\text{Ca}^{2+}$  influx in T lymphocytes from patients with multiple sclerosis. *Proc. Natl. Acad. Sci. USA* 91:4825-29
139. Bubien JK, Zhou LJ, Bell P, Frizzell RA, Tedder TF. 1993. Transfection of the CD20 cell surface molecule into ectopic cell types generates a  $\text{Ca}^{2+}$  conductance found constitutively in B lymphocytes. *J. Cell Biol.* 121:1121-32
140. Smeland B, Godal T, Rudd E, Baiske K, Funderud S, Clark BA, Pfeiffer-Ohlsson S, Ohlsson R. 1985. The specific induction of myc protooncogene expression in normal human B cells is not a sufficient event for acquisition of competence to proliferate. *Proc. Natl. Acad. Sci. USA* 82:6253-59
141. Kansas GS, Tedder TF. 1991. Transmembrane signals generated through MHC class II, CD19, CD20, CD39, and CD40 antigens induce LFA-1-dependent and -independent adhesion in human B cells through a tyrosine kinase-dependent pathway. *J. Immunol.* 147:4094-102
142. Hoth M, Penner R. 1992. Depletion of intracellular calcium stores activates a calcium current in mast cells. *Nature* 355:553-56
143. Hoth M, Penner R. 1993. Calcium release-activated calcium current in mast cells. *J. Physiol.* 465:359-86
144. Parekh AB, Terlau H, Stühmer W. 1993. Depletion of  $\text{InsP}_3$  stores activates a  $\text{Ca}^{2+}$  and  $\text{K}^+$  current by means of a phosphatase and a diffusible messenger. *Nature* 364:814-18
145. Hoth M, Fasolato C, Penner R. 1993. Ion channels and calcium signaling in mast cells. *Ann. NY Acad. Sci.* 707:198-209
146. Fasolato C, Innocenti B, Pozzan T. 1994. Receptor-activated  $\text{Ca}^{2+}$  influx: how many mechanisms for how many channels? *Trends Pharmacol. Sci.* 15:77-83
147. Byerly L, Hagiwara S. 1988. Calcium channel diversity. In *Calcium and Ion Channel Modulation*, ed. AD Grinnell, D Armstrong, MB Jackson, pp. 3-18. New York: Plenum
148. Franzius D, Hoth M, Penner R. 1994. Non-specific effects of calcium entry antagonists in mast cells. *Pflügers Arch.* 428:433-38
149. Mason MJ, Mayer B, Hymel LJ. 1993. Inhibition of  $\text{Ca}^{2+}$  transport pathways in thymic lymphocytes by econazole, miconazole, and SKF 96365. *Am. J. Physiol.* 264:C654-62
150. Chung SC, McDonald TV, Gardner P. 1994. Inhibition by SKF 96365 of  $\text{Ca}^{2+}$  current, IL-2 production and activation in T lymphocytes. *Br. J. Pharmacol.* 113:861
151. DeCoursey TB, Chandy KG, Gupta S, Cahalan MD. 1985. Voltage-dependent ion channels in T-lymphocytes. *J. Neuroimmunol.* 10:71-95
152. Wacholtz MC, Cragoe EJ Jr, Lipsky PE. 1993. Delineation of the role of a  $\text{Na}^+/\text{Ca}^{2+}$  exchanger in regulating intracellular  $\text{Ca}^{2+}$  in T cells. *Cell. Immunol.* 147:93-109
153. Donnadieu E, Trautmann A. 1993. Is there a  $\text{Na}^+/\text{Ca}^{2+}$  exchanger in macrophages and in lymphocytes? *Pflügers Arch.* 424:448-55
154. Ng J, Fredholm BB, Jondal M, Andersson T. 1988. Regulation of receptor-mediated calcium influx across the plasma membrane in a human leukemic T-cell line: evidence of its dependence on an initial calcium mobilization from intracellular stores. *Biochim. Biophys. Acta* 971:207-14
155. Ng J, Gustavsson J, Jondal M, Andersson T. 1990. Regulation of calcium influx across the plasma membrane of the human T-leukemic cell line, JURKAT: dependence on a rise in cytosolic free calcium can be dissociated from formation of inositol phosphates. *Biochim. Biophys. Acta* 1053:97-105
156. Haverstick DM, Gray LS. 1993. Increased intracellular  $\text{Ca}^{2+}$  induces  $\text{Ca}^{2+}$  influx in human T lymphocytes. *Mol. Biol. Cell* 4:173-84
157. Alvarez J, Montero M, García-Sancho J. 1991. Cytochrome P-450 may link intracellular  $\text{Ca}^{2+}$  stores with plasma membrane  $\text{Ca}^{2+}$  influx. *Biochem. J.* 274:193-97
158. Koch BD, Faurot GR, Kopanitsa MV, Swinney DC. 1994. Pharmacology of a  $\text{Ca}^{2+}$  influx pathway activated by emptying the intracellular  $\text{Ca}^{2+}$  stores in HL-60 cells: evidence that a cytochrome P-450 is not involved. *Biochem. J.* 302:187-90
159. Randriamampita C, Tsien RY. 1993. Emptying of intracellular  $\text{Ca}^{2+}$  stores releases a novel small messenger that


 $K^+$  AND  $Ca^{2+}$  CHANNELS IN LYMPHOCYTES 653

- stimulates  $Ca^{2+}$  influx. *Nature* 364:809-14
160. Bird GSJ, Putney JW Jr. 1993. Inhibition of thapsigargin-induced calcium entry by microinjected guanine nucleotide analogues. *J. Biol. Chem.* 268:21486-88
  161. Fasolato C, Hoth M, Penner R. 1993. A GTP-dependent step in the activation mechanism of capacitative calcium influx. *J. Biol. Chem.* 268:20737-40
  162. Vostal JG, Jackson WL, Shulman NR. 1991. Cytosolic and stored calcium antagonistically control tyrosine phosphorylation of specific platelet proteins. *J. Biol. Chem.* 266:16911-16
  - 162a. Lee K-M, Toscas K, Villereal ML. 1993. Inhibition of bradykinin- and thapsigargin-induced  $Ca^{2+}$  entry by tyrosine kinase inhibitors. *J. Biol. Chem.* 268:9945-48
  - 162b. Sargeant P, Farndale RW, Sage SO. 1994. Calcium store depletion in dimethyl BAPTA-loaded human platelets increases protein tyrosine phosphorylation in the absence of a rise in cytosolic calcium. *Exp. Physiol.* 79:269-72
  163. Xu X, Star RA, Tortorici G, Muallem S. 1994. Depletion of intracellular  $Ca^{2+}$  stores activates nitric-oxide synthase to generate cGMP and regulate  $Ca^{2+}$  influx. *J. Biol. Chem.* 269:12645-53
  164. Bahnsen TD, Pandolfi SJ, Dionne VE. 1993. Cyclic GMP modulates depletion-activated  $Ca^{2+}$  entry in pancreatic acinar cells. *J. Biol. Chem.* 268:10808-12
  165. Zweifach A, Lewis RS. 1995. Rapid inactivation of depletion-activated calcium current (ICRAC) due to local calcium feedback. *J. Gen. Physiol.* In press
  166. Zweifach A, Lewis RS. 1994. Two mechanisms of  $Ca^{2+}$ -dependent inactivation of depletion-activated  $Ca^{2+}$  channels. *Biophys. J.* 66:A153
  167. Choquet D, Parisier M, Amigorena S, Bonnerot C, Fridman WH, Korn H. 1993. Cross-linking of IgG receptors inhibits membrane immunoglobulin-stimulated calcium influx in B lymphocytes. *J. Cell Biol.* 121:355-63
  168. Diegel ML, Rankin BM, Bolen JB, Dubois PM, Kiener PA. 1994. Cross-linking of Fc gamma receptor to surface immunoglobulin on B cells provides an inhibitory signal that closes the plasma membrane calcium channel. *J. Biol. Chem.* 269:11409-16
  169. Hess SD, Oortgiesen M, Cahalan MD. 1993. Calcium oscillations in human T and natural killer cells depend upon membrane potential and calcium influx. *J. Immunol.* 150:2620-33
  170. Wilson HA, Greenblatt D, Poenie M, Finkelman FD, Tsien RY. 1987. Cross-linkage of B lymphocyte surface immunoglobulin by anti-Ig or antigen induces prolonged oscillations of intracellular ionized calcium. *J. Exp. Med.* 166:601-6
  171. Berridge MJ. 1993. Inositol trisphosphate and calcium signalling. *Nature* 361:315-25
  172. Fewtrell C. 1993.  $Ca^{2+}$  oscillations in non-excitable cells. *Annu. Rev. Physiol.* 55:427-54
  173. Lewis RS, Grissmer S, Cahalan MD. 1991. Role of  $K^+$  channels in regulating calcium signaling in leukemic T lymphocytes. *Biophys. J.* 59:13a